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Abstract 
The natural history of follicular lymphoma is heterogeneous with numerous relapses 
and remissions over many years. A substantial number of patients suffer an 
aggressive disease course with death due to disease within 5 years of diagnosis. The 
prognosis is significantly worse in patients (10-68%) who transform to an aggressive 
histology. The clinical parameters used to stratify patients with this disease have 
limited discriminative power and new prognostic biomarkers are required. Insights 
into the biology of the disease, with identification of potential therapeutic targets are 
also required. Analysis of paraffin embedded diagnostic FL biopsies from 
populations of patients at the extremes of overall survival (<5 years and >15 years) 
demonstrated that expression of CD4 T lymphocytes and a perifollicular location of 
forkhead box protein P3 were significantly more common in diagnostic biopsies 
from patients who lived >15 years. Patients with high numbers of intrafollicular CD4 
T lymphocytes and higher numbers of CD68 positive macrophages were more likely 
to undergo rapid transformation to diffuse large B cell lymphoma (DLBCL). 
Analysis of sequential biopsies pre-and post-transformation from patients with FL 
who subsequently transformed to DLBCL demonstrated high numbers of CD68 
positive macrophages in the majority of cases. The overall survival from 
transformation was reduced in patients in whom the number of FOXP3 positive T 
cells decreased/remained low compared to patients in whom the number of FOXP3 
positive T cells increased/remained high.  
Analysis of biopsies pre-and post-transformation from patients with FL who 
subsequently transformed, identified mutation of TP53 in 28% of cases suggesting a 
limited role in the process of transformation. The immunocytochemical expression of 
MDM2, the TP53 regulator, was significantly higher on transformation. The 
phenotype of transformed FL was confirmed immunocytochemically as Germinal 
Centre type and two potential drug targets, Aurora Kinase B and nm23, were 
confirmed as being up-regulated on transformation.  
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1.1 General introduction 
Mammalian immunity is a sophisticated system which has evolved to protect the 
body against pathogens. It is composed of two arms, innate immunity and adaptive 
immunity. The innate immune system responds in a predetermined fashion whereas 
the cells of the adaptive immune system, lymphocytes, have the capacity to respond 
to specific antigens. There are two lymphocyte lineages, B lymphocytes and T 
lymphocytes. Both lineages originate from the bone marrow; however maturation of 
T lymphocytes occurs in the thymus. Both mature B and T lymphocytes possess 
membrane receptors which allow them to recognise antigen. The antigen receptors 
present on B lymphocytes are immunoglobulin (Ig) which recognise free antigen. T 
lymphocytes can only recognise antigen when bound in a complex to major 
histocompatibility complex (MHC) on the surface of antigen presenting cells (APC) 
(Zinkernagel RM, Doherty PC 1974; Zinkernagel RM, Doherty PC 1975). Broadly, 
there are two kinds of T lymphocytes, T helper cells and T cytotoxic cells but this is 
now known to be oversimplistic. The cytotoxic T cells kill cells infected with 
pathogens and the helper T cells coordinate the immune response.  
 
Lymphoid organs are tissues composed of lymphocytes surrounded by a supportive 
framework of non-lymphoid cells. It is here that the cells of the immune system 
mature and interact with pathogens. Lymphoid organs are classed as either central or 
peripheral. The central organs, the bone marrow and thymus, are the locations where 
lymphocytes are produced. The peripheral organs are where interaction with 
pathogen occurs, the adaptive responses are initiated and lymphocytes are 
maintained. Lymph nodes comprise part of the peripheral lymphoid system and are 
composed of dense collections of lymphoid tissue. Normally lymph nodes are not 
palpable but infiltration by malignancy or reaction to immune stimulus causes an 
increase in their size and allows detection. 
 
The peripheral lymph nodes act to filter lymph and allow interaction of antigens, 
antigen presenting cells and lymphocytes in order to initiate an immune response. 
 
1.2 Histological Structure 
Structurally, the lymphoid areas of lymph nodes are divided into three main areas; 
the cortex, the paracortex and the medulla. Each area contains distinct populations of 
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lymphoid cells, which perform different functions. The remainder of the lymph node 
is composed of fibrous tissue forming a capsule and supporting trabeculae, blood 
vessels and lymphatic sinuses. 
 
The cortex (superficial cortex) is composed of lymphoid follicles, which form the B 
cell area of the lymph node and are responsible for humoral immunity. Lymphoid 
follicles can take the form of either primary or secondary depending on their 
activation status.  
 
Primary follicles are usually rounded and orientated with their long axis 90° to the 
capsule of the lymph node. The cells within the primary follicle are inactivated or 
resting B lymphocytes. Secondary follicles have been activated in response to 
antigen and are composed of a densely packed mantle area composed of small 
lymphoid cells surrounding a germinal centre (GC). The germinal centre contains 
proliferating lymphocytes in all stages of maturation along with stromal cells and 
antigen presenting cells. The lymphocytes within the germinal centre are 
predominantly B lymphocytes, which may be small cleaved centrocytes or large 
centroblasts. Occasional scattered T lymphocytes are present. On activation the 
germinal centre assumes polarity with a peripheral light area, as seen by 
haematoxylin and eosin (H&E) staining, composed mainly of centrocytes and a 
central dark area composed of centroblasts. The centroblasts have a high level of 
mitotic activity and eventually differentiate into centrocytes (Stevens A, Lowe J 
2005). Centroblasts are large cells with vesicular nuclei, prominent nucleoli 
occupying a peripheral location and a small amount of basophilic cytoplasm 
(Nathwani BN et al. 2001). On initiation of the immune response those lymphocytes 
which are the most specific for the antigen are selected to survive and undergo clonal 
proliferation. Other less specific lymphocytes undergo apoptosis. The surviving 
centroblasts proliferate and mature into centrocytes which produce immunoglobulins 
and migrate to the light area of the germinal centre. Some of these cells will become 
memory B cells; other cells will mature into plasma cells, migrate to the medulla and 
produce antibody. Thus the reactive germinal centre contains highly mitotic cells 
juxtaposed with numerous apoptotic cells and apoptotic debris. The mantle zone is 
composed entirely of B lymphocytes including memory B cells. The cells at the 
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edges of the mantle zone are less tightly packed and possess more cytoplasm forming 
a marginal zone (Figures 1 and 2). 
 
Figure 1 Histological structure of a reactive lymph node stained with haematoxylin 
and eosin low power photomicrograph original magnification x5  
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Figure 2 Histology of H&E stained reactive lymph node, A) original magnification 
x10, B) germinal centre original magnification x40 
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The paracortical area is the area extending between the lymphoid follicles and 
contains lymphoid cells, principally T lymphocytes, and venules. The T lymphocytes 
are of varying sizes as they represent different stages of response to antigen 
stimulation. Mitotic figures may also be present. Interspersed between the T 
lymphocytes are interdigitating cells, professional antigen presenting cells, which are 
essential for the successful initiation of immune response to antigen.  
 
The medulla is composed of cords of lymphoid cells, which form sinuses and extend 
into the cortex of the lymph node when stimulated by antigen. The medulla 
represents the area of the node where plasma cell differentiation and proliferation 
occurs. Admixed with the plasma cells are numerous macrophages, monocytes and 
mast cells. 
 
The capsule of the lymph node and trabeculae are mainly composed of fibroblasts 
along with blood vessels, smooth muscle and nerves. The lymphoid cells are 
supported by a reticular stroma composed of reticular cells and reticulum fibres.  
 
1.3 B lymphocyte development and antigen expression  
B lymphocyte development begins in the bone marrow and the fundamental event is 
Ig gene rearrangement beginning with Ig heavy chain gene rearrangement on 
chromosome 14q32. The initial step involves joining of the diversity (D) and joining 
(J) regions to form the DJ segment and subsequent linkage to the variable (V) 
segment resulting in a functional heavy chain V-D-J region (Tonegawa S 1983) 
(Figure 3).  
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Figure 3 Diagram of VDJ rearrangements in the immunoglobulin heavy chain gene. 
(Reproduced with permission from N Holmes Cambridge University) 
 
The successful rearrangement of the Ig heavy chain results in suppression of the 
other copy by allelic exclusion and initiates the rearrangement of the light chain loci. 
There are two light chain loci, kappa (κ) and lambda (λ). Initially, rearrangement of 
the κ light chain locus on 2p12 is begun but if unsuccessful the λ light chain locus on 
22q11 is rearranged. Cells producing κ light chains have been demonstrated to have 
unrearranged λ chains whereas those producing λ light chains have rearranged and 
inactivated κ chains (Hieter et al. 1981, Korsmeyer SJ et al. 1982). The process of 
recombination is performed by recombination activating gene-1 (RAG-1) (Schatz 
DG, Oettinger MA, Baltimore D 1989) and recombination activating gene-2 (RAG-
2) (Oettinger MA et al. 1990). If functional heavy and light chains are not produced, 
the cell undergoes apoptosis within the bone marrow. Surviving cells mature to form 
naïve B cells expressing IgM and IgD as a result of alternative splicing of the 
constant region genes. Encounter with specific antigen causes naïve B cells to 
proliferate and stop production of IgD. This proliferation occurs in the GC of 
reactive lymph nodes and some of these proliferating cells will produce IgM. Within 
GC the B cell blasts undergo somatic hypermutation of the V region resulting in 
some cells with increased affinity for the antigen. These cells preferentially expand 
and any cells with a lower affinity to the antigen undergo apoptosis. This process is 
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known as affinity maturation and produces the secondary antibody response 
(Griffiths GM et al. 1984; Paul WE et al. 1967). Activation by antigen causes class 
switching to occur allowing production of antibodies of isotypes IgG, IgA or IgE. 
The heavy chain constant region genes are situated at the 3’ end of the locus and 
ordered from 5’ to 3’; µ,δ,γ,α,ε. Initially IgM is the only functionally Ig transcript but 
eventually a specific constant region is selected and the others deleted (Andersson J, 
Coutinho A, Melchers F 1978; Gearhart PJ, Hurwitz JL, Cebra JJ 1980). 
 
The stages of normal B lymphocyte development are fundamental to understanding 
the classification of B cell lymphomas (Table 1). The earliest B lineage committed 
cell is the progenitor B cell (pro-B). These are blast cells which undergo Ig gene 
rearrangement. Once gene rearrangement has occurred and cytoplasmic µ is 
expressed the cell is known as a pre-B cell and light chain gene rearrangement occurs 
with eventual surface expression of IgM. Both pro and pre-B cells express terminal 
deoxynucleotidyl transferase (TdT) a DNA polymerase which helps add to diversity 
of the lymphocyte antigen recognition sites by addition of nucleotides. The cell is 
now an immature B cell. These cells circulate in the bloodstream and form primary 
follicles and mantle zones in the primary and secondary lymphoid organs. Naïve 
mature B cells undergo blastic transformation on encountering antigen and 
proliferate. These B blasts then migrate into the centre of primary lymphoid follicles 
and form a germinal centre (Liu YJ et al. 1991). The blast cells are called 
centroblasts and often down-regulate Bcl-2 protein increasing their susceptibility to 
apoptosis (Hockenbery DM et al. 1991; McDonnell TJ et al. 1989; Nunez J et al. 
1990). Centroblasts will become centrocytes, cells which express surface Ig but may 
have undergone class switching and somatic mutation. The cells with high affinity 
for the antigen are rescued from apoptosis by the process of binding to antigen in the 
processes of follicular dendritic cells (FDCs). These cells up-regulate Bcl-2 protein 
(Liu YJ et al. 1991). Bcl-6 expression is down-regulated as a result of interaction 
with CD23 on follicular dendritic cells (FDCs) and CD40 ligand (CD40L) on T 
lymphocytes (Cattoretti G et al. 1995; Pittaluga S et al. 1996). B cell lymphocyte 
development is a complex and highly organized process. The stages of differentiation 
can be assessed by expression of cell surface proteins which can be recognized by 
monoclonal antibodies. 
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Table 1 B lymphocytes and neoplastic equivalents 
 
B CELLS SURFACE MARKERS NEOPLASTIC 
EQUIVALENT 
Pro B cell Tdt, CD19, CD22, CD34 Lymphoblastic lymphoma    
(B cells) 
Pre B cell Tdt, CD9, CD19, CD34, 
CD10 
Lymphoblastic lymphoma  
(B cells) 
Immature B cell CD19, CD20, CD10, Ig Lymphoblastic lymphoma  
(B cells) 
Mature naïve B cell CD19, CD20, CD23, 
CD5 
Small lymphocytic 
lymphoma, Mantle cell 
lymphoma 
Germinal centre cell CD10, CD19, CD20, 
CD23, CD5 
Follicular lymphoma, 
Diffuse large B cell 
lymphoma, Burkitts 
lymphoma 
Memory B cell CD19, CD20, CD79a Marginal zone 
lymphoma, small 
lymphocytic lymphoma 
Plasma cell CD38 Plasmacytoma, myeloma 
 
Adapted from Küppers R et al. 1999 and Dey P 2006 
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All the B lymphocytes present within lymphoid follicles express the pan B cell 
markers CD19, CD20 and CD22. CD19 is a cell membrane antigen, which is present 
in all B lymphocytes except plasma cells. Its expression occurs very early in B 
lymphocyte development and so may be more sensitive than CD20 in identifying 
lymphoblastic populations (Nadler LM et al. 1983). CD20 is a phosphoprotein, 
which is expressed on the cell membrane of B lymphocytes (Stashenko P et al. 1980) 
and the majority of B cell lymphomas (Nadler LM et al. 1981). It is not expressed by 
pre B cells or plasma cells (Tedder TF et al. 1985). CD22 expression is limited to 
resting and activated B lymphocytes and is a two chain glycoprotein. Its cytoplasmic 
expression is seen very early in B lymphocyte development and is subsequently 
detected on the cell membrane. After activation initially expression increases but is 
subsequently down-regulated. Expression is seen in approximately half of B cell 
lymphomas (Dörken B et al. 1986). CD22 plays an important role in the early stages 
of B cell activation and proliferation (Pezzutto A et al. 1987). The centroblasts within 
the secondary follicles stain positively for CD10 (Harris NL et al. 1984) (Figure 8) 
and Bcl-6 (Cattoretti G et al. 1995) (Figure 9). CD10 was originally detected in 
rabbit kidney brush border and is a neutral endopeptidase (Kerr MA, Kenny AJ 
1974) and subsequently was demonstrated to be an antigen in acute lymphoblastic 
leukaemia; the common acute lymphocytic leukaemia antigen (CALLA) (Greaves 
MF et al. 1975). CD10 is a cell membrane antigen, which is present on follicular 
centre B cells (Weinberg DS et al. 1986), granulocytes (Braun MP et al. 1983) and 
precursor lymphoid cells (Pesando JM et al. 1983). It is a regulator of B cell growth 
and proliferation (Cutrona G et al. 2002). Bcl-6 is a zinc finger transcription factor, 
which is expressed in the nucleus of germinal centre B cells but not by plasma cells 
or immature B cells, suggesting it may play a role in germinal centre development 
and/or function (Cattoretti G et al. 1995). Bcl-2 protein product when down-
regulated makes cells susceptible to apoptotic cell death (Hockenbury DM et al. 
1991). The B lymphocytes in the mantle area show positivity for IgD and bcl-2. 
Centroblasts and centrocytes within reactive follicles are negative for bcl-2 (Figure 
9). B lymphocytes either express κ or λ immunoglobulin light chains in a ratio of 
approximately 2:1. 
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1.4 Other cells in the germinal centre 
Many other cells are also present in the germinal centre and these different 
compartments can be highlighted using immunocytochemistry. Numerous T 
lymphocytes are present and these are identified by positivity for CD3, part of the T 
cell receptor complex. T cell receptor mRNA was identified as specific for T 
lymphoblasts, thymocytes and phytohaemagglutinin activated T lymphocytes and 
was demonstrated to have similarity to both the immunoglobulin light and heavy 
chains (Yanagi Y et al. 1984). A monoclonal antibody was generated against cell 
surface determinants of T lymphocytes and OKT3 was demonstrated to react against 
all human peripheral T lymphocytes (Kung P et al. 1979). Antisera raised against 
CD3 antigen (Mason DY et al. 1988) and subsequently monoclonal antibodies 
generated against CD3 peptide were demonstrated to be able to detect both reactive 
and neoplastic T lymphocytes in paraffin embedded tissue (Mason DY et al. 1989) 
(Figure 10). 
 
 The CD5 antigen is a 65,000-dalton glycoprotein present on the surface of both 
mature and immature T lymphocytes (Royston I et al. 1979). Although initially 
considered to be expressed only on T lymphocytes it has subsequentially been found 
some B cell malignancies including chronic lymphocytic leukaemia (CLL) (Royston 
I et al. 1980) and on subsets of B lymphocytes (Caligaris-Cappio F 1982). 
Traditionally expression of CD5 assessed by immunocytochemistry has been used to 
indicate T lymphocytes as its membrane expression is approximately 30-fold higher 
on T lymphocytes than B lymphocytes (Kaplan D et al. 2001). 
   
The monoclonal antibody Ki67 detects a human nuclear antigen present in 
proliferating cells but not in quiescent cells (Gerdes J et al. 1983). The nuclear 
antigen is present in all stages of the cell cycle except G0 and as such is a reliable 
way to evaluate the proliferation fraction of both reactive and neoplastic tissues 
(Gerdes J et al. 1984) (Figure 11). 
 
The presence of activated B lymphocytes within a primary follicle in lymph nodes 
results in the formation of a germinal centre containing a follicular dendritic cell 
(FDC) meshwork. FDCs capture antigen as immune complexes of antigen, antibody 
and complement and then display, but do not classically present, antigen to B 
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lymphocytes. In vitro data demonstrates that FDCs, in association with T 
lymphocytes, are essential for adhesion and proliferation of B lymphocytes. The 
presence of FDCs induces the B lymphocytes to form large clusters and 
lymphocytes, in contact with FDCs, were resistant to apoptosis (Kosco MH, 
Pflugfelder E, Gray D 1992). Subsequently B lymphocytes are activated so they can 
act as antigen presenting cells for T lymphocytes (Kosco-Vilbois MH, Gray D, 
Scheidegger D, Julius M 1993). The presence of complement receptors on B 
lymphocytes was initially described over thirty years ago (Lay WH, Nussenzweig 
1968; Bianco C, Patrick R, Nussenzweig 1970) resulting in the hypothesis that there 
was an interaction between complement and the humoral immune system. Two 
distinct complement receptors are present on the surface of all mature B 
lymphocytes; CR1 (CD35) and CR2 (CD21) (Tedder TF, Fearon DT, Gartland GL, 
Cooper MD 1983;  Tedder TF, Clement LT, Cooper MD 1984). CD21 is, in addition, 
the receptor for Epstein Barr virus (EBV) on B lymphocytes (Fingeroth JD et al. 
1984). CD21 is associated with a complex of membrane proteins including CD19 
which act as signal transducers once CD21 is bound (Matsumoto AK et al. 1991). 
There are two types of B lymphocytes; B-1 cells which express CD5 and are self 
renewing, producing naïve B cells in lymphoid tissue and B-2 cells which are CD5 
negative and are renewed in the bone marrow. Both cells respond to antigen; 
however the B-1 cells have a more limited antigen recognition repertoire. A murine 
model with deregulation of Cr2 locus demonstrated a reduction in the numbers of B-
1 cells in the peritoneum coupled with a defective humoral immune response to T 
lymphocyte dependent antigens. The reduced humoral response was evidenced by 
reduced numbers and size of germinal centres in the spleen and lowered serum 
antibody levels. Bone marrow transplantation from Cr2 normal donors restored 
humoral immunity to normal (Ahearn JM et al. 1996). This result postulates a role 
for CD21 in antibody response. Further murine models deficient in both CR1 and 
CR2 demonstrated normal B and T lymphocyte development but an impaired 
response to both low and high doses of T cell dependent antigen. The activation of B 
lymphocytes is not completely abolished as there is still generation of germinal 
centres and some secondary antibody response (Molina H et al. 1996). The situation 
is a little less clear in humans than mice. 
 
CD23, also known as FcεRII, is a C type lectin which is the low affinity receptor for 
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immunoglobulin E (IgE). FDCs were isolated from tonsils and reactive lymph nodes 
and the presence of CD23 detected on 50% of the FDC population. FDCs isolated 
from low grade non-Hodgkin lymphoma also expressed the same antigenic profile 
including CD23 indicating that FDCs have the same antigenic profile in both reactive 
and neoplastic lymphoid tissue (Petrasch S et al. 1990). Supernatants containing 
soluble CD23 facilitate the survival of germinal centre B lymphocytes as well as 
encouraging differentiation towards plasma cell morphology. These effects were 
reduced after soluble CD23 was removed from the supernatant. The combination of 
recombinant CD23 with interleukin 1 alpha produced rescue and differentiation of 
germinal centre cells (Liu YJ et al. 1991).  CD21 has been demonstrated to act as a 
ligand for CD23 and the combination of these molecules increases interleukin-4 
induced IgE production by mononuclear cells (Aubry JP et al. 1992).  
 
CD21 and CD23 are also expressed on other cells and immunocytochemistry for 
CD21 and CD23 demonstrates the presence of a follicular dendritic cell meshwork in 
lymphoid tissue (Figure 10). 
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1.5 Principles of Immunocytochemistry 
Immunocytochemistry is a technique which uses antigen-antibody interaction to 
demonstrate the presence of an antigen on a cell. The location of the antigen binding 
is demonstrated either by direct labeling of the antibody or the use of a secondary 
antibody labeling system.  As mentioned, there are two techniques for visualization, 
direct and indirect. The traditional direct method is simple as it requires only one 
reagent with subsequent use of the appropriate chromogen substrate. This technique 
most commonly has a fluorochrome as a conjugate however this would be unsuitable 
for use with tissue when morphological interpretation is required and horseradish 
peroxidase (Nakane P, Pierce GB 1966) or alkaline phopshatase are used instead 
(Figure 4). The indirect method is more complex as a two step process is required, 
the primary antibody is applied initially and a secondary labeled antibody directed 
against the first is then applied (Figure 5). Usually the label is horseradish 
peroxidase and this is used in combination with a chromogen 3,3’-diaminobenzidine 
tetrahydrochloride (DAB). This results in an insoluble, stable brown end-product 
(Graham RC, Karnovsky MJ 1966).  This technique is slightly more complicated 
than the direct method but is more sensitive.  
 
Figure 4 Direct method of immunocytochemistry using peroxidase (P) conjugated 
anti-human antibody 
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Figure 5 Indirect method if immunocytochemistry using a human antibody e.g. from 
a rabbit and a secondary peroxidase (P) conjugated antibody against rabbit 
 
 
 
 
 
 
 
The use of avidin-biotin techniques increased sensitivity of antigen detection. Avidin 
has four binding sites for biotin. Biotin is easily conjugated to antibodies and enzyme 
markers. The secondary antibody is biotinylated and binds to one of the four biotin 
binding sites on the avidin. Peroxidase conjugated biotin is then added and binds to 
the other three biotin binding sites on the avidin (Hsu SM, Raine L, Fanger H 1981) 
(Figure 6).  
 
P 
Antigen 
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Figure 6 Diagrammatic representation of the use of indirect antibody 
immunocytochemistry with the avidin (black) and biotin (yellow) technique. HRP = 
horseradish peroxidase DAB= 3,3’-diaminobenzidine tetrahydrochloride 
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Although the avidin biotin methodology is routinely used in many laboratories there 
are some antigens which require amplification methods in order to be visualized. The 
tyramide amplification technique relies on the ability of phenolic compounds to 
become highly reactive and unstable when oxidized (Gross AJ, Sizer IW 1959). 
Dimerization of proteins can occur when biotinyl tyramide is oxidized (Bobrow MN 
et al. 1989) and this is used in immunocytochemistry to generate reactive biotinyl-
tyramide intermediates which bind to the protein close to peroxidase enzymes. This 
results in numerous biotin signals. Usually the primary antibody is associated with 
the peroxidase enzymes in a routine manner (avidin-biotin complex), the biotinyl 
tyramide and hydrogen peroxide are applied and generate biotin which is used to 
capture the peroxidase enzymes (Adams JC 1992) (Figure 7). 
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Figure 7 Diagrammatic representation of the use of tyramide amplification 
immunocytochemistry with the avidin (black) and biotin (yellow) technique. HRP = 
horseradish peroxidase DAB= 3,3’-diaminobenzidine tetrahydrochloride 
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Tissue used for routine diagnostic histology must be preserved in a fixative, typically 
formalin in the United Kingdom. The material is then processed and embedded in 
paraffin wax prior to sectioning. Cross-linking by the formalin results in masking of 
epitopes of the antigen (Mason JT, O’Leary 1991) and consequently retrieval of the 
antigen must be performed before immunocytochemistry can be performed 
successfully. Typically antigen retrieval is performed in either of the following ways; 
pressure cooking antigen retrieval or proteolytic enzyme digestion. Pressure cooking 
antigen retrieval boils the dewaxed paraffin sections in solutions (usually 0.01M 
citrate buffer (pH 6.0) although this varies with differing antigens) (Norton AJ, 
Jordan S, Yeomans P 1994). The enzyme digestion retrieval technique typically uses 
trypsin or protease (Huang S et al. 1976, Curran RC, Gregory J 1977). The exact 
mechanisms whereby enzymatic digestion releases the antigens is unknown, however 
it is presumed that digestion breaks down formalin crosslinking.  
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 Figure 8 Immunocytochemical phenotype of the germinal centre in a reactive lymph 
node, A) CD10 showing positive staining in GC original magnification x10 B) CD20 
original magnification x10 
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Figure 9 Immunocytochemical phenotype of the germinal centre of a reactive lymph 
nodes, A) Bcl-2 demonstrating negative staining of the germinal centre in a reactive 
follicle original magnification x10, B) Bcl-6 demonstrating positive staining of cells 
within the germinal centre. 
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Figure 10 Immunocytochemistry of the other cells present in the reactive lymph 
node, A) CD3 demonstrating reactive T lymphocytes mainly surrounding the reactive 
follicles but some within the follicles original magnification x10, B)CD21 
demonstrating follicular dendritic meshwork in the follicles original magnification 
x10, C) CD23 demonstrating follicular dendritic meshwork within the follicles 
original magnification x10 
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Figure 11 Immunocytochemistry for the proliferation marker Ki67 within the 
germinal centre of a reactive lymph node demonstrating the presence of numerous 
cells in cell cycle original magnification x10 
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1.6 Mature B cell neoplasms 
Mature B cell neoplasms comprise more than 90% of all lymphoid neoplasms 
worldwide (Anon 1997; Armitage JO, Weisenberger DD 1998) and are more 
common in developed countries. They represent clonal proliferations of B cells in all 
stages of differentiation and the classification of these neoplasms is based to some 
extent upon this phenomenon. 
 
Lymphomas are classified currently using the World Health Organization 
Classification of tumours system which was published in 2001 and has been updated 
in 2008. This system has evolved from a myriad of previous classification schemes 
and is based on the morphology, immunophenotype, genetics and clinical features of 
the disease. 
 
The most common are follicular lymphoma (FL) and diffuse large B cell lymphoma 
(DLBCL) which account for approximately half of all non-Hodgkin’s lymphomas 
(NHL) (Anon 1997; Armitage JO, Weisenberger DD 1998) and myeloma. 
 
1.7 Follicular lymphoma 
Follicular lymphoma is a malignant neoplasm of the follicle centre cells (centrocytes 
and centroblasts) typically with a characteristic follicular pattern of growth. It is the 
most common of the ‘indolent’ NHLs and accounts for 35% of adult NHL in the 
United States and 22% worldwide. Follicular lymphoma was first described in 1925 
by Brill, Baehr and Rosenthal who observed a clinical and pathological disease 
which presented with lymph follicle hyperplasia in the spleen and lymph nodes (Brill 
NE et al. 1925). Subsequently, Baehr and Rosenthal suggested that the disease was a 
tumour of lymph nodes arising in a multifocal pattern (Baehr G; Rosenthal N 1927). 
The possibility of transformation of follicular lymphoma to other lymphoid 
malignancies as part of the natural history of the disease was first observed and 
published in 1938 (Symmers D 1938). 
 
1.7.1 Clinical features 
Follicular lymphoma is a disease seen mainly in adults with a median age at 
presentation of 59 years and a slight female preponderance (Anon 1997). Commonly 
affecting the peripheral lymph nodes it also can involve the spleen, bone marrow and 
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peripheral blood. In patients with widespread disease numerous extra-lymphoid sites 
including the gastrointestinal tract may be affected.  Patients typically present with 
late stage widespread disease however they are usually asymptomatic. The median 
survival is ten years however there is a wide variation in overall survival with some 
patients dying from disease very quickly after diagnosis and others surviving for 
several decades (Figure 12). Death occurs as a result of disease progression in just 
under half of all cases (46%) with another 17% dying as a consequence of treatment 
related complications (Montoto S et al. 2007).  
 
 Figure 12 Overall survival from diagnosis of patients diagnosed with follicular 
lymphoma at St Bartholomew’s Hospital (Montoto S et al. 2005; 2007) 
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1.7.2 Histological structure and grading 
In keeping with the nomenclature and cell of origin the majority of follicular 
lymphomas are composed of neoplastic follicles with a follicular growth pattern. In 
comparison to normal reactive follicles the neoplastic follicles do not possess mantle 
zones or show polarization and are ill defined and closely packed. Neoplastic cells 
are also present in the areas between the follicles. There is usually complete 
effacement of architecture with extension of neoplastic cells over the capsule and 
sclerosis is often observed. Additionally loss of tingible body macrophages is seen 
along with a reduction in the number of apoptotic bodies. Within the follicles the 
neoplastic cells comprise both centrocytes and centroblasts (Figure 13). Recently an 
additional morphological pattern has been described with focal germinal centres 
staining positively for bcl-2 protein with a reactive morphology and 
immunophenotype in the remainder of the lymph node. These bcl-2 positive follicles 
have been shown to express monoclonal IgH gene rearrangements. In some patients 
there was synchronous FL at a different site and other patients subsequently 
developed FL. This pattern has been termed ‘in situ’ follicular lymphoma and may 
represent an early development stage of FL (Cong P et al. 2002). 
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Figure 13  Morphology of follicular lymphoma stained with H&E, A) Low power 
photomicrograph of a neoplastic follicle original magnification x10, B) 
Photomicrograph of a neoplastic follicle original magnification x 40 
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and prominent nucleoli, which are peripherally located. Follicular lymphoma is 
graded according to the number of centroblasts present. The World Health 
Organisation (WHO) recommends a three grade system which is based on the 
number of centroblasts in ten representative neoplastic follicles expressed per 40x 
microscopic field (hpf). Grade 1 contains 0-5 centroblasts/hpf, Grade 2 contains 6-15 
centroblasts/hpf and Grade 3 cases more than 15 centroblasts/hpf (Metter GE et al. 
1985, Nathwani BN et al. 1986). Grade 3 is further divided according to the number 
of centrocytes present; grade 3a contains more than 15 centroblasts/hpf with some 
remaining centrocytes. Grade 3b is composed of sheets of centroblasts with no 
centrocytes. Differences between grade 3a and 3b are not restricted to 
cytomorphologic features but are also seen at the immunohistochemical and 
cytogenetic level (Ott G et al. 2002). Grading appears to correlate with prognosis, 
grade 1 and 2 disease seem to have a similar indolent course with better overall 
survival but worse failure free survival (Martin AR et al. 1995) where grade 3 FL 
behaves in a more aggressive manner with a similar overall outcome to diffuse large 
B cell lymphoma (Bartlett NL et al. 1994; Wendum D et al. 1997). There is however, 
much variability in grading as this is a subjective technique (Metter GE et al. 1985; 
Anon 1997) which may impact treatment decisions.  
The WHO classification advocates that the pattern of nodularity is reported, 
expressed as percentage of nodular areas versus percentage of diffuse areas. The 
pattern is reported as follicular if >75% of the tumour is composed of nodules, 
follicular and diffuse if between 25-75% of the tumour is nodular, and focally 
follicular if <25% of the tumour is follicular. Patients with only focally follicular 
areas (<25%) have significantly worse freedom from progression and overall 
survival at 5 years in comparison to patients with >50% follicularity (Hu E et al. 
1985). The median survival of patients with a follicular pattern was 68.2 months 
compared with 39.6 months in patients with follicular and diffuse pattern (Ezdinli EZ 
et al. 1987). The presence of 50% of a diffuse component predicts a worse overall 
survival and event free survival in grade 3 follicular lymphoma patients treated with 
an anthracycline based regime (Hans CP et al. 2003). 
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1.7.3 Immunocytochemistry 
Immunophenotypically FL tumour cells are positive for pan B cell markers (CD20, 
CD19, CD22), CD10, Bcl-2 and Bcl-6 and negative for CD5. Bcl-2 is positive in the 
neoplastic follicles, which is the opposite pattern to that seen in reactive lymph 
nodes. CD23 and CD21 demonstrate the meshworks of the follicular dendritic cells 
within follicles (Figure 14). Assessment of the proliferation index using 
immunocytochemistry for Ki-67 has shown the proliferation index to be 
independently predictive of outcome in follicular lymphoma (Koster A et al. 2007). 
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Figure 14 Immunocytochemistry to demonstrate the immunophenotype of follicular 
lymphoma, A) CD10 positive in neoplastic follicles original magnification x10, B) 
CD20 positive in both follicles and interfollicular areas original magnification x10, 
C) CD21 positive meshwork in neoplastic follicles original magnification x10, D) 
CD23 positive meshwork in neoplastic follicles original magnification x10, E) BCL-
2 positive in cells within the neoplastic follicle as well as interfollicular cells original 
magnification x10, F) BCL-6 positive in cell in neoplastic follicles original 
magnification x10, G) Ki-67 demonstrating occasional positive cells within 
neoplastic follicles original magnification x10  
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1.7.4 Cytogenetic abnormalities 
Most cases of follicular lymphoma show cytogenetic abnormalities (Tilly H et al. 
1994). The most common genetic abnormality is a translocation involving 
chromosomes 14 and 18 (t(14;18)(q32;q21)). This is seen in approximately 70-95% 
of cases (Horsman DE et al. 1995) and results in the BCL2 gene being juxtaposed to 
the immunoglobulin heavy chain (IGH) gene. This results in overexpression of the 
BCL2 gene. Studies have shown that overexpression of Bcl2 in B cells grown in vitro 
prevents apoptosis even when growth factors are withdrawn (Nunez G et al. 1990). 
This genetic abnormality alone is not sufficient for the development of FL as 
IGH/BCL2 gene rearrangements have been observed at low levels in healthy blood 
donors (Limpens J et al. 1995; Dolken G et al. 1996; Summers K et al. 2001) and in 
benign lymphoid tissue (Limpens J et al. 1991). Cytogenetic differences are seen 
between Grade 3a and Grade 3b cases, and a comparative study of FL grade 3a and 
3b demonstrated t(14;18) in 73% of FL grade 3a cases but only in 13% of Grade 3b 
cases (Ott G et al. 2002). In the majority of cases of FL there are numerous other 
abnormalities most commonly involving chromosomes 1, 2, 4, 5, 13 and 17 or 
additions of X, 7, 12, or 18 (Tilly H et al. 1994). Abnormalities of 6q23-36 are 
detected in between 10-40% of B cell lymphomas. There may be three separate 
tumour suppressor genes within this region as deletions have been demonstrated at 
6q21, 6q23 and 6q25-27 (Offit K et al. 1993). Breaks in 3q27 are observed in 44% of 
FL grade 3b in comparison to 18% of grade 3a (Ott G et al. 2002). The average 
number of genetic aberrations increases with grade with increased numbers of 
complex abnormalities in patients with higher grade tumours (Viardot A et al. 2002).  
 
1.7.5 Treatment and Prognosis 
Follicular lymphoma is a heterogeneous disease with varying survival rates and 
numerous treatment options.  In some patients the disease is relatively indolent, 
however the lymphoma is usually not curable and the median survival is between 8 
and 10 years after diagnosis (Gallager CJ et al.1986) (Figure 12). There are a 
proportion of patients with a significantly shorter duration of survival. Treatment 
options range from a conservative watch and wait policy for those patients who are 
symptom free with no apparent detrimental effect (Brice P et al. 1997, Advani R et 
al. 2004) through more aggressive treatments dependent upon the requirements of 
individual patients. Traditionally, the treatment options include radiotherapy, oral 
Chapter One: Introduction 
60 
chemotherapy and varying combinations of chemotherapeutic drugs (Cohen Y, 
Solal-Celigny P, Polliack A 2003). Radiotherapy has been shown to be curative for 
some patients with early stage low-grade FL (Mac Manus MP, Hoppe RT 1996). The 
alkylating agents cyclophophamide and chlorambucil have used either singly or in 
combination with other agents for many years. The use of single agent treatment has 
shown a response rate of between 50% and 75% in FL (Portlock CS et al. 1976; 
Gallagher CJ et al. 1986). The combination of alkylating agents with anthracyclines 
does not improve the response rate (Dana BW et al. 1993; Peterson BA et al. 2003) 
but may incur less risk of transformation (Young RC et al. 1988). The relatively new 
purine analogs have also shown efficacy in the treatment of non-Hodgkin’s 
lymphomas (Redman JR et al. 1992; Hochster HS et al. 1992). Monotherapy with 
fludarabine produced response rates of 65% to 84% with complete remission in 37% 
to 47% of patients with previously untreated FL (Zinzani PL et al. 2000). In many 
cases, due to the protracted nature of the disease, various combinations of different 
treatment modalities are used. The combination of the purine analogs fludarabine and 
mitoxantrone with dexamethasone is effective in inducing complete remission in 
47% of patients with recurrent and relapsed follicular lymphoma and a partial 
remission in 47% of patients. The median failure free survival time for patients in 
complete remission was 21 months (McLaughlin P et al. 1996). The development of 
a monoclonal antibody to the CD20 antigen has proved to be an exciting and 
extremely valuable addition to the range of therapeutic agents used to treat follicular 
lymphoma. Initial studies showed that the response rate to the drug was 48% with 
only mild toxicity. This figure is compatible to that seen in single agent 
chemotherapy (McLaughlin P et al. 1998). In addition, monoclonal antibodies can be 
used to deliver other therapeutic agents e.g. radioisotopes to the tumour cells (Witzig 
TE et al. 1999). A recent comparison of CHOP +/- rituximab versus fludarabine plus 
mitoxantrone (FM) +/- rituximab as initial treatment has shown that the FM 
combination is more effective than CHOP achieving complete remission in 68% of 
patients compared to 42%. No difference was found in terms of overall survival or 
progression free survival (Zinzani PL et al. 2004). Patients with disseminated disease 
who have not responded to conventional treatment or who have relapsed may benefit 
from intensive therapies such as high dose therapy (HDT) followed by autologous or 
allogeneic bone marrow transplantation (Apostolidis J et al. 2000; Bastion Y et al. 
1995; Bierman PJ et al. 1997). The results from the studies on HDT followed by 
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stem cell transplantation indicate that prolonged failure free survival can be achieved 
by this option however prolonged survival or cure is not attained (Apostolidis J et al. 
2000; Bastion Y et al. 1995; Bierman PJ et al. 1997). 
 
Unfortunately, there is no general consensus on which of these treatments should be 
used for FL (Solal-Celigny P et al. 2004).There is no clear cut pathway for treatment 
of patients with FL and although there is evidence of the use of treatment entities in 
FL there is no evidence as to the order in which these treatments should be used 
(Gribben JG 2007). The use of chemotherapy (single agent or combination) as initial 
treatment in comparison to watch and wait does not improve survival (Brice P et al. 
1997; Young RC et al. 1988). It is also difficult to predict which patients have 
disease which will behave in an aggressive manner and in whom more proactive 
treatment is warranted. A recent multicentre analysis has identified five adverse 
prognostic factors which can segregate patients into three risk groups. The five risk 
factors selected are age (over 60 years compared to 60 years and under), Ann Arbor 
stage (III-IV vs I-II), haemoglobin level (less than 120g/L compared to 120g/L or 
over), number of nodal areas (more than 4 or 4 and under) and serum lactate 
dehydrogenase (LDH) level (high compared to normal or below).  The three risk 
groups are low risk (0-1 adverse factor), intermediate risk (2 factors) and poor risk (3 
or more adverse factors). The 5 year overall survival in the low risk group was 
88.1%, the intermediate risk group between 57.4 and 70.9% and the poor risk group 
43.6%. This index, named the Follicular Lymphoma International Prognostic Index 
(FLIPI), provides a consistent platform for comparison of clinical trials and 
evaluation of new treatments (Solal-Celigny P et al. 2004). In FL patients at first 
relapse/progression, the FLIPI, along with the presence of B symptoms, can predict 
five-year survival from progression and so may help in treatment decisions (Montoto 
S et al. 2004).  There are difficulties with this index as stratification of patients into 
risk groups is limited. In addition, the index is rarely used as a tool to drive treatment 
choices in a clinical setting. 
 
Typically the clinical course of follicular lymphoma is that of a relapsing and 
remitting disease with a reduced response to treatment and duration of remission 
over time with eventual death from disease (Johnson P et al. 1995). 
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1.8 Diffuse large B cell lymphoma (DLBCL) 
Between 25 and 35% of patients with follicular lymphoma transform to diffuse large 
B cell lymphoma (DLBCL) (Acker B et al. 1983; Gallagher CJ et al. 1986; Montoto 
S et al. 2007) (Figure 15). This is a neoplasm of large B cells which typically 
replaces tissue in a diffuse pattern. Within the disease entity several morphological 
variants have been described by the WHO classification system. This disease can 
also arise in patients without a pre-existing lymphoid neoplasm, so called de novo 
DLBCL.  
 
 
Figure 15 Morphology of DLBCL stained with haematoxylin and eosin original 
magnification x40 
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1.8.1 Clinical Features 
Patients with DLBCL typically present with single disease sites however the disease 
is aggressive and will result in death if not treated. A proportion of patients present 
with extranodal disease particularly in the skin and gastrointestinal tract.  
 
1.8.2 Immunocytochemistry 
In keeping with the B cell origin the tumour cells are positive for pan B cell markers 
(CD19, CD20 and CD22). There is variable expression of CD5 (approximately 10% 
of cases) and CD10 (approximately 25% of cases).  Expression of Bcl-2 is more 
commonly seen and is observed in between 30 and 50% of cases. The proliferation 
fraction, as expressed by ki67 expression, is high. Typically there is loss of the FDC 
meshworks identified by CD21 and CD23 immunocytochemistry. 
 
1.8.3 Cytogenetic abnormalities 
The most common translocation in DLBCL is t(14;18) which is detected in 20 - 30% 
of cases (Weiss LM et al. 1987; Offit K et al. 1991a). Translocation of the c-MYC 
gene to the immunoglobulin heavy chain gene; t(8;14) is also observed in a 
proportion of cases (Ladyani M et al. 1991) and confers a worse outcome with 
aggressive disease (Vitolo U et al. 1998). Additional abnormalities have been 
observed which correlate with clinical outcome; patients with breaks at 1q21-23 or 
1p32-36 had a shorter remission time and patients with breaks at 6q21-25 were less 
likely to achieve remission (Offit K et al. 1991). 
 
1.9 Transformation of FL to DLBCL 
 Transformation of FL to aggressive morphology, usually DLBCL, is an area fraught 
with difficulty. The mechanisms of transformation are unclear and as a result, 
prediction of patients who will transform is difficult. Indeed the incidence of patients 
who transform varies widely. Clear evidence of transformation is only provided by 
histological analysis of a biopsy however the biopsy rate is extremely variable. In 
some centres, the presence of clinical symptoms, rapid enlargement of lymph nodes 
or elevation of biochemical markers are sufficient for the diagnosis to be made and 
treatment instigated. Numerous studies over the years have produced data on this 
phenomenon and the incidence ranges from 12% to 68%. A study in 1983 observed a 
12% incidence of transformation in 83 patients with untreated FL followed for a 
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median of 50 months (Horning S; Rosenberg SA 1984). Post-mortem investigations 
have demonstrated a much higher incidence of transformation; 68% (Garvin et al. 
1983). Data from St Bartholomew’s hospital, based on patients with histological 
evidence of transformation, demonstrated transformation in 88 patients out of a 
possible 328 prior to 2000. Transformation occurred during the time between initial 
diagnosis of FL and 16 years after diagnosis however no patient transformed after 
16.2 years (Montoto S et al. 2007).  
 
A study by Bastion et al. identified three factors which indicated patients likely to 
transform; failure to achieve complete remission after primary treatment, low serum 
albumin (<35 g/L) and raised β2-microglobulin (>3 mg/L) at diagnosis. In their 
cohort of patients the median survival time after transformation was only seven 
months and accounted for 44% of deaths (Bastion Y et al. 1997), in keeping with the 
clinical observation that patients who undergo transformation have a poor prognosis. 
This observation is again demonstrated in the data produced by St Bartholomew’s 
Hospital (Figure 16, Figure 17).  
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Figure 16 A Kaplan-Meier curve to show survival from transformation (n=88) in 
patients at St Bartholomew’s Hospital (Montoto S et al. 2007) 
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Figure 17 Overall survival according to transformation (Montoto S et al. 2005; 
2007) 
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A large study of 276 patients assessed the main biological and clinical variables with 
respect to correlation with transformation and survival. Of the 276 patients 30 (11%) 
had undergone histological transformation after a median follow up of 6.5 years. The 
risk of transformation at 10 years and 15 years was 15% and 22% respectively. 
Grade 3 histology and the FLIPI score were of prognostic significance, however in 
grade 1-2 patients only the FLIPI predicted transformation (Gine E et al. 2006). The 
study at St Bartholomew’s hospital also showed the risk of transformation was 
higher in patients with advanced stage at presentation and a high risk FLIPI (Figure 
18) (Montoto S et al. 2005; 2007).  
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Figure 18 Prognostic factors for transformation at diagnosis in patients from St 
Bartholomew’s Hospital (Montoto S et al. 2005; 2007) A) FLIPI at presentation B) 
Stage at presentation 
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The natural history of FL is an indolent disease typically characterized by numerous 
relapses and remissions. The relationship of relapse and disease progression and 
transformation is also unclear. Analysis of the data from St Bartholomew’s Hospital 
shows a constant rate of transformation for each episode of relapse; 17%, 14%, 14% 
and 14% for 1st, 2nd, 3rd and 4th episodes respectively (Figure 19) (Montoto S et al. 
2005; 2007). 
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Figure 19 Risk of transformation at each disease relapse in patients from St 
Bartholomew’s Hospital (Montoto S et al. 2005; 2007) 
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1.9.1 Mechanisms of transformation 
As indicated previously, the mechanisms by which transformation of FL to DLBCL 
occur are incompletely understood. A number of cytogenetic abnormalities, both 
gains and losses, have been reported which may be important in the pathogenesis of 
transformation.   
 
1.9.1.1 Chromosome gains 
Gains in the region 2p13-16 were detected by comparative genomic hybridization 
(CGH) and PCR analysis of this region identified amplification of the REL gene in 
half of a small group of patients with FL who subsequent transformed (Goff LK et al. 
2000).  
 
Gain at chromosome 7 has been observed in 30% of Non-Hodgkins lymphoma cases 
with the t(14;18) and was associated with a diffuse pattern. Gain of chromosome was 
present in 52% of patients with a diffuse pattern compared to 15% of patients with a 
follicular growth pattern (Armitage JO et al. 1988). A larger study identified a gain 
of chromosome 7 as the most common cytogenetic abnormality in t(14;18) 
lymphomas (Johansson B, Mertens F, Mitelman F 1995). A further study identified a 
gain of chromosome 7, in particular 7p, in 5 out of 6 cases at the time of 
transformation. Loss of 9q in combination with gain of 7p was observed in 4 out of 5 
cases of FL grades 1 or 2 which transformed to DLBCL (Boonstra R et al. 2003).  
 
Gains in chromosome 12q12-14 were detected in 52% of transformed cases but were 
not present in the preceding FL sample. Patients with gains in this region tended 
towards a poorer outcome in comparison to patients without this cytogenetic 
alteration although this did not reach statistical significance (Hough RE et al 2001). 
Analysis of three genes which map to this area; CDK2, CDK4 and GADD153 in a set 
of 44 paired FL/DLBCL samples (22 patients) demonstrated deregulation of CDK2 
and CDK4 genes at both a genetic and protein level suggesting a functional role for 
these genes in the transformation process. The expression of GADD153 protein was 
not detected in most cases (Al-Assar O et al 2006). Patients with abnormalities of 
6q23-26 were at significantly higher risk of transformation to DLBCL (Tilly H et al. 
1994). 
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1.9.1.2 Chromosome losses 
A commonly implicated gene in transformation is TP53 (Sander CA et al. 1993) 
which is located at chromosome 17p13. Loss of 17p has been linked to both inferior 
survival and a shorter time to transformation (Tilly H et al. 1994). The possible role 
of TP53 in transformation will be discussed in Chapter 2. 
 
The presence at time of diagnosis of FL of a deletion involving bands 6q23-26 is 
significantly associated with increased risk of transformation and a shorter survival 
time (Tilly H et al. 1994). 
 
Losses of 5p and 8q have also been observed in transformation samples in 
comparison to antecedent FL biopsies (Hough RE et al 2001).  
 
1.9.1.3 p16INK4a 
The use of polymorphic microsatellite markers in the 9p21 region, which contains 
the tumour suppressor genes p15INK4B (CDKN2B) and p16INK4A  (CDKN2), in a series 
of 11 paired FL and transformed DLBCL samples, identified deletions exclusively in 
the DLBCL samples in 8 of 11 cases (73%). Six of these were homozygous (54%) 
and two were hemizygous (18%). Immunocytochemistry demonstrated positive 
staining for p16 in FL tumour cells in nine available cases which were evaluable, 
with reduced protein expression in 4 of the 9 (44%) cases of DLBCL. All 4 cases 
demonstrated homozygous mutation deletions at 9p21. The remaining 5 cases with 
p16 protein expression retained at least one 9p21 allele (Elenitoba-Johnson KSJ et al. 
1998). A further study identified p16 alterations as an infrequent event in NHL but 
loss of protein expression was associated with aggressive tumours and a potential 
role in transformation (Pinyol M et al. 1998). These results suggest genetic loss in 
the region of 9p21 involving p16 and possibly p15 may be important in the process 
of transformation.  
 
1.9.1.4 BCL-2 
Alterations in Bcl-2 are implied as a result of the t(14;18) in FL however, additional 
genetic abnormalities have been identified upon transformation to DLBCL. Biopsies 
from eight patients with FL were analysed, of which 6 transformed to DLBCL. A 
high level of conservation of the bcl-2 gene was observed during the t(14;18) and 
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morphological alteration. Three DLBCL samples contained 11 point mutations in the 
open reading frame which were not present in the antecedent FL samples suggesting 
that transformation may be associated with somatic point mutation of the bcl-2 gene 
(Matolcsy A et al. 1996). The presence of bcl-2 rearrangement in de novo DLBCL 
correlates with worse outcome (Yunis JJ et al. 1989). 
 
1.9.1.5 BCL-6 
An important gene in the pathogenesis of de novo DLBCL is the Bcl-6 proto-
oncogene which is located on 3q27. The product is a 79-kilodalton protein 
homologous with zinc finger-transcription factors (Ye BH et al. 1993a, Ye BH et al. 
1993b) and is essential for germinal centre formation (Ye BH et al. 1997). 
Rearrangements of Bcl-6 have been detected in approximately 40% of cases of 
DLBCL (Lo Coco F et al. 1994) and correlate with a favourable clinical outcome 
(Offit K et al. 1994). In a third of DLBCL samples the Bcl-6 gene is truncated within 
the 5’ noncoding sequences indicating that its expression is deregulated (Ye BH et al. 
1993b). Bcl-6 is able to function as a transcriptional repressor (Seyfert VL et al. 
1996) and is expressed by centroblasts and centrocytes in germinal centres as well as 
CD4 T lymphocytes. The presence of Bcl-6 protein in FL and DLBCL independent 
of gene rearrangement suggests that Bcl-6 is regulated during B cell development 
and plays a role in germinal centre formation (Cattoretti G et al. 1995).  Expression 
of the Bcl-6 protein is seen in both FL and DLBCL (Onizuka T et al. 1995). The 
frequency of alterations of the Bcl-6 gene in FL is much lower than de novo DLBCL 
ranging from 6-14% (Bastard C et al. 1994; Lo Coco F et al. 1994; Otsuki T et al. 
1995). The incidence of Bcl-6 gene rearrangements in transformed FL varies; the 
study by Otsuki et al. 1995 demonstrated an incidence of 17.3%. Eleven cases of 
transformed FL with the antecedent FL biopsies were available and in only two of 
these cases was Bcl-6 rearranged. In both cases the rearrangements were present in 
both FL and transformed samples suggesting Bcl-6 rearrangements are not 
temporally associated with transformation (Otsuki T et al. 1995). In contrast, a study 
by Lossos and Levy observed new mutations in Bcl-6 in 5 out of 7 transformed FL 
samples which were not present in the preceding FL biopsy. The numbers of 
mutations ranged from 1 to 6 and clustered in areas of the 5’ noncoding regulatory 
region of the Bcl-6 gene (Lossos IS, Levy R 2000). This result suggests that 
deregulation of Bcl-6 may be important in the pathogenesis of transformation. Bcl-6 
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has been demonstrated to repress the gene coding for ATR which is important in 
sensing DNA damage. Reduction in the levels of ATR in B lymphocytes by Bcl-6 
allowed primary centroblasts to survive DNA damage. This was mediated by 
reduced phosphorylation of histone H2AX and the checkpoint regulator Chk1. The 
levels and function of ATR were restored by CD40-mediated disruption of the Bcl-6 
complex (Ranuncolo SM et al. 2007). In addition Bcl-6 can downregulate the 
expression of p53 (Phan RT, Dalla-Favera R 2004). 
 
Much of the emphasis has been on evaluation of mutations and their contribution to 
the process of transformation. There has been very little investigation into the role 
which the microenvironment has to play in transformation and a single event which 
results in transformation has not been identified. This suggests that there may be 
several pathways which result in transformation of FL to DLBCL and an interaction 
between mutations and the microenvironment may play a role in this process. 
Transformation is such an adverse event that the ability to predict those patients 
likely to transform at diagnosis would be extremely valuable. 
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1.10 The role of the microenvironment in lymphomagenesis 
Speculation on the role that the immune system plays in the development and 
progression of malignant tumours is not a recent development. Virchow suggested in 
1863 that there may be a causal relationship between chronic inflammation and the 
development of cancer (Balkwill F, Mantovi A 2001). There are several pieces of 
evidence which support this idea. In those malignancies where infectious agents are a 
known causal agent the initial response to the infection is inflammatory, for example 
Helicobacter pylori infection increases the risk of developing gastric cancer by an 
odds ratio of 2.77 (Forman D et al. 2001). Infection with Hepatitis C virus is a well 
recognized risk factor for the development of hepatocellular carcinoma (Colombo M 
et al. 1989; Hasan F et al. 1990).  In addition, the increased risk of patients with 
autoimmune disease, such as ulcerative colitis, in developing malignancy indicates a 
role for inflammation in oncogenesis (Gyde SN et al. 1988). These findings are 
counterintuitive to the known role of the immune system. There is an expectation 
that the immune system should mount an anti-tumour reponse however the tumour – 
immune microenvironment interaction appears to be extremely complex and this is 
reflected by the numerous and often conflicting observations about the numbers and 
types of tumour infiltrating lymphocytes (TILs) within malignancies and correlation 
of these with prognosis for example, in patients with melanoma there have been 
reports of improved prognosis in patients with TILs (Clemente CG et al. 1996) whilst 
other reports have found no association (Barnhill RL et al. 1996). Recent data 
suggests that the absence of TILs in a primary cutaneous melanoma predicts sentinel 
lymph node metastasis in patients, SLN involvement is the most important predictor 
of survival in patients with melanoma (Taylor RC et al. 2007).  
 
1.10.1 TILs in FL 
There are several lines of evidence that the immune microenvironment is important 
in the biology of FL. Numerous CD4 T lymphocytes have been observed 
predominantly in the interfollicular areas, as well as the neoplastic follicles of FL 
(Swerdlow SH et al. 1985). Significantly more CD4+ T lymphocytes have been 
observed in the biopsies of untreated FL patients who underwent spontaneous 
regression than in the biopsies of those who did not (Strickler JG et al. 1988). These 
observations suggested that T lymphocytes might have an important role in FL. Gene 
expression profiling of FL biopsies from untreated patients produced two gene 
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expression signatures which allowed grouping of patients into quartiles with large 
differences in survival. These signatures were demonstrated to be a result of gene 
expression by tumour infiltrating cells and were independent of clinical parameters. 
The two signatures were denominated immune-response 1 (IR1) and immune-
response 2 (IR2). The IR1 response was associated with favourable prognosis and 
included genes coding for T lymphocyte markers and macrophages markers. The IR2 
response associated with poor prognosis, and contained genes for markers expressed 
by macrophages, dendritic cells or both (Dave SS et al 2004).  Supporting evidence 
at a protein level was provided by immunohistochemical analysis of 99 diagnostic 
FL lymph node biopsies which demonstrated a correlation between increased 
numbers of CD68 positive macrophages and poor prognosis. However, analysis of T 
lymphocyte markers did not identify an improved prognosis with their expression as 
suggested by the IR1 response (Farinha P et al. 2005).  
 
1.10.2 Regulatory T lymphocytes  
There is growing interest in the role of the T-regulatory (Treg) cell subset in human 
diseases. The demonstration of T lymphocytes which could suppress the immune 
system was shown by transfer of antigen experienced T lymphocytes into naïve mice 
producing antigen specific tolerance (Gershon RK, Kondo K 1971). It was not until 
the identification of a population of CD4 T lymphocytes with high levels of CD25 
expression which could prevent autoimmunity in mice, that interest in these cells 
became widespread (Sakaguchi S et al. 1995). These CD4+CD25+ regulatory T cells 
account for approximately 10% of CD4+ T lymphocytes in the spleen and lymph 
nodes of normal mice (Cederbom L et al. 1998) but only 1-2% of the CD4 postive T 
lymphocytes in humans (Baecher-Allan C et al. 2001) In murine models CD25 is an 
acceptable marker to delineate a Treg as the animals are maintained in pathogen free 
environments. In humans, exposure to antigens produces an increase in CD25 
positive effector T lymphocytes. Therefore a marker specific for T regulatory cells 
was required. Genetic mutations of the transcription factor, FOXP3, in both mice and 
humans were identified as the defect resulting in fatal autoimmune disease in the 
scurfy mice (Brunkow ME et al. 2001) and human X-linked neonatal diabetes 
mellitus, enteropathy and endocrinopathy (IPEX) (Bennett CI et al. 2001) Using a 
Foxp3gfp reporter allele in mice, Foxp3 expression was demonstrated to be restricted 
to only Tregs (Fontenot JC et al. 2005a). Deletion of germline Foxp3 in mice 
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resulted in a lack of Tregs in the thymus and development of autoimmune disease 
which could be ameliorated by the adoptive transfer of Tregs into Foxp3 deficient 
neonates (Fontenot JD et al. 2003; Fontenot JD et al. 2005a). Furthermore, the 
continued expression of Foxp3 is required in mature Tregs to maintain the 
suppressive function of Tregs. Loss of Foxp3 in these cells allowed reversal of the 
Treg transcriptional program and the production of proinflammatory cytokines with 
pathogenic potential. (Williams LH, Rudensky AY 2007). Regulatory T cells 
originate in the thymus (Modigliani Y et al. 1996). 
 
1.10.2.1 Types of regulatory T cells 
Several types of T regulatory cells have been defined. Naturally occurring Tregs, 
which are produced in the thymus and are exported as fully functional cells (Itoh M 
et al. 1999). The other subtypes are induced regulatory cells; Tr1 cells are generated 
from chronically activated CD4+ T lymphocytes in both mice and humans in the 
presence of IL10. This subset of cells produce high levels of IL-10, low levels of IL-
2 and no IL-4 and can suppress the proliferation of CD4+ T lymphocytes in response 
to antigen. They can also prevent colitis induced in SCID mice by pathogenic 
CD4+CD45RBhigh splenic T lymphocytes (Groux H et al. 1997). Th3 cells, can be 
generated in vivo after oral administration of antigen and produce TGF-β as well as 
IL-4 and IL-10 (Chen Y et al. 1994). Finally a small population of regulatory cell 
which express CD8 as opposed to CD4 have been identified (Xystrakis E et al. 
2004).  
 
1.10.2.2 Functions of regulatory T cells 
Functionally Tregs do not proliferate when stimulated via the T cell receptor (TCR) 
but can proliferate when stimulated by interleukin-2 (IL-2) (Thornton AM, Shevach 
EM 1998; Thornton AM, Shevach EM 2000). Indeed IL-2 signalling is required for 
maintenance of optimal Treg function in vivo (Fontenot JD et al. 2005b). When 
activated by their TCR, Tregs suppress proliferation of CD4+ T lymphocytes 
(Thornton AM, Shevach EM 1998) and CD8+ T lymphocytes (Piccirillo CA, 
Shevach EM 2001) by inhibiting IL-2 mRNA transcription (Thornton AM, Shevach 
EM 1998). The suppression is dependent on cell-contact and is cytokine independent 
in those Tregs produced in the thymus (Thornton AM, Shevach EM 2000; Piccirillo 
CA, Shevach EM 2001). Tregs are also able to suppress production of IL-4 and IFN-
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γ suggesting that Foxp3 may block transcriptional activators required for activation 
of multiple cytokine genes. In support of this theory, Foxp3 was demonstrated to 
associate with the nuclear factor of activated T cells (NFAT) and NF-κB in murine 
models. This prevented endogenous expression of the target genes of NFAT and NF-
λB which include cytokine genes (Bettelli E, Dastrange M, Oukka M 2005). The 
target genes of Foxp3 are key modulators of T cell activation and function and the 
major effect of Foxp3 is to suppress the activation of genes responsible for T cell 
stimulation (Marson A et al. 2007). Although Foxp3 function is required for 
regulatory T cell suppressor function it also increases pre-established molecular 
features of regulatory T cells including anergy and dependence on IL-2. In addition, 
Foxp3 modifies cell surface and signalling molecules including suppressing the 
cyclic nucleotide phosphodiesterase 3B which is essential to regulatory T cell 
maintenance (Gavin MA et al. 2007). 
 
1.10.2.3 The role of regulatory T cells in cancer 
The role of the T-regulatory (Treg) cell subset in the tolerance or suppression of 
malignancy is now being unravelled. Infiltrating Tregs are associated with 
suppression of tumour specific T cell immunity and poor prognosis in ovarian 
carcinoma (Curiel, TJ et al. 2004) amongst numerous other epithelial malignancies 
(Loddenkemper C et al. 2006, Fu J et al. 2007). Increased numbers of regulatory T 
cells have been observed in the metastatic lymph nodes of patients with malignant 
melanoma which actually inhibit the function of infiltrating cytotoxic T lymphocytes 
and CD4 positive non regulatory T lymphocytes (Viguier M et al. 2004). In 
haematological malignancy the picture is much less clear. Functional Treg have been 
identified in B-Non Hodgkin’s Lymphomas (Carrreras J et al. 2006; Yang ZZ et al. 
2006) and expression of forkhead transcription factor 3, (FOXP3), the defining 
antigen of Tregs, has been shown to correlate with improved outcome in FL 
(Carreras J et al. 2006).  
 
FOXP3 has three functional domains: a C2H2 zinc-finger motif (amino acids 200-
223) whose function is unknown, a leucine-zipper-like motif (aa 240-261) and the 
carboxy-terminal forkhead domain (aa 338-421) which binds DNA. Mutations 
causing IPEX having been detected in the forkhead domain, the leucine zipper and 
the N-terminal portion of the protein (Lopes JE et al. 2006). Mutation in the leucine 
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zipper domains impairs dimerization and suppressive function (Chae WJ et al. 2006). 
Foxp3 is constitutively localized in the nucleus and this requires sequences at both 
the amino and C-terminal ends of the forkhead domain. A functional domain in the 
N-terminal half of Foxp3 is required for repression of transcription from a 
constutively active and a NF-AT inducible promoter (Lopes JE et al. 2006). FOXP3 
protein is detected as a doublet (Yagi H et al. 2004; Walker MR et al. 2003, Scotto L 
et al. 2004) with the lower band of the doublet representing a splice isoform lacking 
exon 2 (Yagi H et al. 2004, Scotto L et al. 2004). The splice variant lacking exon 2 
and a newly identified variant lacking both exons 2 and 7 are both functional 
inhibitors of human CD4+ T-cell activation (Smith EL et al. 2006).  
 
1.10.3. Tumour associated macrophages 
Tumour associated macrophages (TAMs) have been analysed in numerous tumours 
including breast (Leek RD et al. 1996), bladder (Hanada T et al. 2000), and prostate 
(Lissbrant IF et al. 2000) cancer and have been associated with inferior survival. In 
some malignancies, stomach (Ohno S et al. 2003), colorectal (Funada Y et al. 2003) 
and melanoma (Piras F et al. 2005) high numbers of TAMs have been correlated with 
favourable prognosis. In follicular lymphoma the lymphoma-associated macrophage 
(LAM) content is an independent predictor of survival with increased numbers being 
associated with poor overall survival (Farinha P et al. 2005).  
 
1.10.4 The role of the immune microenvironment in transformation of FL to DLBCL 
The role the microenvironment may play in the process of transformation of FL to 
DLBCL has not been fully explored. The observations made in FL and in de novo 
diffuse large B-cell lymphoma suggest that it may play an important role. The data in 
de novo diffuse large B-cell lymphoma is from several studies with conflicting 
results; low numbers of CD8 positive T lymphocytes were associated with a poor 
outcome in one study (Lippman SM et al. 1990) however the presence of >15% of 
activated cytolytic T lymphocytes was strongly associated with failure to reach 
complete remission, with a poor progression-free and overall survival in a different 
study (Muris JJ et al. 2004). The presence of high numbers of CD4 positive T 
lymphocytes was associated with significantly longer 5 year failure-free survival as 
well as being an independent predictor of relapse free and overall survival (Ansell 
SM et al. 2001). This was also demonstrated in a study using flow cytometry where 
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cases with high numbers of T lymphocytes (>20%) and a CD4:CD8 ratio of >2.0 
demonstrated significantly improved overall survival (Xu Y et al. 2001). A recent 
study using immunocytochemistry on paraffin embedded tissue in 195 patients has 
described significantly improved outcome in patients with a small number of 
cytotoxic T-cell intracytoplasmic antigen-1 (TIA-1) however, there was no 
correlation with the number of regulatory T cells (Hasselblom S et al. 2007). There 
has been little published work in transformation although Carreras et al. (2006) 
demonstrated that increased number of FOXP3 positive cells were associated with 
improved survival in FL patients and a marked reduction in FOXP3 positive cell 
number was observed on transformation of FL to DLBCL (Carreras J et al. 2006).  
 
 1.11 Aims and Objectives 
Follicular lymphoma is a heterogeneous disease typically characterized by numerous 
relapses and remissions. At presentation, it is extremely difficult to predict which 
patients will have aggressive disease and die rapidly of disease and those in whom 
the disease pursues a more indolent cause. In addition, a substantial proportion of 
patients will transform to aggressive histology which is a clinically catastrophic 
event. There has previously been a great deal of work on the genetic defects which 
contribute to the development of FL as well as transformation to DLBCL. Recently, 
there has been interest in the role the microenvironment plays in lymphomagenesis, 
disease progression and transformation of FL to DLBCL. The main hypothesis of 
this thesis is that the immune microenviroment has an impact on the natural history 
of follicular lymphoma. The primary aim of this thesis is to examine the role the 
microenvironment has in the natural history of follicular lymphoma and in patient 
outcome. In addition, a limited study of some putative molecular mechanisms, as 
well as the impact of the immune microenvironment in transformation of FL to 
DLBCL are investigated. 
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2.1 Materials and method for cell culture 
2.1.1 Materials 
 
RPMI medium 
500 milliliters (mLs) of RPMI 1640 medium with Glutamax I (Gibco) was enriched 
with 10% foetal calf serum (FCS) (v/v) (Gibco) and 1% streptomycin/penicillin 
added. The RPMI solution was then filtered through a 0.2 millimetre (mm) mesh of a 
Stericup vacuum driven filtration system (Millipore, Billerica, MA).   
 
2.1.2 Methods 
All glassware used for cell culture was heated to 220˚C for 12 hours to ensure 
sterility from endotoxins. Cells frozen in liquid nitrogen were removed and thawed 
rapidly at 37˚C and the sample added dropwise to 10 mLs of RPMI/FCS/antibiotic 
solution. The solution was centrifuged for 5 minutes 1200rpm at 19˚C and the 
supernatant removed. The cell pellet was resuspended and 10mLs of 
RPMI/FCS/antibiotic solution added. The solution was centrifuged again for 5 
minutes 1200rpm at 19˚C and the supernatant removed. The cell pellet was 
resuspended with 10 mLs of RPMI/FCS/antibiotic solution. 10mLs of 
RPMI/FCS/antibiotic solution was placed in a sterile medium sized culture flask 
(200mLs) (Nunc, Denmark) and the cell suspension added. Cells were grown as a 
monolayer in sterile flasks in a humidified atmosphere at 37˚C containing 5% carbon 
dioxide. At 80% confluency the cells were passaged by trypsinisation. The media 
was discarded and 10mLs of 0.05% tryspin was added to the flask and incubated for 
4 minutes at 37°C. The cells were detached from the flask and were removed. Cells 
were pelleted by centrifugation at 1,300g for 5 minutes, re-suspended in medium and 
split and transferred into new flasks.  
 
2.2 Materials and methods for Flow cytometry 
2.2.1 Materials 
Buffer (Miltenyi Biotec Inc, Earhart Avenue, CA, USA) 
Phopshate buffered saline (PBS), pH 7.2, 0.5% bovine serum albumin (BSA), and 
2mM EDTA 
 
FcR Blocking Reagent (Miltenyi Biotec Inc, Earhart Avenue, CA, USA) 
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Human IgG 
 
Fixation and Permeabilization solution (Miltenyi Biotec Inc, Earhart Avenue, CA, 
USA) 
Fixation/Permeabilization Solution 1 (Miltenyi Biotec Inc, Earhart Avenue, CA, 
USA) diluted 1:4 with Fixation/Permeabilization Solution 2 (Miltenyi Biotec Inc, 
Earhart Avenue, CA, USA) 
 
Permeabilization Buffer (Miltenyi Biotec Inc, Earhart Avenue, CA, USA) 
Dilute 10X Permeabilization buffer (Miltenyi Biotec Inc, Earhart Avenue, CA, USA) 
with distilled water to 1:10 concentration 
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Table 2 Antibodies used for Flow Cytometry 
 
Antigen Conjugate Dilution Amount 
(µL) 
Isotype Manufacturer 
CD3 APC 1:11 10 IgG2a Miltenyi Inc 
CD4 FITC 1:11 10 IgG2a Miltenyi Inc 
CD8 FITC 1:11 10 IgG2a Miltenyi Inc 
CD19 APC 1:11 10 IgG1 Miltenyi Inc 
CD25 PE 1:11 10 IgG2b Miltenyi Inc 
CD127 PE 1:10 20 IgG1 eBioscience 
FOXP3 APC 1:11 10 Mouse IgG1 Miltenyi Inc 
Isotype 
control 
FITC 1:11 10 Mouse 
IgG2a 
Miltenyi Inc 
Isotype 
control 
APC 1:11 10 Mouse IgG1 Miltenyi Inc 
Isotype 
control 
AAPC 1:11 10 Mouse 
IgG2a 
Miltenyi Inc 
Isotype 
control 
PE 1:11 10  Mouse 
IgG2b 
Miltenyi Inc 
Isotype 
control 
PE 1:11 20 Mouse IgG1 Miltenyi Inc 
 
2.2.2 Methods 
2.2.2.1 Separation of peripheral blood mononuclear cells from fresh peripheral blood 
Twenty mLs of fresh peripheral blood were added to the same volume of RPMI 
(Gibco) in a 50mL falcon tube. Approximately 5mLs of RPMI and peripheral blood 
were layered onto 5mLs of lymphoprep (Axis-Shield, Oslo, Norway) in 15mL falcon 
tubes. The tubes were centrifuged at 524g for 25 minutes at 19 degrees centigrade 
(˚C). The monolayer was removed from each tube and placed in a 50mL falcon tube. 
Washing buffer (sterile RPMI with fetal calf serum) was added to a total volume of 
50mLs. This was centrifuged at 393g for 10 minutes. The supernatant was discarded 
and the cells resuspended in 5mLs of washing buffer. A cell count and viability 
assessment was performed using Trypan Blue (Sigma, Ayrshire, UK). 5µL of cells 
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were added to 5µL of trypan blue (1:2 dilution) (Sigma) and 10µL added to the 
haemocytometer chamber. The number of live (white) and dead (blue) cells was 
counted in 25 squares. Following counting of the cells cell viability and 
concentration were calculated.  
 
Cell viability: number of unstained cells/ total number of cells and multiplied by 100 
to give percentage 
Cell concentration (cell/mL) number of cells x dilution factor x 10,000 
 
Aliquots of 1 million cells were removed for flow cytometry analysis at this point 
and stored on ice.  
 
2.2.2.2 Thawing of cryopreserved cells 
The vial was removed from liquid nitrogen and thawed immediately in a water bath 
at 37˚C and transferred to an empty sterile 15mL Falcon tube. RPMI medium 
(Gibco) was added dropwise to a volume of 10mL. The tube was centrifuged at 393g 
for 10 minutes at room temperature. The supernatant was removed and the pellet 
resuspended in 5mLs of RPMI (Gibco). Approximately 5mLs of RPMI and thawed 
cells were layered onto 5mLs of lymphoprep (Axis-Shield, Oslo, Norway) in 15mL 
falcon tubes. The tubes were centrifuged at 524g for 25 minutes at 19 degrees 
centigrade (˚C). The monolayer was removed from each tube and placed in a 50mL 
falcon tube. Washing buffer (sterile RPMI with fetal calf serum) was added to a total 
volume of 50mLs. This was centrifuged at 393g for 10 minutes. The supernatant was 
discarded and the cells resuspended in 5mLs of washing buffer. A cell count and 
viability assessment was performed using Trypan Blue (Sigma, Ayrshire, UK). 5µL 
of cells were added to 5µL of trypan blue (1:2 dilution) (Sigma) and 10µL added to 
the haemocytometer chamber. The number of live (white) and dead (blue) cells was 
counted in 25 squares. Aliquots of 1 million cells were removed for flow cytometry 
analysis at this point and stored on ice.  
 
2.2.2.3 Surface antibody labelling 
Aliquots of 1 million cells were placed on ice for flow cytometry analysis. One mL 
of degassed buffer was added to each aliquot and the samples centrifuged at 393g for 
10 minutes at 4-8ºC. Ten µL of each required antibody was then added to the 
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appropriate tubes and the samples incubated for 10 minutes at 4ºC. The cells were 
then washed in degassed buffer and centrifuged at 393g for 10 minutes at 4ºC. The 
supernatant was removed and the cells resuspended in 500µL of degassed buffer. 
 
2.2.2.4 Intracellular labelling 
After surface antigen labelling the cells were centrifuged for 10 minutes at 393g and 
4-8ºC. The supernatant was removed and up to 1 million cells were resuspended in 
1mL of cold Fixation/Permeabilization Solution. The cells were mixed well and 
incubated for 30 mins in the dark at 4-8ºC. One million cells were washed with 1mL 
of cold buffer and centrifuged for 5mins at 393g at 4-8ºC and the supernatant was 
removed. The cells were rewashed in 1mL of cold permeabilization buffer and 
centrifuged for 5mins at 393g and 4-8ºC. The cells were resuspended in 80µL of cold 
1X permeabilization buffer. Then 20µL of FcR Blocking reagent was added, mixed 
well and the cells refrigerated at 4-8ºC for 5 minutes. The 10µL of FOXP3 antibody 
were added and incubated in the dark for 30 minutes at 4-8ºC. The cells were then 
washed with 1mL of cold permeabilization buffer and centrifuged for 5 minutes at 
393g at 4-8ºC and the supernatant removed completely. The cell pellet was 
resuspended in 500µL of buffer. 
 
2.2.2.5 Flow Cytometry and analysis 
Flow cytometry was performed on a LSR cytometer (BD Biosciences, Cowley, 
Oxford). FlowJo Software version 8.1 (Tree Star) was used for analysis. The initial 
voltage settings were obtained using an unlabelled cell sample. The unlabelled cell 
sample was also used to draw a gate over the lymphocyte region as determined by 
forward (FSC) and side scatter (SSC). Compensation levels between FL1 (FITC) and 
FL2 (PE) were set using cell samples stained with a single fluorochrome.  
 
2.3 Materials and method for immunocytochemistry 
2.3.1 Materials 
Citrate Buffer for Antigen Retrieval 
 50ml Antigen unmasking solution (H-3300) (Vector Laboratories) was added 5 litres 
(L) distilled water, mixed and the pH checked to ensure it was within the range of 
6.0-6.5 
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 Pronase antigen retrieval 
50 milligrams (mg) of pronase (p5147) was added to 50 millilitres (mL) phosphate 
buffer 
 
 1% Bovine Serum Albumin (BSA) With Azide 
2 grams (g) Bovine Serum Albumin was added to 200mL Phosphate buffer and 0.2g 
sodium azide and dissolved at room temperature. The pH was checked to ensure it 
was between 7.4-7.6 
 
 0.1% Tween Buffer 
500 microlitres (µl) Polyoxyethylene Sorbitan Monolaurate (Tween 20) was added to 
500mL Phosphate buffer 
 
 Phosphate Buffer 
72.5g Di-sodium hydrogen orthophosphate (Sorensen’s salt) and 11.5g Sodium 
dihydrogen orthophosphate were added to 1L distilled water and dissolved using the 
hot plate. The solution was made up to 5L with distilled water and the pH checked to 
ensure it was pH 7.6 
 
Vector Elite ABC Kit (PK6100, Vector Laboratories, Peterborough, UK) 
 20µl from bottle A and 20µl from bottle B were mixed with 1000µl of Phosphate 
buffer and allowed to stand for 30 minutes before use. 
 
Diaminobenzidine (DAB) solution  
One Kemtec DAB tablet was dissolved in 10mls of distilled water and allowed to 
stand for 15 minutes. 
 
2.3.2 Method 
Paraffin embedded 4µm sections were cut and placed on TESPA (3-aminopropyl-
triethoxysilane) coated slides. The slides were dewaxed by immersion twice for 5 
minutes in each xylene and were then placed in absolute alcohol for 2 minutes. 
Endogenous peroxidase activity was blocked by immersion in 400mL of Industrial 
Methylated Spirits and 8mL of Hydrogen peroxide. The slides were then taken to tap 
water. Antigen retrieval was performed using one of the three methods described 
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below and the slides washed in tap water and 0.1% Tween buffer (2 x 2 mins). The 
primary antibody was applied at the appropriate dilution for the time recommended 
by the manufacturer. The primary antibody was diluted with 1% BSA and azide. The 
sections were then washed with 0.1% Tween buffer (2 x 1 minutes) and the 
secondary antibody of biotinylated universal antibody applied at a dilution of 1:200 
using 1% BSA with azide as the diluent for thirty minutes. The third layer is then 
made up using the Vector Elite ABC Kit. The sections were washed in 0.1% Tween 
buffer (2 x 1 minute) and the Vector Elite ABC kit applied for 20 minutes.  The 
diaminobenzidine solution was then prepared. The sections were washed in 0.1% 
Tween buffer (3 x 1 minute). The diaminobenizidine solution was then activated; for 
every milliliter (mL) of DAB solution 10µl of 3% hydrogen peroxide was added to 
activate. The activated DAB solution was applied and left for 10 minutes and the 
sections were then washed in tap water. The slides were stained with haematoxylin 
for five minutes to highlight the nuclei and were then rinsed in tap water. The slides 
were placed in acid alcohol for 2 seconds and the placed in running tap water for 5 
minutes. The slides were then dehydrated and coverslipped. 
 
2.3.3 Antigen retrieval using pressure cooking antigen retrieval method 
The hotplate was switched on and set to full heat, 3 litres of Vector Antigen 
Unmasking Solution (H-3300, Vector Laboratories, Peterborough, UK) was placed 
in the pressure cooker and the lid replaced. The solution was warmed until boiling 
and then removed from the heat source and the slides placed in the liquid ensuring 
they were completely covered and the lid closed. The cooker was placed back on the 
heat source and the pressure selector set to level 2. The solution was allowed to 
reheat and heating continued until a steady flow of steam was produced from the 
outlet valve. The timer was set for 10 minutes when a steady flow of steam is 
produced from the outlet valve. When finished the pressure was released gradually 
by slowly reducing the pressure selector. Once the pressure selector dropped, the lid 
was removed and tap water added to the cooker and the slides allowed to stand for 5 
minutes. The slides were then removed and placed immediately in tap water. The 
slides were then placed in phosphate buffered saline (PBS) ready for application of 
the antibody. 
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2.3.4 Antigen retrieval using pronase 
The sections were placed in the pronase solution at 37˚C for 15 minutes. 
 
2.3.5 Double immunocytochemistry 
First primary antibody: the slides were de-paraffinised by immersion in xylene twice 
for five minutes each and were dehydrated through a series of alcohols twice for 
three minutes. Endogenous peroxidase activity was blocked by immersion in 400mL 
of Industrial Methylated Spirits and 8mL of Hydrogen peroxide. The slides were then 
rinsed in running tap water. The relevant antigen retrieval technique for the antigen 
was then performed.  The slides were rinsed in running tap water and transferred to 
wash buffer (TBS-T). The slides were incubated in protein blocking solution (5% 
normal horse serum) for 20 minutes. The excess blocking solution was tipped off and 
without rinsing the slides were incubated with the primary antibody for 40 minutes to 
1 hour at an appropriate dilution for the antibody. The sections were washed in buffer 
twice for two minutes each and the slides were then incubated with the secondary 
antibody (biotinylated anti-mouse IgG 1:200) for 30 minutes. The sections were then 
washed in buffer twice for two minutes. The ABC horseradish peroxidase reagent 
was applied and incubated for twenty minutes. The slides were then incubated with 
DAB solution for ten minutes and transferred to running tap water for two minutes to 
stop the reaction. The sections were then washed twice for two minutes in buffer. 
 
Second primary antibody: the ready-to-use double stain blocking solution 
(EnVision™ double stain system)(Dako UK Ltd, Ely, Cambs) was applied for three 
minutes. The slides were then incubated with ready to use avidin blocking solution 
(Vector Laboratories Inc, California) for fifteen minutes and were rinsed briefly with 
wash buffer. The slides were then incubated with biotin blocking solution (Vector 
Laboratories Inc, California) for fifteen minutes and they were then washed twice for 
two minutes. The slides were incubated with protein blocking solution for twenty 
minutes, the excess tipped off and slides incubated with the primary antibody diluted 
in protein blocking solution for 40 minutes to an hour at an appropriate dilution for 
the antibody. The slides were then washed in wash buffer twice for two minutes and 
the incubated with the secondary antibody for 10 minutes (biotinylated anti-mouse 
IgG 1:200). The slides were then washed twice with wash buffer for two minutes. 
The ABC-alkaline phosphatase (20µl/ml of both A and B in PBS) was applied for 30 
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minutes and the slides were then washed twice in wash buffer for two minutes. The 
fast Red solution was prepared by mixing 100 parts of Permanent Red-Substrate 
Buffer with 1 part of Permanent Red Chromogen (Dako EnVision™ double stain 
system) (Dako UK Ltd, Ely, Cambs) and incubated for twenty minutes. The slides 
were stained with haemtoxylin for three minutes. The slides were allowed to air dry 
and were coverslipped using an aqueous mountant. 
 
2.4 Materials and method for immunofluorescence Vector M.O.M immunodetection 
kit (Vector Laboratories, Inc, California) 
 
2.4.1 Materials 
 
M.O.M Diluent 
600µl of Protein Concentrate stock solution to 7.5ml of Phosphate Buffered Saline 
(PBS) 
 
M.O.M Biotinylated Anti-Mouse IgG Reagent 
Add 10µl of stock solution to 2.5ml of M.O.M diluent 
 
Fluorescein Avidin DCS 
Add 40µl of stock solution to 2.5ml of PBS  
 
Texas Red Avidin DCS 
Add 40µl of stock solution to 2.5ml of PBS  
 
2.4.2 Method 
Paraffin embedded 4µm sections were cut and placed on TESPA coated slides, 
dewaxed and blocked with hydrogen peroxide/methanol solution. Sections were 
incubated for 5 minutes in working solution of M.O.M diluent to block protein. 
Excess M.O.M diluent was tipped off the sections and the primary antibody diluted 
in M.O.M diluent to the appropriate concentration. The sections were incubated 
according to recommendations of the manufacturer. The sections were washed in 
0.1% Tween buffer twice for two minutes. The secondary antibody, M.O.M 
Biotinylated Anti-Mouse IgG reagent was applied to the sections and incubated for 
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20 minutes.  The sections were washed in 0.1% Tween buffer twice for 5 minutes 
each. The Fluorescein avidin conjugate was applied to the sections for 5 minutes; the 
sections were then washed twice for 5 minutes each with 0.1% Tween buffer. The 
sections were incubated with avidin solution for 15 minutes, rinsed with 0.1% Tween 
buffer and then incubated in biotin solution for 15 minutes. The sections were then 
washed with 0.1% Tween buffer twice for two minutes. The sections were incubated 
in M.O.M diluent for five minutes, the excess diluent was then tipped off and the 
secondary antibody diluted to the appropriate concentration. The sections were then 
washed twice for two minutes in 0.1% Tween buffer. The secondary antibody of 
M.O.M biotinylated ant-mouse IgG reagent was applied to the slide and incubated 
for 20 minutes. The sections were then washed twice for two minutes with 0.1% 
Tween buffer and the Texas Red avidin applied at a concentration of 1:200 and 
incubated for 10 minutes. The sections were then washed in 0.1% Tween buffer 
twice for five minutes and then mounted using Vectashield mounting media.  
 
2.5 Tissue microarray construction 
2.5.1 Preparation of the Donor Blocks and Slides 
A fresh H&E slide was obtained from each donor block and used as a guide to select 
the region for sampling. The appropriate area was marked on the H&E slide and 
donor blocks aligned with the appropriate marked H&E slides. Donor blocks were 
required to be at least 1mm in thickness. 
 
2.5.2 Preparation of the Recipient (Array) Block 
Embedding paraffin wax was melted and poured into the mold. A cassette was 
placed on top of the melted paraffin until cooled. The block was checked to ensure 
the surface was flat and no air bubbles were trapped within the block. The recipient 
blocks were at least 5mm in thickness. 
 
2.5.3 Array Design 
The array pattern was planned prior to coring tissue encompassing the number of 
samples to be arrayed. An asymmetrical pattern was constructed to aid orientation 
before analysis. Punch size of 1.0mm diameter was used with spacing of 2.0mm 
between the cores and three cores from each sample arrayed. Control appendix and 
tonsil tissue was included in the array. 
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2.5.4 Array Construction 
The recipient block was inserted into the holder and the clamping screws tightened to 
prevent slippage of the block. The block within the holder was placed against the 
location curbs, which is maintained in place by magnets. The depth stop was adjusted 
to ensure the punch stopped at the correct depth and a hole cored in the empty 
recipient block using the smaller punch core. At this point the micrometer was set to 
zero. Release of the paraffin core was aided by rotating the punch by 45°. The donor 
block bridge was placed over the recipient block holder and the larger punch 
swiveled into sampling position. The marked H&E slide was aligned with the 
corresponding tissue block. When correctly aligned remove the H&E slide was 
removed and the punch pushed downwards to core the sample. Once the sample had 
been obtained, the bridge was removed and the punch pushed downwards until the 
tip reached the top of the hole in the recipient array block. In this position the stylet 
was used to push the tissue core into the hole in the recipient block created by the 
smaller punch.  
 
2.5.5 Sectioning the Array Block 
Prior to sectioning the block was placed in a chamber heated to 37°c for 10-15 
minutes. This enabled improved adherence of the tissue cores to the recipient block. 
Once warmed and slightly malleable a glass slide was used to level the wax surface. 
A standard microtome technique was used to section the array block. 
 
2.6 Materials and Methods for Western Blotting 
2.6.1 Materials 
Extraction/Labelling buffer 
10mLS of extraction/labelling buffer (Clontech Lab Inc.) and 1 tablet of protease 
inhibitor cocktail (Roche Diagnostics) 
 
BCA™ Reagent A (Pierce, Rockford, IL) 
Sodium carbonate, sodium bicoarbonate, bicinchoninic acid and sodium tartrate in 
0.1M sodium hydroxide 
 
BCA™ Reagent B (Pierce, Rockford, IL) 
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4% cupric sulfate 
 
BCA™ Working reagent (Pierce, Rockford, IL) 
Mix 50 parts of BCA™ Reagent A with 1 part of BCA™ Reagent B. On addition of 
reagent B to reagent A, turbidity was observed which disappeared to leave a clear 
green working reagent 
 
Running buffer 
950mLs of deionised water and 50mLs of Novex® Tris-Acetate SDS Running 
Buffer 20X (Invitrogen, Carlsbad, CA, USA) 
 
Transfer buffer 
950mLs of deionised water and 50mLs of NuPAGE® Transfer Buffer 20X 
(Invitrogen, Carlsbad, CA, USA) 
 
Washing buffer (TBS-Tween) 
900mLs of deionised water and 100mLs of 10 x TBS (24.2 grams of Trizma base, 80 
grams of NaCl made up to 1 litre with deionised water, pH to 7.6 with concentrated 
hydrochloric acid) and 100µL of Polyoxyethylene Sorbitan Monolaurate (Tween 20) 
 
Blocking buffer 
10g Marvel milk powder and 200mLs of 0.1% TBS-Tween 
 
2.6.2 Methods 
2.6.2.1 Cell lysis and preparation of protein homogenate 
Once the cells were 80% confluent the media was removed and 10mLs of 0.05% 
trypsin was added to the flask. This was incubated for 5 minutes at 4˚C and then 
tapped to ensure all the cells had detached. Fifteen mLs of media was then added and 
the cell suspension was transferred to a falcon tube and centrifuged for 5 minutes at 
393g and 19˚C. The supernatant was discarded and the cell pellet resuspended in 25 
mLs of PBS. The cell suspension was centrifuged for 5 minutes at 393g and 19˚C 
and the supernatant removed completely. The cell pellet was placed in a -80˚C 
freezer for 5 minutes and was then resuspended in 200µL of Extraction/labeling 
buffer (Clontech Lab Inc.) and homogenized. The mixture was transferred to an 
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eppendorf tube and centrifuged for 10 minutes at 14000rpm (Eppendorf centrifuge 
5417R) and 4˚C. The supernatant was transferred to a new eppendorf and stored at -
80˚C. 
 
2.6.2.2 Protein quantification using the BCA™ Protein Assay Kit (Pierce, Rockford, 
IL) 
The protein content of each cell lysate was measured using the BCA™ Protein Assay 
kit which combines the reduction of Cu+2 to Cu+1 by protein in an alkaline medium 
with a sensitive colorimetric detection of the Cu+1 using a reagent containing 
bicinchoninic acid (BCA). The end reaction product is composed of two molecules 
of BCA with a single cuprous ion and absorbs at 562nm which is linear over 
increasing protein concentrations. A series of proteins of known concentrations are 
prepared and assayed alongside the samples before the concentration of the sample is 
determined based on the standard curve.  
 
Table 3 Preparation of Diluted Albumin (BSA) Standards (adapted from BCA™ 
Protein Assay Kit datasheet) 
Vial Volume of Diluent Volume and 
Source of BSA  
Final BSA 
concentration 
A 0 300µl of Stock 2,000µg/ml 
B 125µL 375µl of Stock 1,500µg/ml 
C 325µL 325µl of Stock 1,000µg/ml 
D 175µL 175µl of vial B 
dilution 
750µg/ml 
E 325µL 325µl of vial C 
dilution 
500µg/ml 
F 325µL 325µl of vial E 
dilution 
250µg/ml 
G 325µL 325µl of vial F 
dilution 
125µg/ml 
H 400µL 100µl of vial G 
dilution 
25µg/ml 
I 400µL 0 0µg/ml = Blank 
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Twenty five microlites of each standard or sample was pipetted into a microplate 
well in duplicate and 200µl of the working reagent added to each well and the plate 
was mixed on a plate shaker for 30 seconds. The plate was covered and incubated at 
37˚C for 30 minutes. The plate was cooled to room temperature and the absorbance 
measured at 562nm on a plate reader. 
 
2.6.2.3 Protein preparation for sodium dodecyl sulphate (SDS)-polyacrylamide gel 
electrophoresis (PAGE) 
15µg of cellular lysate as determined above was added to reducing agent and buffer. 
The volume of the cellular lysate was divided by 4 to obtain the volume of buffer 
required and by ten to calculate the volume of reducing agent required. The samples 
were then heated to 95˚C for 10 minutes and cooled on ice.  
 
2.6.2.4 Determination of relative molecular weight by SDS-PAGE electrophoresis 
Novex® Sharp Pre-stained Protein Standard (Invitrogen, Carlsbad, CA, USA) was 
used to visualize the protein molecular weight. The standard consists of 12 pre-
stained protein bands ranging from 3.5 -260kDa. Ten microlitres of standard was run 
alongside the samples on each gel to allow the relative size of the protein of interest 
to be determined.  
 
2.6.2.5 Western Blotting using XCell SureLock™ Mini-Cell (Invitrogen, Carlsbad, 
CA, USA) 
A 1.0mm ten well NuPAGE® 3-8% Tris-Acetate gel (Invitrogen, Carlsbad, CA, 
USA) was placed in the XCell SureLock™ Mini-Cell having removed the packaging 
and the tape from the gel cassette. The comb was removed and the wells gently 
pipetted with running buffer. The buffer core containing the electrodes and terminals 
was inserted into the chamber of the XCell SureLock™ Mini-Cell. The gel cassettes 
were then inserted into the chamber, one cassette was placed behind the core and the 
other in front of the core. The Gel Tension Wedge was inserted into the chamber and 
the lever closed to push the gels firmly against the buffer core. The buffer chamber 
was then filled with running buffer and checked to endure no leakage occurred. The 
Novex® Sharp Pre-stained Protein Standard (Invitrogen, Carlsbad, CA, USA) was 
loaded into the first well of each gel and the cellular lysates were loaded into the 
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other wells. Sample buffer was loaded into any unused wells. The lower buffer 
chamber was filled with 600mL of running buffer and electrophoresis of the gel was 
performed at a constant voltage of 200V for 35 minutes.  
 
2.6.2.6 Electroblotting of separated protein in the SDS-PAGE gel onto Amersham 
Hybond ECL nitrocellulose membrane using the XCell II™ Blot module (Invitrogen, 
Carlsbad, CA, USA) 
After electrophoresis the protein in the gel was transferred to the surface of a thin 
support membrane. This was accomplished by placing the gel next to the membrane 
and they were placed in a voltage gradient perpendicular to the gel. Negatively 
charged molecules migrated from the gel towards the positive electrode and 
deposited on the membrane. The gels were removed from the plastic plate and 
electroblotted onto nitrocellulose membranes (Amersham Hybond ECL 
Nitrocellulose membrane, GE Healthcare Ltd, Buckinghamshire, UK)). The blotting 
pads were soaked in transfer buffer until saturated and air bubbles were removed by 
squeezing the blotting pads whilst submerged in transfer buffer.  The gel was then 
placed on a piece of filter paper on top of the blotting pads and the membrane was 
layered on top of the gel and air bubbles removed by rolling a pipette over the 
membrane. The final blotting pad was placed on top of the membrane the stack 
transferred into the cathode core of the blot module with the gel being closest to the 
cathode. The anode core was then placed on top of the stack. The gel membrane 
sandwich and blotting pads in the cathode core were placed in the XCell II™ Blot 
module. The gel membrane sandwich was covered with transfer buffer. The gels 
were electroblotted at a constant voltage of 18V for 2 hours at room temperature.   
 
2.6.2.7 Antibody staining of western blots  
Determination of protein expression was assessed by antibody staining. Membranes 
were also stained with a GAPDH antibody to ensure equal loading of the samples per 
lane. Membranes were blocked with 5% (w/v) milk (Marvel) and TBST (0.1%) for 1 
hour. The membranes were washed twice in TBST for 6 minutes. The primary 
antibody was then applied overnight at 4°C. The membranes were washed twice 
again for 6 minutes and the secondary horseradish peroxidase-conjugated applied.  
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2.6.2.8 Antibodies used for immunoblotting and dilutions used 
The following primary antibodies were used in Western blot experiments: 
monoclonal Mouse Anti-Human p53 Protein Clone DO-7 (Dako Ltd, Cambridge, 
UK) (1: 1000), monoclonal anti-human murine double minute 2 (MDM2) gene 
product Clone 1B10 (Novocastra, Newcastle, UK) (1:500) and anti-human mouse 
anti-p21Cip1/WAF1 Clone EA10 (Zymed Laboratories, South San Francisco, California, 
USA) (1:500) and anti-human rabbit polyclonal Clusterin-α/β antibody Clone H-330 
(Santa Cruz Biotechnology, Inc, USA)(1:200). A horseradish peroxidase-conjugated 
polyclonal rabbit anti-mouse IgG1 was used as secondary antibody for mouse 
primary antibodies at 1:2000 (Dako Ltd, Cambridge, UK) and a horseradish 
peroxidase-conjugated polyclonal goat anti-rabbit IgG1 was used as secondary 
antibody for rabbit primary antibodies at 1:2000 (Dako Ltd, Cambridge, UK). Excess 
secondary antibody was removed by a further four washes of 15 minutes each in 
TBST. 
 
2.6.2.9 Visualisation of protein bands using enhanced chemiluminescence  
The protein bands were visualised using an enhanced chemiluminescence (ECL-plus) 
(GE Healthcare Ltd, Buckinghamshire, UK) visualisation system. Hydrogen 
peroxide catalyses the oxidation of luminal in alkaline conditions and the luminal 
decays to ground state via a light emitting pathway. Membranes were incubated with 
ECL for 2 minutes before the excess was blotted away and exposed to blue light 
sensitive autoradiography film, Hyperfilm™ ECL (GE healthcare Ltd, 
Buckinghamshire, UK) for 5 seconds to 30 mins depending upon the strength of the 
bands.  
 
2.6.2.10 Control antibody to ensure equal loading of wells 
After the initial protein bands were visualized, the membranes were reblocked using 
5% (w/v) milk (Marvel) and TBST (0.1%) for 1 hour. The membranes were washed 
twice in TBST for 6 minutes. The GAPDH antibody (Cell Signaling) was then 
applied at a dilution of 1:2000 at room temperature for one hour. The membranes 
were washed twice again for 6 minutes and the secondary horseradish peroxidase-
conjugated applied for one hour at room temperature. Excess secondary antibody 
was removed by a further four washes of 15 minutes each in TBST. The protein 
bands were visualised using an enhanced chemiluminescence (ECL-plus) (GE 
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Healthcare Ltd, Buckinghamshire, UK) visualisation system. 
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CHAPTER THREE: 
The role of p53, MDM2 and WAF-1 in transformation 
of follicular lymphoma to diffuse large B cell lymphoma 
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3.1 Introduction 
Although follicular lymphoma has a median survival from diagnosis of between 
eight to ten years (Gallagher CJ et al. 1986), a substantial proportion of these patients 
will transform to a high grade more aggressive lymphoma usually diffuse large B cell 
lymphoma. (Hubbard SM et al. 1982; Acker B et al. 1983; Bastion Y et al. 1997, 
Montoto S et al. 2007). These patients typically respond poorly to therapy and have a 
poor prognosis (Gallagher CJ et al. 1986; Bastion Y et al. 1997). Although many 
potential oncogenic events have been linked to the process of transformation 
including mutation of the TP53 tumour suppressor gene, the molecular mechanisms 
and their relationship to transformation are, at present, poorly understood.  
 
The aim of this study was to identify the frequency of p53 mutation in transformed 
follicular lymphoma and correlate the timing of its occurrence to the process of 
transformation. In addition, the use of immunocytochemistry as a surrogate to 
mutation analysis in identifying p53 mutations was assessed. The protein expression 
of MDM2 and p21, as targets of wild type p53, was analysed in relation to p53 
mutational status to determine if immunocytochemistry is an adequate surrogate for 
determining genomic mutation.  
 
3.1.1 TP53 
The TP53 gene was initially discovered in 1979 and originally was proposed to be an 
oncogene (Lane DP, Crawford LV 1979; Linzer DI, Levine AJ 1979). The protein 
product of the gene was shown to complex with the SV40 T antigen in SV40 
transformed cells (Lane DP, Crawford LV 1979; Linzer DI, Levine AJ 1979; Sarnow 
P, Ho YS, Williams J, Levine AJ 1982). Subsequent work revealed that the normal 
wild type protein acts as a tumour suppressor gene. Using TP53 cDNA-genomic 
hybrid clones it was demonstrated that a mutation at position 135 was required to 
activate the p53 protein for cooperation with the ras oncogene. Additionally, other 
mutations in TP53 were able to activate and transform rat embryo cells with the ras 
oncogene suggesting that there is prevention of wild-type p53 function by mutation, 
which would be in keeping with TP53 being a tumour suppressor gene (Hinds P, 
Finlay CA, Levine AJ 1989). DNA clones of wild type TP53 were able to prevent the 
transformation of primary rat embryo fibroblasts by E1A, an adenovirus protein 
which is an oncoprotein, plus ras or mutant TP53 and ras activated oncogenes. This 
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further indicated that p53 can act to block transformation of fibroblasts (Finlay CA, 
Hinds PW, Levine AJ 1989). The human TP53 gene is located on chromosome 
17p13 (Isobe M et al. 1986). The half life of p53 protein is extended to many hours 
in transformed cells containing complexes of DNA tumour viruses in comparison to 
a half life of between 6 and 30 minutes in non transformed cells (Oren M, Maltzman 
W, Levine AJ 1981). The regulation of the quantity of p53 protein is controlled at 
both mRNA and protein stability level; regulation of protein degradation is 
responsible for turnover of the protein (Reich NC, Oren M, Levine AJ 1983). 
Mutations in TP53 which cause structural alteration of the protein product and 
increased stability of the protein product result in the ability to detect it by 
immunocytochemical staining (Gannon JV et al. 1990). Analysis of murine p53 
mRNA levels demonstrated the presence of transcripts in both normal and malignant 
tissue; levels in normal tissue were low but were vastly increased in tumours (Rogel 
A et al. 1985). Mutations in TP53 occur in numerous human tumours; most tumours 
with allelic deletions of chromosome 17p contain point mutations of TP53. These 
mutations are predominantly located in four hotspots which correspond to the four 
most conserved regions of the genes. However, allelic deletion is not essential for 
point mutation to occur. These results suggest that mutations of TP53 may be 
important in the development of many malignancies (Nigro JM et al. 1989). The 
location of the TP53 gene is a region shown to be a site of recurrent loss in 
transformation of FL to DLBCL (Hough RE et al. 2001, Goff LK et al. 2000, 
Martinez-Climent JA et al. 2003). Wild type p53 protein acts to inhibit DNA 
synthesis at G1 in cells after DNA damage, caused both by pharmacological means 
or γ irradiation has occurred (Kastan MB et al. 1991; Kuerbitz SJ et al. 1992). Wild 
type p53 protein also activates apoptotic pathways (Debbas M, White E 1993). Given 
this major function, it is easy to understand why reduced activity of p53 results in 
genomic instability and inappropriate survival of damaged cells, essential factors in 
tumourigenesis.  
 
The ability to control apoptosis is important to the role of TP53 as a tumour 
suppressor gene. A study by Lowe et al. (1994) has shown that the absence of p53 
within mouse embryonic fibroblasts immortalized the cell and increased cell growth. 
In addition, the lack of p53 allowed an oncogene to convert the phenotype of the 
cells into a tumorigenic one (Lowe SW et al. 1994). Its presence in solid tumours 
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correlates both with unfavourable prognosis (Isola J et al. 1992; Silvestrini R et al. 
1993) and resistance to treatment (Visakorpi T et al. 1992). Mutations of TP53 are so 
common in human solid tumour malignancy that their presence may be essential to 
the development of malignancy. This inference is supported by the observation that 
even in neoplastic cells with normal TP53 alleles other mechanisms upstream of 
TP53 act to reduce the expression of the protein or alter its function. This includes 
overexpression of the regulatory protein MDM2 (Momand J et al. 1992; Finlay CA 
1993). Mutant TP53 may act in two different ways to promote neoplastic 
development, it may complex with wild type normal TP53 and prevent its normal 
function, a dominant negative effect (Blagosklonny MV 2000). A second method 
may be gain of function whereby the mutant protein actively promotes 
carcinogenesis although the exact mechanisms by which this occurs remain unclear 
(van Oijen MG, Slootweg PJ 2000). Mutation of TP53 is a less common occurrence 
in haematological malignancies than in solid tumours. Analysis of samples from 37 
patients with multiple myeloma demonstrated a TP53 mutation in only one case 
(Preudhomme C et al. 1992) and 8 out of 112 patients with acute myeloid leukaemia 
(AML) had a TP53 mutation (Fenaux P et al. 1992a). Analysis of samples from 
patients with chronic lymphatic leukaemia (CLL) established mutation in 4 out of 39 
cases. All patients with TP53 mutation had 17p monosomy and the presence of 
mutation was linked to advanced clinical stage (Fenaux P et al. 1992b). 
 
Although mutation of TP53 is a common occurrence in many malignancies the exact 
temporal relationship between acquisition of mutation and development of neoplasia 
is variable. Oesophageal malignancies have been shown to accumulate TP53 
mutations at an early stage with mutated forms being detected in the metaplastic cells 
of Barrett’s oesophagus. Genetic abnormalities within regions of Barrett oesophagus, 
which involve TP53 can be detected can be present as many as six years prior to the 
development of malignancy (Barrett MT et al. 1999). In contrast allelic deletions of 
TP53 are a later event in the development of gastric carcinoma (Rhyu MG et al. 
1994). A theory to explain this surmises that the nature of the stress activating the 
p53 pathway determines the stage at which mutation occurs. In malignancies where 
there is a high degree of environmental insult as a contributory cause, for example 
carcinoma of the lung, the p53 pathway is activated in stressed cells as a defensive 
mechanism. Damaged cells as a result, undergo apoptosis or repair and consequently 
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only those cells with mutated TP53 are able to survive. However, in those 
malignancies where mutagens are not a direct cause, genetic alterations occur which 
activate the p53 pathway by oncogenic stress. In cells with normal p53 function, the 
cell cycle will be halted and only those with mutated TP53 will survive (Guimaraes 
DP, Hainaut P 2002).  
 
Chemotherapy regimes aim to prevent proliferation of malignant cells and if possible 
cause their death. One mechanism of causing cell death is via apoptosis. Observation 
of tissue morphology of the small intestine in mice showed that the number of cells 
undergoing apoptosis was increased from that seen in normal proliferating cells after 
injection of various chemotherapeutic agents. There was no evidence of coagulative 
necrosis (Searle J et al. 1975). Mouse embryonic fibroblasts deficient in p53 can be 
sensitised to undergo apoptosis in response to radiation and chemotherapeutic agents 
by an oncogene (adenovirus E1A gene) but p53 is necessary for this process (Lowe 
SW et al. 1993). Inactivating mutations of TP53 may contribute to chemoresistance 
of some malignant neoplasms. Murine studies have demonstrated that p53 containing 
tumours treated with radiation or adriamycin showed increased levels of apoptosis 
and responded better to treatment in comparison to p53 deficient tumours (Lowe SW 
et al. 1994).  
 
The TP53 gene possesses a transcriptional activation sequence, which regulates the 
expression of many different genes possessing a p53 binding site (Unger T et al. 
1992). These include MDM2 (Barak Y et al. 1993, Chen CY et al. 1994) and 
p21Waf1/CIP1 (El-Diery WS et al.1993). 
 
3.1.2 Mouse double minute-2 protein (MDM2) 
MDM2 protein was initially detected in a complex with p53 and inactivates its 
transactivation function (Momand J et al 1992). MDM2 and p53 act to regulate each 
other, the transcription of MDM2 is enhanced by wild type p53 (Barak Y et al. 
1993). The N-terminal portion of the human MDM2 protein is critical for complex 
formation with p53 (Chen J, Marechal V, Levine AJ 1993) and the residues 
important for binding of p53 to mdm2 are the same residues involved in 
transactivation (Kussie PH et al 1996). This indicates that MDM2 inhibits p53 
function by disruption of its interaction with transcription machinery (Chen J, 
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Marechal V, Levine AJ 1993). MDM2 protein can inhibit all three actions of wild-
type and mutated p53 protein; transcriptional activation, repression and mutant 
protein activation. Thus when MDM2 protein is overproduced, which may result in 
transformation of a cell or tumour formation, all the functions of p53 are inactivated 
(Chen J, Lin J, Levine AJ 1995). MDM2 also acts by ubiquitin-mediated proteolysis 
to target p53 for degradation (Haupt Y et al. 1997). Thus a regulatory loop is formed 
between the two genes which regulates their trancription (Chen CY et al. 1994). The 
MDM2 gene is located on chromosome 12q13-14 and encodes a nuclear protein 
(Oliner JD et al. 1993). Overexpression of the MDM2 gene is seen in many human 
cancers especially sarcomas (Cordon-Cardo C et al. 1994) with varying impact on 
prognosis. These observations and evidence that MDM2 protein can inactivate p53 
mediated transcriptional activation suggested that its ability to promote 
tumourigenesis is a result of inactivating p53 (Leach FS et al. 1993; Oliner JD et al. 
1992).  This was subsequently proved when MDM2 was shown to inhibit growth 
suppression and apoptosis mediated by p53 in tumour derived cells (Chen CY et al. 
1994; Chen J et al.1996). In murine models deletion of Mdm2 results in embryonic 
lethality which is overcome by the loss of p53 (de Rozieres S et al 2000).   
 
3.1.3 p21WAF1/CIP1  
p21WAF1/CIP1 is located on chromosome 6p and is a downstream target of wild type 
p53 which can induce its transcription. It is a cyclin dependent kinase inhibitor 
involved in regulation of the cell cycle (Harper JW et al. 1993). Activation of p53 as 
a result of DNA damage causes downstream transcriptional activation of 
p21WAF1/CIP1. This then acts to inhibit cyclin dependent kinases and arrests the cell 
cycle at the G1-S phase. p21WAF1/CIP1 also prevents activation of DNA polymerase 
and thus inhibits DNA replication in S phase (Waga S et al. 1994). Mutant p53 is 
unable to activate transcription of p21WAF1/CIP1 (Dulic V et al. 1994). 
Immunocytochemically, the distribution of p21WAF1/CIP1 expression in normal human 
adult tissues showed intense nuclear staining in a subset of nuclei in the thyroid, 
prostate, muscle, kidney, brain, testes and gastrointestinal therapy with very little 
staining in lymph nodes, liver, spleen, brain, heart and lung.  Immunocytochemical 
expression of p21WAF1/CIP1 in DNA damaged human skin (by UV radiation) was 
nuclear in location and increased as was p53 expression. This was only observed 
after the skin was treated with UV radiation. Analysis of p21WAF1/CIP1 promoter 
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sequences revealed that this induction was probably mediated by conserved p53 
binding sites. Within the colonic epithelium there was a strict topological restriction 
of p21WAF1/CIP1, the Ki67 positive proliferating compartment of epithelial cells ceased 
near the base of the crypt and became Ki67 negative and p21WAF1/CIP1 positive. This 
effect was lost in colonic tumours suggesting that loss of the topological control may 
be a feature of neoplastic transformation (El-Diery WS et al. 1995). 
 
3.1.4 Aim of this study 
Previous studies have identified mutation of TP53 and overexpression of the protein 
at immunocytochemical level in transformed follicular lymphoma (Sander CA et al. 
1993, Lo Coco F et al. 1993). Despite small numbers of cases the implication is that 
TP53 mutation is acquired prior to transformation to DLBCL, however the exact 
temporal relationship is uncertain as is the length of latency period between mutation 
and transformation. In addition, the use of immunocytochemistry as a surrogate for 
mutation of TP53 is currently used. This work aimed to assess the correlation 
between mutation at the gene level and protein overexpression. This may be of 
increasing importance with the development of p53 directed therapy. 
 
3.2 Material and Methods 
3.2.1 Patient Samples 
Ethics approval was obtained for this project from the local regional ethics board. 
Twenty nine patients who were diagnosed with follicular lymphoma (FL) and 
subsequently transformed to diffuse large B cell lymphoma (DLBCL) were identified 
and ninety-one lymphoma specimens from these patients retrieved from the archives 
of St. Bartholomew’s Hospital. To be included in this study the presence of a biopsy 
of FL and a subsequent biopsy confirming transformation to DLBCL under the 
WHO criteria were required. Where available, additional biopsy samples obtained 
both pre- and post-transformation, were analysed. Presentation lymph nodes were 
available in 13 patients, the relatively small number reflecting the fact that many 
patients are originally diagnosed elsewhere and subsequently referred to the cancer 
centre at St Bartholomew’s Hospital.  
 
3.2.2 TP53 mutation detection 
Genomic DNA was extracted from snap-frozen lymph nodes and the entire coding 
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sequence of TP53 was examined. This was carried out by polymerase chain reaction 
(PCR), fluorescent single strand conformation polymorphism (FSSCP) analysis and 
direct sequencing.  PCR amplification was carried out using Amplitaq Gold 
polymerase (Applied Biosystems, Warrington, UK) in the manufacturers’ buffer, 
200µm of each dNTP; 0.5pmol/µl of each primer and 2ng/µl genomic DNA. For 
FSSCP, the primers were labelled with FAM or HEX and the fluorescent-labelled 
PCR products were diluted from 1:10 to 1:40 with water according to the yield. 1-2µl 
of diluted product was mixed with 0.5µl of ROX-500 size standards (Applied 
Biosystems) and 10.5µl of HI-Deionised Formamide (Applied Biosystems). The 
samples were denatured at 95°C for 2 minutes and subsequently snap cooled on ice. 
FSSCP analysis was carried out on a 3100 Genetic Analyser (Applied Biosystems) at 
18 and 30°C using 5% Genescan polymer containing 10% glycerol and 1 x TAPS 
buffer with EDTA. Data was analysed using Genescan 3.7.1 and Genotyper 2.5 
software (Applied Biosystems). Two independent observers visually examined each 
electropherogram trace. 
Bidirectional sequencing was carried out using BigDye Terminator chemistry 
(Applied Biosystems) and the primers for PCR. Electrophoresis was performed on a 
310 Genetic Analyser (Applied Biosystems) and the data analysed using Sequence 
Analysis 3.0 (Applied Biosystems); SeqMan (DNAStar, Madison, WI, USA) and by 
visual inspection of the electropherograms. Nucleotide number was assigned 
according to sequence U94788. LOH was examined at five common polymorphic 
sites: 11827 G>C, 11992 C>A, 11951_11952ins16, 12139 G>C and 17708 A>T. The 
PowerPlex16 multiplex PCR single tandem repeat (STR) genotyping system 
(Promega, Southhampton, UK) was performed according to the manufacturer’s 
instructions. The above work was performed with AJ Davies, C Taylor, LK Goff, S 
Iqbal and D Cuthbert-Heavens. 
 
3.2.3 Validation of monoclonal antibody specificity using Western blotting 
The cell lines BT549 (Human Mono Epithelial Breast Infiltrating Carcinoma) and 
CRL2366 (Human Mono Fibroblast Glioblastoma) (both obtained from Cell 
Services, CRUK) were cultured in RPMI with 10% fetal calf serum (Gibco) and 1% 
streptomycin/penicillin (Clare Hall, CRUK). The protein from the cell lines was 
extracted using 200 µL of extraction /labelling buffer (Clontech Lab Inc.) and the 
Chapter Three p53, MDM2, WAF-1 
 
107 
amount of protein analysed using the BCA™ Protein Assay Kit (Pierce, Rockford, 
IL). Fifteen micrograms of protein was suspended with loading buffer and reducing 
agent and denatured by heating at 95˚C for ten minutes. The mixture was loaded onto 
the gel and run for 35 minutes at 200V. The gel was transferred to a nitrocellulose 
membrane and blocked for one hour with blocking solution. The primary antibody 
was incubated overnight at 4˚C at dilutions of 1:1000 for p53, 1:500 for MDM2 and 
1:500 for p21. The secondary antibody was applied at a dilution of 1:2000 for two 
hours.  
 
3.2.4 Immunocytochemistry 
Paraffin blocks from 77 of the 91 samples analysed for TP53 mutation were available 
for immunocytochemical analysis. Both FL and DLBCL samples were available in 
20 out of the 29 patients. 
 
3.2.4.1 P53 Immunocytochemistry 
The antibody used to perform immunocytochemistry was monoclonal Mouse Anti-
Human p53 Protein Clone DO-7 (Dako, Glostrup, Denmark). Tissues processed by 
standards protocols had 4µm sections were cut and placed on TESPA (3-
aminopropyl-triethoxysilane) coated slides, were then dewaxed with xylene and 
rehydrated through graded alcohols and non-specific binding blocked with hydrogen 
peroxide/methanol solution. Antigen retrieval was performed overnight at 60°c using 
50mLs of antigen unmasking solution (H-3300, Vector Laboratories, Peterborough, 
UK). Primary antibody was diluted and incubated at 1:100 for 40 minutes. Sections 
were then stained using the Vector Elite ABC kit (PK6100, Vector Laboratories, 
Peterborough, UK) and chromogen diaminobenzidine (Biostat, Stockport, UK).  
 
3.2.4.2 MDM2 Immunocytochemistry 
The antibody used was monoclonal anti-human murine double minute 2 (MDM2) 
gene product Clone 1B10 (Novocastra, Newcastle, UK). This was performed exactly 
as described above except antigen retrieval which was performed using pressure 
cooking antigen retrieval method (Norton AJ et al. 1994) using Vector Antigen 
Unmasking Solution (H-3300, Vector Laboratories, Peterborough, UK). The primary 
antibody was diluted and incubated at 1:100 overnight.  
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3.2.4.3 WAF-1 (p21) Immunocytochemistry 
The antibody used was monoclonal anti-human mouse anti-p21Cip1/WAF1 Clone EA10 
(Zymed Laboratories, South San Francisco, California, USA). This was performed as 
described above using the pressure cooking method of antigen retrieval (Norton AJ 
et al. 1994) and application of the primary antibody at a dilution of 1:100 overnight 
at 4ºC. 
 
All biopsies from every patient were stained with each monoclonal antibody and for 
each antibody an individual negative control was also produced. 
 
3.2.5 Immunocytochemical Scoring 
For each antibody the staining was assessed to ensure appropriate staining was seen 
in accordance with the monoclonal antibody datasheet and published literature. The 
percentage of positive cells was recorded for each individual antibody. Only nuclear 
staining was considered positive for all three antibodies. In the cases of FL the entire 
section was initially scanned at low power (magnification x5) and the number of 
positive cells within ten complete follicles subsequently scored at x40 magnification. 
In the cases of DLBCL the entire section was initially scanned at low power 
(magnification x5) and the number of positive cells scored within ten fields at x40 
magnification. If more than one block of tissue was available for scoring from each 
sample the median of the scores was calculated.  
 
3.2.6 Statistical Analysis 
Differences between the immunocytochemical staining within subgroups were 
analysed using the nonparametric Mann-Whitney U test with significance set at 
p<0.05. Differences in subgroup survival were assessed using the log-rank test. 
Survival data was analysed using Kaplan Meier method. 
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3.3 Results 
The presence of TP53 mutations at a genomic and protein level were examined in 
biopsies from the 29 patients with FL who subsequently transformed to DLBCL 
Ninety one tissue samples were studied for mutations at the genomic level and 
seventy seven samples were analysed for proteomic mutations using 
immunocytochemistry. The prevalence of TP53 mutation was assessed and 
correlated with survival. The genomic mutation status was correlated with tissue 
expression of p53, MDM2 and p21 proteins. 
 
3.3.1 Patient Characteristics 
The median age of the patients at transformation was 52 years with a range from 27 
years to 73 years. After presentation, transformation occurred after a median of 3.8 
years (range 11 weeks to 15.2 years) and after a median of 3 prior therapies (range 0-
13).  
 
3.3.2 Mutational Analysis of TP53 
The entire coding sequence of TP53 and the first non-coding exon were analysed. 
This did not demonstrate any mutations in the 13 biopsies obtained at initial 
diagnosis of FL. 
 
All twenty nine patients suffered a recurrence of lymphoma and ten mutations were 
detected in eight of these patients (28%). Five of these mutations were missense 
mutations, which resulted in a single amino acid substitution. The remaining 
mutations were made up of two nonsense mutations, a branch site mutation, a splice 
mutation and an insertion.  All of the mutations were detected within exons 5-7 
despite screening of the entire coding sequence. The identified mutations were 
observed in FL samples in 4/29 (14%) patients and 7/29 (24%) transformed FL (t-
FL) patients (Figure 20) (p=0.1). 
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Figure 20 Diagrammatic illustration of serial biopsies obtained from 29 patients with 
FL which transformed to DLBCL analysed for TP53 mutations (Davies AJ et al. 
2005 with permission). 
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In five patients mutations were present in the t-FL sample but not in the preceding 
FL sample. Three of these patients acquired the mutation at the time of 
transformation and all underwent an aggressive clinical course with poor outcome. 
Of the eight patients with mutations, six of these suffered recurrence of their 
lymphoma after successful treatment for t-FL. In four of these patients an identical 
mutation was detected, two of these patients relapsed with FL and two relapsed with 
t-FL. One patient was treated to complete remission for t-FL and subsequently 
attained a mutation in a FL sample seven years later. In the final patient the mutation 
was eradicated and the recurrent FL sample contained wtTP53 suggesting relapse 
from a clone that had not undergone transformation. 
 
In three patients, mutation of TP53 was observed in a FL sample prior to 
transformation. The time period between detection of the mutation and 
transformation to DLBCL differed and was 6 months, 2.5 years and 4 years 
respectively. Thus the presence of a mutation in TP53 does not necessarily indicate 
that transformation to DLBCL is imminent.  
 
No significant difference in survival from diagnosis or survival from time of 
transformation was detected between those patients with a TP53 mutation and those 
without mutation (p=0.19 and p=0.45 respectively).  
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3.3.3 Validation of antibody specificity by Western Blotting 
The specificity of the antibodies used for immunocytochemistry was validated on 
BT549 (Human Mono Epithelial Breast Infiltrating Carcinoma) and CRL2366 
(Human Mono Fibroblast Glioblastoma). These cells lines were recommended by the 
manufacturer of the antibody for western blotting.  
 
Figure 21 Western Blot of the BT549 and CRL2366 cell lines demonstrating a 
strong band at 53Kda in the BT549 lane and a fainter band in CRL2366 using the 
monoclonal antibody to p53 (Mouse Anti-Human p53 Protein Clone DO-7 (Dako, 
Glostrup, Denmark)). 
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 Figure 22 Western Blot of the BT549 and CRL2366 cell lines demonstrating five 
bands at 90 KDa, 85KDa, 76KDa, 74KDa and 57-58KDa in both cell lines using the 
monoclonal antibody to MDM2  (monoclonal anti-human murine double minute 2 
(MDM2) gene product Clone 1B10 (Novocastra, Newcastle, UK)) 
 
 
 
 
   
 
 
 
           GAPDH 
 
 
 
 
The presence of alternatively spliced MDM2 proteins has been previously reported. 
Within cell cultures, polypeptides with molecular weights of 90KDa, 85 KDa, 
76KDa, 74KDa and 57-58KDa have been detected (Olson DC et al. 1993). The 
presence of different splice forms has also been detected in epithelial tumours 
including breast carcinoma (Bueso-Ramos CE et al. 1996) and bronchogenic 
carcinoma (Gorgoulis VG et al. 1996).  
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Figure 23 Western Blot of the BT549 and CRL2366 cell lines demonstrating a band 
at 21 Kda in both cell lines using the monoclonal antibody to p21 (monoclonal anti-
human mouse anti-p21Cip1/WAF1 Clone EA10 (Zymed Laboratories, South San 
Francisco, California, USA)) 
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3.3.4 Immunocytochemical Analysis of p53 Expression  
Positive staining for p53 was assessed as more than 10% positive nuclear staining 
(Leroy et al. 2002). Seventy-seven blocks from 29 patients were sectioned, stained 
and analysed. Of these seventy seven samples, 14 had mutated TP53 and 63 had wild 
type TP53. Immunocytochemistry was negative in 49 (64%) of these sections. Of the 
fourteen samples with known TP53 mutation, nine of the fourteen (64%) stained 
positively for p53 protein. There was a high association of immunocytochemical 
overexpression with the presence of missense mutations (82%). Sixty three samples 
were available from patients with wild type TP53 and 45 of these cases (71%) 
showed negative staining. However, eighteen non-mutated samples stained positively 
for p53 protein (29%). (Figure 24) 
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 Figure 24 p53 immunocytochemistry demonstrating, A) negative staining in FL OM 
x40, B) positive staining in DLBCL OM x40 from the same patient 
 
A 
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3.3.5 Immunocytochemical Analysis of Mdm2 Expression 
Nuclear staining was considered positive in the analysis of Mdm2 protein expression. 
Morphologically Mdm2 was seen to be expressed in the main by centroblasts and 
this was reflected in an increasing percentage of positive cells in higher grades of FL. 
Higher expression in DLBCL samples was seen (mean 72%; 95% confidence 
interval 68-76%) in comparison to FL (mean 58%; 95% confidence interval 54-
62%). This observation was statistically significant p <0.001. (Figure 25 and Figure 
26) 
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 Figure 25 Immunocytochemistry for MDM2, A) FL demonstrating some positive 
staining for MDM2 protein OM x40, B) DLBCL demonstrating increase in positive 
staining with MDM2 OM x40 
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Figure 26  Comparison of MDM2 protein expression by immunocytochemistry in 
FL versus DLBCL. The mean level of expression is indicated by the black bar 
(Davies AJ et al. 2005 with permission). 
 
 
 
 
3.3.6 Immunocytochemical Analysis of p21 Expression 
Nuclear staining was considered positive in the analysis of p21 protein expression 
(Fredersdorf S et al. 1996). The majority of samples were negative for p21, with 
positive staining in nineteen of seventy-one samples assessed (27%). There was no 
correlation between p21 protein expression and histological type. There was no 
correlation between TP53 mutation and p21 protein expression. 
 
3.3.7 Correlation of p53, MDM2 and p21 Immunocytochemical Expression 
There was no correlation between the expression of either MDM2 or p21 proteins 
and the presence of TP53 mutation. MDM2 expression was observed in 67% (95% 
CI: 63-70%) of samples with wtTP53 and in 62% (95% CI: 55-68%) of samples with 
mutated TP53. Lack of p21 staining was present both in samples with wtTP53 and 
mutated TP53. 
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3.4 Discussion 
 In contrast to other studies (Sander CA et al. 1993; Lo Coco F et al. 1993) which 
were performed on a smaller number of patients, this analysis of paired FL and 
transformed FL samples from a large cohort of patients’ has shown that mutation of 
TP53 is not prerequisite for transformation in the majority of cases. Although no 
TP53 mutations were present in initial diagnostic FL samples, the presence of TP53 
mutation in FL samples prior to transformation (14% of samples) suggests that 
mutation may be an early event in the natural history of FL for some patients who 
eventually transform to high-grade lymphoma. The previous studies demonstrated 
widely disparate frequencies of TP53 mutation with 26% (Sander CA et al. 1993) 
and 80% (Lo Coco et al. 1993) respectively in the transformed samples. The present 
study demonstrated mutations in recurrence samples in 28% of patients from the 91 
biopsies analysed. In this study, the presence of a TP53 mutation in FL did not 
correlate with reduced overall survival. This may be explained by data demonstrating 
that mutation of TP53 at codons 248 and 273 does not result in any alteration of 
protein conformation or abnormal localization. Indeed wild type activity could be 
elicited (Ory K et al. 1994). Codons 175, 248 and 273 are considered mutation 
hotspots accounting for 22% of mutations in human cancers (Caron de Fromental C, 
Soussi T 1992).  
 
The dogma within the field of haematological malignancy, despite evidence from a 
study in 1993 (Villuendas R et al 1993), assumes the presence of TP53 mutation 
based on positive immunocytochemical staining for p53 protein. This work has 
demonstrated that the presence of immunocytochemical staining cannot be used as a 
surrogate for genomic mutation detection in FL and transformed FL. This concurs 
with previous work which has shown over several histological types of non-
Hodgkin’s lymphoma that detection of protein over-expression is not dependent 
upon TP53 gene mutation and conversely that the absence of protein does not 
exclude mutation. Nonsense mutations of TP53 will result in lack of detectable 
protein (Villuendas R et al. 1993). The detection of p53 protein by 
immunocytochemistry in the absence of TP53 mutations has been previously 
observed in lymphomas (Martinez-Delgado B et al. 1997) and this observation 
indicates that there may be an alternative mechanism for accumulation of p53 protein 
independent of mutations. There has been increasing interest in the use of small 
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molecule inhibitors as therapeutic strategies in cancer particularly those which target 
the p53 pathway. It is essential that accurate determination of TP53 mutational status 
is obtained if this therapy is to be used appropriately in the clinic as their therapeutic 
action depends the presence of wild type TP53 (Vassilev LT et al 2004).  
 
It is evident from these results that transformation of FL to DLBCL is, in most 
patients, unrelated to TP53 mutation. The increased expression of MDM2 in 
transformed DLBCL is independent of p53 status and suggests that it is the result of 
a different mechanism. Previous work in chronic lymphatic leukaemia (CLL) and 
other B cell NHL has produced similar results although over-expression of MDM2 
was seen at a higher frequency in lower grade lymphomas. There was a correlation 
with gene over-expression and advanced stage (Watanabe T et al. 1994).  A separate 
study showed MDM2 over-expression in a small number of transformed DLBCL 
cases. Cases of indolent NHL demonstrated no MDM2 over-expression at diagnosis 
(Møller MB, Nielsen O, Pedersen NT 2002). Within FL a recent study has 
demonstrated an increased percentage of grades 3a and 3b FL to be MUM1-positive 
as compared to FL grades 1 and 2 (78.9% versus 7.4%)  and 90% of the grade 3b FL 
cases were positive. In addition, there was a higher incidence of cases with a DLBCL 
component in MUM1-positive cases than MUM1-negative case (Naresh KN 2007). 
 
There must be additional mechanisms driving the transformation process. Gene 
expression profiling has identified two gene expression signatures associated with 
transformation; one with increased expression of c-myc and genes regulated by c-myc 
and the second with decreased expression of these genes (Lossos IS et al 2002).  
Transgenic mice which overexpress the c-Myc oncogene under the control of the 
immunoglobulin heavy chain gene develop B cell lymphomas after a latent period of 
several months (Adams JM et al. 1985).  Within this murine model TP53 acts as a 
tumour suppressor and inactivation of the gene results in increased aggressiveness 
and speed of onset (Schmitt CA et al. 1999). Additionally, disruption of apoptosis by 
overexpression of BCL2 produces an advantage for tumour formation and is 
independent of the TP53 mutational status (Schmitt CA et al. 2002). Mdm2 
haploinsufficiency in this model strikingly inhibits lymphoma development; 
transgenic mice with loss of one Mdm2 allele had significantly delayed development 
of tumours and increased life span with increased susceptibility of B cell 
Chapter Three p53, MDM2, WAF-1 
 
121 
lymphocytes to apoptosis. This suggests that targeting MDM2 may be an effective 
method of slowing or abrogating tumour development and may act by enhancing 
apoptosis via the p53 pathway (Alt JR et al. 2003). Recently, small-molecule 
inhibitors of MDM2, the Nutlins, have been developed. These compounds have been 
demonstrated to bind MDM2 in the p53-binding pocket. Cell lines treated with 
Nutlin-1 were shown to accumulate wild-type p53 and then elevate levels of MDM2 
and p21 protein consistent with activation of the p53 pathway in these cancer cells. 
This increase in p53 protein was due to reduced degradation as transcription of the 
p53 gene was not affected by administration of the drug.  Cell cycle arrest was 
demonstrated at the G1 and G2 phases. A variable dose dependent antiproliferative 
and cytotoxic effect was also observed which was linked to the p53 status of the cell 
lines. The IC50 values in cells with wild type p53 were considerably lower than in 
cells with mutant p53. Finally, Nutlin-3 can suppress the growth of murine tumour 
xenografts (Vassilev LT et al. 2004). Clinical trials of these drugs in patients with a 
variety of haematological malignancies have produced encouraging results. In acute 
myeloid leukaemia (AML), treatment with Nutlin-3 produced apoptosis in samples 
with wild-type p53. Inhibition of MDM2 enhanced the cytotoxic effects of 
doxorubicin and cytosine arabinoside in AML blasts (Kojima K et al. 2005). Similar 
results were demonstrated in myeloma, with apoptosis of neoplastic cells in the 
presence of bone marrow stromal cells, without damage to the stromal cells (Stühmer 
T et al. 2005). In chronic lymphatic leukaemia (CLL) Nutlin-3 produced apoptosis in 
cells with wild type p53. In addition, human T lymphocytes were less sensitive to 
nutlin-3 than CLL cells (Coll-Mulet L et al. 2006).  
 
The results of this study establish mutations in TP53 as being a minor contributor to 
the process of transformation however targeting MDM2 overexpression in 
transformed cases may be a more effective treatment option.  
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CHAPTER FOUR: 
Validation of Tissue Microarray methodology for 
the evaluation of genes implicated in 
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4.1 Introduction 
The explosion of new technology such as cDNA microarrays has allowed the 
evaluation of gene expression in tissue samples. The results have revealed many 
potentially important genes involved in the development of malignancy in numerous 
types of tumours. This wealth of information has the potential to overwhelm 
scientists who are trying to identify those genes which are essential in the 
development of malignancy within a particular type of tissue. In order to determine if 
a gene has prognostic or therapeutic potential the protein expression in many samples 
from numerous patients needs to be analysed. Protein expression is more indicative 
of function than gene expression as numerous post-translational modifications may 
occur. There are limitations in assessment of protein expression. Traditional tissue 
samples are formalin fixed paraffin embedded tumour blocks. To assess protein 
expression in this material there must be an antibody to the protein of interest, which 
is effective in paraffin embedded tissue. In order that sufficient patient samples can 
be assessed to validate the importance of a particular gene numerous sections would 
need to be cut, stained and assessed. This is expensive in the use of valuable tissue 
samples, time and reagents.  
 
4.1.1 Tissue Microarray 
In order to address this disadvantage a technique called Tissue Microarray (TMA) 
has been developed. Small cores of tissue are taken from the paraffin embedded 
tissue blocks of the whole biopsy. To do this, haematoxylin and eosin slides of the 
whole tissue section are assessed and the areas of interest marked by the reviewing 
pathologist. The slide is aligned with the correct block and cores are taken from the 
area of interest and embedded into a fresh paraffin wax block. Core sizes can vary 
from 0.6mm to 3mm. The resulting block can contain as many as 1000 cores of 
tissue samples and depending upon the thickness of the donor blocks can allow as 
many as 150 sections to be cut from the same block. This has the result of amplifying 
rare material as well as providing a high throughput technique for assessment of 
protein expression. An additional advantage is that standardization of 
immunocytochemistry across all the tissue samples is achieved.  
 
A concern with this technique is that the samples of tumour obtained will not be 
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representative of the biological properties of the entire tumour. Numerous studies 
have been carried out since the initial description of this technology, which indicate 
that with correct sampling this is not problematic. The data in the initial paper 
describing TMA showed a correlation of 84% between TMA immunocytochemistry 
and tissue homogenates for oestrogen receptor (ER) levels. This is in keeping with 
the correlation between full section immunocytochemistry and tissue homogenates 
for ER (Kononen J et al. 1998). A subsequent study in breast carcinomas showed that 
analysis of two 0.6mm tissue cores for the antigens of the oestrogen receptor (ER), 
progesterone receptor (PR) and Her2/neu was comparable to full sections in more 
than 95% of cases.  The same authors also presented data suggesting that antigens 
within paraffin embedded tissues retain their antigenicity for many years, in some 
cases over six decades (Camp RL, Charette LA, Rimm DL 2000). A further study in 
breast malignancy assessed TMAs in the analysis of three prognostic markers in a 
series of 533 breast tumours. Four 0.6mm cores were sampled from each tumour, one 
core from the central area and three from peripheral regions. Evaluation of large 
section staining as compared to TMA was performed for ER, PR and p53. A single 
TMA core correlated with full sections in about 95% of cases for ER, 75-81% for PR 
and 70-74% for p53. However, a single core was sufficient for association between 
clinical outcome and molecular alterations to be identified (Torhorst J et al. 2001). 
Another study in a different disease entity assessed 59 fibroblastic tumours for their 
expression patterns of p53, ki-67 (a proliferation marker) and the product of the 
retinoblastoma gene (pRB) (Hoos A et al. 2001). The cut-off value for evaluating a 
case as positive was 10% for p53 and 20% for ki67. The assessment of pRB was 
more complex and included negative cases resulting from a lack of protein 
expression due to either mutation or deletion, strongly positive cases resulting from 
nonfunctional hyperphosphorylated protein (Cote RJ et al. 1998) and cases which 
were moderately positive as a result of expression of wild type protein.  The results 
show that concordance with full section ICC is reduced in cases where complex 
phenotypes are assessed however an increase in the number of cores assessed, in this 
case to three, can improve this concordance. The analysis of three cores per sample 
resulted in concordance of 96%-98% for two phenotypes and 91% in assessing the 
more complicated pRB (Hoos A et al. 2001). Several studies have been performed 
using TMA in Hodgkins and Non-Hodgkins lymphomas with favourable correlation 
with full sections (Natkunam Y et al. 2001; Rassidakis GZ et al. 2002; Hedvat CV et 
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al. 2002). 
 
4.1.2 Gene expression profiling in haematological malignancy  
The value of gene expression profiling in haematological malignancies was 
demonstrated by early studies in de novo DLBCL which generated gene expression 
signatures capable of dividing patients into prognostic groups (Alizadeh et al. 2000). 
Further studies have focused on follicular lymphoma. The importance of the 
microenvironment in FL was highlighted by a study which analysed 191 lymph node 
biopsies and produced two signatures correlating with outcome. Immune response-1 
(IR-1) was associated with good prognosis and included genes for T lymphocytes, 
immune response-2 (IR-2) correlated with poor prognosis and included genes for 
dendritic cells and some macrophage markers. These signatures were independent of 
clinical parameters (Dave S et al. 2004). A subsequent study analysed 80 FL patients 
lymph node biopsies and demonstrated that a number of genes could differentiate 
between aggressive and indolent disease and the use of these gene signatures could 
give a more accurate prediction of clinical behaviour than clinical parameters or 
histological grade (Glas AM et al. 2005).  
 
4.1.3 Activated-B-cell-like versus Germinal-centre-B-like groups of DLBCL 
De novo DLBCL is a heterogeneous disease both morphologically and clinically. 
Durable remissions with anthracycline based chemotherapy are achieved in 40-50% 
of patients (Coiffier B 2001) however accurate prediction of patients who need 
aggressive treatment is essential. Currently the International Prognostic Index (IPI) is 
used for prognostication (The International Non-Hodgkin’s Lymphoma Prognostic 
Factors Project 1993) however this has limited discriminative power. Gene 
expression profiling has allowed de novo DLBCL into prognostically significant 
subgroups; activated-B-cell-like (ABC), germinal-centre-B-like (GCB) and type 3. 
Patients with an ABC genotype have a worse prognosis (34% 5-year overall 
survival) than patients with GCB genotype (76% 5-year overall survival) (Alizadeh 
et al. 2000; Wright et al 2003). The type 3 group is heterogeneous but appears to 
have a similarly poor outcome to the ABC group. The use of cDNA microarrays is 
expensive and restricted to large laboratories, as well as requiring fresh tissue. The 
translation of these gene profiling experiments to immunocytochemistry would 
enable the use of this information in a much wider clinical setting as well as 
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validating the genetic data at a protein level on a large number of cases. Hans et al 
used immunoctyochemistry on TMA composed of 152 cases of DLBCL to evaluate 
the predictive markers CD10, BCL-6 and IRF4/MUM1 to accurately subdivide 
DLBCL into the prognostically relevant subgroups using cDNA microarrays as gold 
standard (Hans CP et al 2004). 
 
GCB phenotype was indicated by CD10+, BCL-6-, MUM-1- or CD10-, BCL-6+, 
MUM-1- and non-GCB phenotype CD10-, BCL-6-, MUM-1+ or CD10-, BCL-6+/-, 
MUM-1- (Figure 27). 
 
Figure 27 Decision tree for immunoperoxidase TMA classification of DLBCL 
(adapted from Hans CP et al. 2004) 
 
The expression of CD10 or BCL-6 correlated with improved overall survival 
however expression of MUM1 was associated with worse outcome. Cases were 
classified using CD10, Bcl-6 and MUM1 expression and 64 cases (42%) classed as 
GCB and 88 cases (58%) non-GCB. The 5 year overall survival for the GCB group 
was 76% compared to 34% for the non-GCB group which was similar to the overall 
survival using the cDNA microarrays (Hans CP et al. 2004). This data demonstrated 
CD10 
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cases) 
+ 
- 
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cases) 
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that immunocytochemistry had a role in validating gene array data at a protein level 
in tumour tissue. This work presented here assessed the phenotype of DLBCL arising 
from transformed FL to ascertain whether the known germinal centre origin of FL is 
maintained on transformation. 
 
4.1.4 Multiple Myeloma Oncogene 1/ Interferon Regulatory Factor - 4 
(MUM1/IRF4) 
 The MUM1 gene was first identified in multiple myeloma cells lines in which a 
recurrent translocation t(6;14)(p25;q32) positioned the immunoglobulin heavy-chain 
(IgH) locus next to MUM1/IRF4 gene, a member of the interferon regulatory factor 
(IRF) family (Iida S et al. 1997). The resulting overexpression of MUM1 gene has 
been shown to have a possible role in tumourigenesis (Iida S et al. 1997). Murine 
models deficient in IRF4 showed defective immunoglobulin production as well as 
defects in cytotoxic and anti-tumour T lymphocyte responses suggesting a functional 
role in both B and T lymphocytes (Mittrucker H et al. 1997). MUM1 has also been 
shown to alter the expression of cytokine genes in T lymphocytes. The production of 
interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 10 (IL-10) and interleukin 13 
(IL-13) is strongly increased if MUM1 expression is produced in T lymphocytes 
which lack endogenous MUM1. MUM1 also interacts with a member of the NFAT 
family of transcriptional repressors and immunosuppressants which target NFAT 
activation can abrogate the MUM1 induced production of cytokines (Hu CM et al. 
2002). Stable expression of MUM1 in a lymphoid cell line in which it is normally 
deficient produces an enhanced apoptotic response on engagement of the Fas 
receptor. Mice deficient in MUM1 have defective activation-induced cell death 
suggesting that MUM1 is important in the regulation of apoptosis within lymphoid 
cells (Fanzo JC et al. 2003).  Subsequent development of a monoclonal antibody 
Mum1p demonstrated tissue expression of the human MUM1/IRF4 protein in the 
cytoplasm and nuclei of plasma cells and in a small number of light zone germinal 
centre B lymphocytes. The positive germinal centre B lymphocytes differed 
phenotypically from the majority of germinal centre B lymphocytes and mantle B 
lymphocytes. The MUM1 positive cells were Bcl6 and Ki67 negative whereas 
MUM1 negative cells were Bcl6 and Ki67 positive and mantle cells were negative 
for all three markers. Analysis of single MUM1 positive germinal centre cells using 
polymerase chain reaction confirmed B cell origin and the number of somatic 
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mutations demonstrated the cells to be of germinal centre or post germinal centre 
stage. In addition, there was expression of the MUM1 protein in 
lymphoplasmacytoid lymphomas, multiple myeloma and three quarters of diffuse 
large B cell lymphomas (DLBCL).  There was coexpression of Bcl-6 and MUM1 in 
approximately half of the DLBCL whereas the expression of these markers in normal 
B lymphocytes is mutually exclusive (Falini B et al. 2000).  
 
4.1.5 Forkhead box protein P1 (Foxp1) 
Foxp1 is a member of the Fox family of winged helix/forkhead DNA-binding 
proteins which act as transcriptional repressors. Foxp1 maps to the chromosome 
region 3p14.1 and many tumours show alterations in this region (Pandis N et al. 
1993; Fujino T et al. 1994). Analysis of both mRNA and protein expression levels 
has demonstrated a difference between normal and malignant tissue. 
Immunohistochemical analysis of a variety of malignant tumours demonstrated 
altered levels and location of expression of the protein in many neoplastic cells.  
Within normal tissues, the presence of FOXP1 protein has been observed in B 
lymphocytes in the mantle zone and some germinal centre cells (Banham AH et al. 
2001). Absence of the Foxp1 gene causes a defect in the early development of B 
lymphocytes. There is a block on transition from pro-B cell to pre-B cell and reduced 
levels of V(D)J recombination (Hu H et al. 2006). Analysis of diagnostic lymph node 
biopsies from patients with DLBCL using immunohistochemistry has demonstrated a 
high level of expression in 23/126 patients. The presence of FOXP1 correlated with 
poor prognosis and was only observed in patients who lacked the GC phenotype 
(Barrans SL et al. 2004). Further investigation has revealed a significant association 
between the expression of FOXP1 and worse survival in patients with DLBCL. 
Patients with FOXP1 positive tumours had a median overall survival of 1.6 years in 
comparison to patients with FOXP1 negative tumours who had a median overall 
survival of 12.2 years (Banham AH et al. 2005). Follicular lymphoma cells 
demonstrated positive expression of Foxp1, by immunohistochemistry in 11 out of 
13 cases, with all being of lower grade. The two cases which did not express FOXP1 
were grade 2 or 3 (Brown P et al. 2005). The expression of FOXP1 has also been 
shown to correlate with outcome in patients with de novo MALT lymphomas and 
indeed identify a subset of these low grade lymphomas which were likely to 
transform to aggressive DLBCL (Sagaert et al 2006). As part of the study 
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investigating antigenic differences between ABC and GCB DLBCL Hans et al also 
evaluated other immunohistochemical markers including FOXP1. Positive staining 
for FOXP1 was observed in 61% of DLBCL and its expression was seen in 71% of 
non-GCB cases as compared to 48% of GCB cases. There was no correlation with 
overall survival or event free survival (Hans CP et al. 2004). In addition to 
identifying whether FL transformed to DLBCL of GC or ABC like phenotype we 
wished to see if the FOXP1 result in de novo DLBCL was replicated in transformed 
FL. 
 
4.1.6 Gene expression profiling of pre- and post-transformation sample of FL 
Previous gene expression profiling on haematological malignancies suggested that 
gene expression profiling is a powerful tool with which to examine potential genetic 
differences in pre- and post transformation samples.  
 
As previously indicated, transformation of follicular lymphoma to an aggressive high 
grade lymphoma is a common and adverse prognostic event. The gene expression 
data was obtained from lymph node samples of follicular lymphoma (FL) which 
subsequently transformed to diffuse large B cell lymphoma (DLBCL) using the 
Lymphochip cDNA microarray. A list of seventy-six genes whose expression was 
significantly altered on transformation was generated using the random variance 
model t-test. The cut off value for P was set at <0.001. Twenty nine genes 
demonstrated up-regulation and 47 genes are down-regulated upon transformation 
(Davies AJ et al. 2006). In order to assess concordance between mRNA and protein 
expression, gene products were chosen for further study using 
immunocytochemistry. Within the up-regulated genes nucleoside dephosphate kinase 
A (nm23-H1) which showed a log2 fold change of 0.85 was chosen for further study. 
This gene was of additional interest as elevated serum levels of nm23-H1 have been 
detected by ELISA in patients with aggressive non-Hodgkin’s lymphoma and acute 
myeloid leukaemia and correlated with poor prognosis (Niitsu N et al 1999; Niitsu N 
et al 2000). The fold change represents the average change in expression (log2) 
across 20 samples between FL and DLBCL.
 
One of the up-regulated genes with the 
power to differentiate between FL and transformed DLBCL samples is a 
chromosomal passenger protein called Aurora Kinase B (AURKB). Although less 
significantly up-regulated than the other genes, with a log2 fold change of 0.64, 
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AURKB was worthy of investigation because a small molecule inhibitor of AURKB 
was already being investigated in acute myeloid leukaemia. CR2 (CD21) and FCER2 
(CD23) were the most significantly down-regulated and their protein expression was 
analysed. The expression of a third protein, FOXP1, was also analysed. Although 
this gene was not differentially expressed between FL and transformed FL, the 
presence of FOXP1 correlated with poor prognosis in de novo DLBCL and was only 
observed in patients who lacked the GC phenotype (Barran SL et al. 2004). As part 
of this study was to investigate the phenotype of transformed FL we wished to 
investigate whether the FOXP1 result in de novo DLBCL was replicated in 
transformed DLBCL. The protein expression of these genes was analysed on an 
independent validation set of 34 patients with at least one pre-transformation and one 
post-transformation paraffin embedded biopsy. 
 
4.1.7 Aurora Kinase B (AURKB) 
Cellular division is an essential and complex process and, of necessity, is tightly 
regulated. The final stage of mitosis is cytokinesis where two daughter cells are 
produced each containing a single complete set of chromosomes.  In order to achieve 
this, during the cell cycle chromosomes must be correctly bi-orientated and aligned. 
Extensive investigation into the mechanisms by which this occurs have been 
undertaken. Within Drosophila a serine/threonine protein kinase, Aurora, was 
identified where mothers with mutant aurora would produce embryos with closely 
paired centrosomes at inappropriate stages in mitosis. In addition these embryos 
would develop interconnected spindles with shared poles. In larvae with amorphic 
alleles there is mitotic arrest and pupal lethality with the formation of large circular 
monopolar spindles suggesting that the centrosomes have failed to separate and form 
a bipolar spindle (Glover DM et al. 1995). The budding yeast Saccharomyces 
cerevisiae possesses a kinase Ip1l which is required to ensure chromosome 
segregation. In yeast with mutant kinase uneven DNA staining density was present 
near the ends of opposite elongated spindles suggesting unequal segregation of 
chromosomes at the poles (Franscisco L, Wang W, Chan CSM 1994). A mammalian 
version related to Drosophila Aurora and Saccharomyces cerevisiae Ip1l was 
identified in the rat. This was named Aurora and Ip1l-like midbody-associated 
protein (AIM-1). Both mRNA and protein for AIM-1 are expressed in the G2/M 
phase of the cell cycle and begin to localize as a broad band in the midzone of the 
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central spindle in late anaphase. By telophase and cytokinesis AIM-1 is concentrated 
at the midbody. The expression of kinase inactive AIM-1 often results in failure of 
cytokinesis with resulting cell polyploidy (Terada Y et al. 1998). In humans, two 
homologues of the Drosophila Aurora and yeast Ip1l kinase genes were initially 
identified and named aurora1(aurora B) and aurora2 (aurora A). They were 
identified using a PCR screening technique aiming to identify protein kinases which 
were overexpressed in colonic carcinomas. The aurora2 kinase was demonstrated to 
be equivalent structurally and functionally to the yeast kinase Ip1l whereas aurora1 
kinase demonstrated a different biological activity. Both aurora1 and aurora2 mRNA 
and protein levels and activity were highest at the G2/M phase of the cell cycle 
although aurora2 kinase activity was maximal prior to the highest level of aurora1 
activation. Both kinases were demonstrated to localize to mitotic structures 
suggesting a role in chromosome segregation. The aurora2 gene was shown to map 
to chromosome 20q13 (Bischoff JR et al. 1998). This locus is overexpressed in many 
malignancies (Muleris M et al. 1987, Bigner SH et al 1988, Iwabuchi H et al 1995, 
Kallioniemi A et al. 1994, Tanner MM et al 1994, Tanner MM et al 1996). Aurora2 
mRNA levels were demonstrated to be up-regulated in numerous tumour cell lines. 
In addition, Aurora2 DNA was amplified and its RNA overexpressed in 52% of 
primary rectal carcinomas studied. Overexpression of aurora2 is able to transform 
rat fibroblasts suggesting its role as an oncogene. High expression of aurora1 
transcript is seen in tissues with a rapid turnover such as fetal liver and epithelial 
cells but low levels are present in normal tissues. It is also overexpressed in many 
diverse tumour cell lines (Bischoff JR et al. 1998). These findings taken with the 
observations by Terada et al. that expression of AIM1 mutant disrupts the formation 
of the cleavage furrow and prevents separation at the final stage of cytokinesis 
suggest that members of the aurora1 kinase family are required for the completion of 
cytokinesis. A defect in this family would result in cells with abnormal amounts of 
DNA and polyploidy, findings which are often seen in malignant cells. Aurora B 
(Ip1lp) phosphorylates kinetochore components in budding yeast and is essential for 
ensuring chromosome segregation by correcting errors in microtubule attachment 
(Biggins S et al 1999). In order to achieve this Aurora B kinase targets checkpoint 
proteins BubR1, Mad2 and Cenp-3 to kinetochores resulting in the coupling of 
chromosome alignment with anaphase (Ditchfield C et al 2003). Aurora kinase B 
also phosphorylates the microtubule depolymerase MCAK and regulates both its 
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location and activity during mitosis suggesting that Aurora kinase B may biorient 
chromosomes by directing MCAK to depolymerise incorrectly oriented kinetochore 
microtubules (Lan W et al 2004). The addition of an Aurora kinase B inhibitor, 
Hesperadin, to mammalian cells increased the incidence of mal-orientated 
chromosomes (Hauf S et al 2003). The small molecule inhibitors ZM447439 and 
VX-680 inhibit both the proliferation and survival of tumour cells (Ditchfield C et al 
2003; Harrington EA et al 2004). However, ZM447439 is not selective for Aurora B 
and also inhibits Aurora kinase A (Ditchfield C et al 2003) and VX-680 inhibits 
Aurora A more potently than Aurora B (Harrington EA et al 2004). Recent work had 
demonstrated that inhibition of Aurora B kinase activity produces similar effects to 
those achieved by ZM447439 and a novel compound which is over 100 times more 
specific for Aurora kinase B over Aurora kinase A in vitro produces similar 
phenotypes to those produced by ZM447439. Inhibition of Aurora kinase B activity 
produces a profound anti-proliferative effect indicating that it is an attractive drug 
target (Girdler F et al 2006).  
 
4.1.8 Nucleoside dephosphate kinase A (nm23) 
The nm23 gene family is a family of metastasis suppressor genes important in 
oncogenesis and metastasis. The first member of the family identified was nm23-H1 
and its levels were reduced in highly metastatic tumours in rodents in comparison to 
tumours with low metastatic ability. The mechanisms by which they mediate these 
effects are unclear (Steeg PS et al. 1988; Lascu I, Gonin P 2000). Nm23-H1 is a 
nucleoside diphosphate kinase (NDP kinase) (Wallet V et al. 1990; Biggs J et al 
1990) which acts to provide cells with high energy nucleosides other than ATP 
(Parks RE Jr, Agarwal RP 1973). Elevated serum levels of nm23-H1 have been 
detected by ELISA in patients with aggressive non-Hodgkin’s lymphoma and acute 
myeloid leukaemia and correlated with poor prognosis (Niitsu N et al 1999; Niitsu N 
et al 2000). In addition, serum nm23-H1 levels have been shown to be an 
independent prognostic factor in patients with DLBCL and peripheral T cell 
lymphoma (Niitsu N et al. 2001). Analysis of tissue DLBCL samples using 
immunocytochemistry demonstrated strong positivity in 58.1% and this correlated 
with the serum level. The overall survival and progression free survival rates were 
lower in patients with tumours positive for nm23 in comparison to patients with 
nm23 negative tumours. This difference was also identified on comparison of the 
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serum levels of nm23 suggesting that the lymphoma cells produce nm23 (Niitsu N et 
al 2004). 
 
4.1.9 Complement Receptor 2 (CR2/CD21) and CD23/FcεRII 
Follicular dendritic cells are essential to both normal and neoplastic follicle 
formation within lymphoid tissue and are essential for adhesion and proliferation of 
B lymphocytes (Kosco MH, Pflugfelder E, Gray D 1992). The antibodies for CD21 
and CD23 are used routinely to demonstrate the presence of FDC meshwork. Several 
studies have suggested that loss of FDC antigen in the stroma of FL may serve as a 
surrogate marker of tumour progression (Chang KC et al 2003). An 
immunocytochemical study observed the presence of FDC meshworks as more 
clearly defined in low grade lymphomas in comparison to high grade and loss of the 
FDC meshworks prior to transformation despite morphologically clear follicles being 
present (Shiozawa E et al 2003).  The gene expression profiles demonstrated the 
most significantly down-regulated genes on transformation of FL to DLBCL were 
CR2/CD21 and CD23 and so their protein levels were analysed in tissue using 
immunocytochemistry. 
 
4.1.10 Aims 
The aim of this work was initially to validate TMA as a method to assess protein 
expression by innumocytochemistry in FL and DLBCL. Once the methodology was 
validated, a further study to examine the results of TMA use within our department 
as compared to published results was performed. Finally, using an independent set of 
pre-transformation and post-transformation patient samples to those analysed in the 
gene expression set (Davies AJ et al. 2006) TMA was used to validate the results 
obtained by gene expression profiling at a protein level and try to gain an insight into 
the mechanisms of transformation as well as confirm novel up-regulated genes as 
potential prognostic biomarkers or therapeutic targets.  
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4.2 Materials and methods 
4.2.1 Patient selection 
Ethics approval was obtained from the local regional ethics committee. Paired pre 
and post transformation samples (n=126) were obtained from 35 patients diagnosed 
with FL who subsequently transformed to DLBCL. A second TMA comprising 31 de 
novo DLBCL samples was produced for methodological validation. 
 
4.2.2 Construction of Tissue Microarray 
Tissue microarrays (TMA) were constructed of 1mm cores of patient tissue taken 
from representative areas of lymphoma (>5 neoplastic follicles for FL)  using pre-
marked H&E stained sections and from reactive tonsil and appendix controls, in 
triplicate using a manual arrayer (Beecher Scientific, Silver Spring, MD) as 
previously described (Hedvat CV et al. 2002; Kononen J et al. 1998). Approximately 
120 cores were applied per slide. All cores from a single patient were randomly 
included on the same TMA. 
 
4.2.3 Immunohistochemistry of validation panel 
Paraffin embedded 4µm sections were cut and placed on TESPA coated slides, 
dewaxed and blocked with hydrogen peroxide/methanol solution. Antigen retrieval 
was performed as detailed in Table 4. Primary antibody was diluted as detailed in 
Table 4. Sections were then stained using the Vector Elite ABC kit (PK6100, Vector 
Laboratories, Peterborough, UK) and chromogen diaminobenzidine (Biostat, 
Stockport, UK). 
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Table 4 Validation panel antibodies 
ANTIBODY MANUFACTURER 
AND CLONE 
CONTROL ANTIGEN 
RETRIEVAL 
DILUTION 
CD3 Labvision CD-3-SP7 Tonsil Pressure 
cooking 
20:5000 
CD5 Novocastra NCL-
CD4-368 
Tonsil Pressure 
cooking 
1:50 
CD10 Novocastra NCL-
CD10-270 clone 
56C6 
Tonsil Pressure 
cooking 
25:1000 
CD20 Dako M755 Tonsil Pressure 
cooking 
20:8000 
CD21 Novocastra NCL-
CD21-2G9 
Tonsil Pressure 
cooking 
1:50 
CD23 Novocastra NCL-
CD23-1B12 
Tonsil Pressure 
cooking 
1:50 
BCL2 Dako clone 124 Tonsil Pressure 
cooking 
100:5000 
BCL6 Dako clone PG-B6p Tonsil Pressure 
cooking 
100:4000 
Ki67 Dako M7240 Tonsil Pressure 
cooking 
10:10000 
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4.2.4 Optimisation of novel antibodies for immunohistochemistry 
Paraffin embedded 4µm sections were cut and placed on TESPA coated slides, 
dewaxed and blocked with hydrogen peroxide/methanol solution. Data sheets 
provided by antibody manufacturers provided appropriate control for titration and 
detail antigen retrieval. If no pretreatment was advised three different techniques 
were tried; no pre-treatment, pronase digestion for 15 minutes and pressure cooking. 
The primary antibody dilution was applied in dilution 1/50, 1/100 and 1/200 unless 
data sheet advised otherwise. The primary antibody was diluted with 1% BSA and 
azide. Sections were then stained using the Vector Elite ABC kit (PK6100, Vector 
Laboratories, Peterborough, UK) and chromogen diaminobenzidine (Biostat, 
Stockport, UK). Staining specificity and intensity was assessed and dilution further 
titrated if necessary. If slides were staining correctly with a known positive control 
all details of manufacturer, clone, pretreatment requirements, antibody dilution and 
known positive control were recorded for future use.  
 
4.2.5 Immunohistochemistry of novel antibodies 
This was carried out as described in the above sections. Antibody retrieval and the 
dilutions used are presented in Table 5. 
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     Table 5 Novel antibodies dilution and antigen retrieval 
ANTIBODY MANUFACTURER 
AND CLONE 
CONTROL ANTIBODY 
RETRIEVAL 
DILUTION 
Aurora B Abcam (ab2254) Cervix Pressure 
cooking 
1:600 
Nm23 Novocastra (NCL-
nm23 clone 37.6) 
Tonsil None required 1:250 
FoxP1 Gift from A. 
Banham, Oxford 
 
 
Tonsil Pressure 
cooking with 
tyramide 
amplification 
1:40 
Mum1/IRF4 
(Multiple 
Myeloma 
Oncogene 1) 
Dako (MUM1p) Tonsil Pressure 
cooking 
1:100 
 
 
4.2.6 Analysis of Tissue Microarrays 
The entire TMA cores were analysed by myself and independently by another 
histopathologist and the number of positive cells expressed as an average percentage 
per high power field (x40 magnification). In the case of small differences in 
percentage (5-10%) an average of the two scores was used as the score. In the cases 
of large differences of score between the two histopathologists (<10% of cases) the 
cases were reviewed by both the scoring histopathologists and consensus reached in 
all cases.  
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4.3 Results 
4.3.1 Establishment of Transformed Tissue Microarray (TMA) 
To accommodate the samples, four TMAs (transformation TMA) were produced 
each containing approximately 96 cores (Figure 28A). Each patient sample was 
arrayed in triplicate and control lymphoid tissue cores (appendix and tonsil) were 
included in each array (Figure 28B and C). Complete pre and post transformation 
sample pairs were assessable in 100 samples (35 patients).  
 
In addition, a separate array composed of de novo DLBCL was constructed 
containing 31 initial diagnostic samples of tumour from 31 patients arrayed in 
triplicate. Control lymphoid tissue cores (appendix and tonsil) were included in the 
array. 
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 Figure 28 Tissue Microarray composition, A) H&E slide of TMA, B) H&E stained 
reactive tonsil core 1 mm diameter OMx5, C) H&E stained appendix core 1 mm 
diameter OMx5 
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4.3.2 Correlation of TMA cores with full sections 
To evaluate the accuracy with which the TMA cores were representative of full 
tissue sections scoring of routine diagnostic immunocytochemistry (CD3, CD5, 
CD10, CD20, CD21, CD23, BCL-2, BCL-6 and Ki67) was performed on TMA cores 
and full sections of ten samples identified at random from the cohort of patients in 
the study. The concordance between TMA and full sections was >90% (Table 6). 
 
Table 6 Correlation of TMA cores with full sections immunocytochemistry  
 
Antibody 
assessed 
TMA scoring correlated with 
full section scoring 
TMA scoring did not correlate 
with full section scoring 
CD3 100% (10/10) 0%   (0/10) 
CD5 100% (10/10) 0%   (0/10) 
CD10 100% (10/10) 0%   (0/10) 
CD20 100% (10/10) 0%   (0/10) 
CD21 100% (10/10) 0%   (0/10) 
CD23 50%   (5/10) 50% (5/10) 
Bcl-2 100% (10/10) 0%   (0/10) 
Bcl-6 90%   (9/10) 10% (1/10)) 
Ki-67 80%   (8/10) 30% (3/10) 
Overall correlation  = 91% 
 
 
Corroboration of gene expression profiling has previously been performed using 
immunocytochemistry and TMA by Hans et al. (2004) who demonstrated 
reproduction of gene expression results by immunocytochemistry in 71% of GCB 
and 88% of non-GCB cases as compared to cDNA microarray (Hans CP et al. 2004). 
This result was used as a yardstick for this work.  
 
4.3.3 Transformed FL is mainly of germinal centre (GC) like phenotype  
The antibody panel identified by Hans et al. (2004) was applied initially to a TMA 
composed of 31 de novo DLBCL samples arrayed in triplicate to ensure that it 
performed as published. The adequacy of this TMA was assessed using a routine 
panel of diagnostic antibodies (CD3, CD5, CD10, CD20, CD21, CD23, CD138, 
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BCL-2, BCL-6, Ki67). If only two cores from a sample were assessable the 
consensus of two cores was accepted (5% of cases). In the event of the loss of two 
cores with only a single assessable core, the result from this was disregarded and 
marked as absent.  
 
In the de novo DLBCL TMA 11/31 (35%) had a GC phenotype. Of these 11 cases, 6 
cases (55%) were CD10+ and 5 cases (45%) were CD10-, BCL-6+, MUM-1-. This 
was similar to the results obtained by Hans et al. (2004) who observed 42% of 152 
DLBCL cases analysed were GC type. The 20/31 non GC cases (65%) were 
composed of 18/20 (90%) CD10-, BCL-6+, MUM-1+ and 2/20 (10%) CD10-, BCL-
6-. The 5 year overall survival for GC patients in this study was 73% and 51% for 
non-GC patients (p=0.00002). The 5 year overall survival for GC patients in the 
study by Hans et al. (2004) was 76% compared to 34% for the non-GC patients. 
 
The transformation TMA was then used to investigate the phenotype of transformed 
DLBCL. Of the transformation samples, 31/35 (89%) demonstrated a GC-like 
phenotype (28/35 (80%) CD10+ and 3/35 (9%) CD10-, BCL-6+, MUM-1-). The 
remaining cases, 3/35 (9%) were of non-GC phenotype (CD10-, BCL-6+, MUM-1+) 
and one case was unclassifiable due to an absence of scorable cores for MUM-1. 
 
4.3.4 Identification of proteins of potential therapeutic value  
Of the genes which were significantly up-regulated on transformation in the 
previously described gene array data AURKB and nm23 were chosen for further 
study.  
 
Levels of AURKB transcript were demonstrated to increase on transformation in a 
subset of patients. Analysis of the AURKB protein by immunohistochemistry 
demonstrated a nuclear staining pattern with obvious staining of chromosomes 
undergoing mitosis, in keeping with its role as a chromosomal passenger protein. 
Within normal germinal centres very few centroblasts (<5%) were positive for 
AURKB and this value was taken as negative for the neoplastic samples. AURKB 
protein expression increased on transformation in 13/33 (40%) of patients (Figure 
29). There was low expression of the protein in both FL and transformed DLBCL in 
18/33 (55%) of patients and a decrease in protein level in 2/33 (6%) of patients.  
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Duration of survival was not significantly different from transformation in patients 
with increased AURKB on transformation compared to those with decreased 
expression (p=0.6) (Figure 30). There was no difference in overall survival either in 
patients with increased or decreased expression of AURKB on transformation 
(Figure 31). 
 
Figure 29 Immunocytochemistry for AURKB demonstrating increase in expression 
in DLBCL transformed from FL, A) FL OM x40, B) DLBCL OM x40 
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Figure 30 Kaplan-Meier estimate of survival from transformation by Aurora Kinase 
B expression (p=0.8).Blue indicates samples which were negative for expression of 
Aurora Kinase in both the FL and transformed DLBCL samples. Red indicates those 
samples where an increase in expression of Aurora kinase was observed in the 
transformed DLBCL sample. 
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Figure 31  Kaplan-Meier estimates of overall survival of patients with transformed 
FL by expression of AURKB (p=0.2). Blue indicates samples which were negative 
for expression of Aurora Kinase in both the FL and transformed DLBCL samples. 
Red indicates those samples where an increase in expression of Aurora kinase was 
observed in the transformed DLBCL sample. 
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Analysis of nm23 protein by immunocytochemistry demonstrated weak positive 
cytoplasmic staining in endothelial cells in both FL and DLBCL in accordance with 
previous work (Niitsu N et al 2004). Only cytoplasmic staining within tumour cells 
was considered to be positive (Figure 32). 
 
Figure 32  Immunocytochemistry staining for nm23, A) FL demonstrating absence 
of staining for nm23 OM x20, B) FL staining positively for nm23 OM x40, C) 
DLBCL staining positively for nm23 OM x40  
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Expression of nm23 protein increased or remained high on transformation in 12/23 
(52%) of patients and decreased or remained low in 11/23 (48%). There was no 
difference in overall survival of patients with increased or decreased expression of 
nm23 or in time to transformation (Figures 33 and 34). 
 
Figure 33 Kaplan-Meier estimates of overall survival of patients with FL who 
transform to DLBCL based on expression of nm23 (p=0.43). Blue indicates cases 
with low expression of nm23 in both the FL and transformed DLBCL or a decrease 
in expression on transformation of FL to DLBCL. Red indicates cases with high 
level of expression of nm23 in both FL and transformed DLBCL or an increase in 
expression level on transformation. 
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Figure 34 Kaplan-Meier estimates of time to transformation of patients with FL who 
transform to DLBCL based on expression of nm23 (p=0.22). Blue indicates cases 
with low expression of nm23 in both the FL and transformed DLBCL or a decrease 
in expression on transformation of FL to DLBCL. Red indicates cases with high 
level of expression of nm23 in both FL and transformed DLBCL or an increase in 
expression level on transformation. 
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4.3.5 Analysis of FOXP1 expression in de novo DLBCL and transformed FL 
Assessment of staining with the antibody to FOXP1 demonstrated clean nuclear 
staining and the cutoff for positive staining was set at 30% in keeping with other 
studies (Barrans SL et al. 2004; Banham AH et al. 2005). Of the 31 cases of de novo 
DLBCL analysed, 11/31 (35%) were classified a GC phenotype and 20/31 (65%) 
were of non-GC phenotype. Thirty cases were available for analysis of FOXP1 
expression, 22/30 (73%) staining positively and 8/30 (27%) showing staining at 
levels less than 30% (classed as negative). Of the GC phenotype cases (n=11); 6 
cases (60%) were FOXP1 positive and 4 cases (40%) were FOXP1 negative. One 
case was unassessable for FOXP1 staining due to insufficient cores available for 
assessment. The non-GC phenotype cases (n=20) demonstrated positive staining in 
16/20 (80%) and negative staining in 4/20 (20%).  
 
Within the t-FL group all three cases of non-GC phenotype demonstrated positive 
staining of tumour cells (100%). These results are similar to those observed by Hans 
et al. (2004) who demonstrated increased expression of FOXP1 in non-GC 
phenotype cases (Hans CP et al. 2004).   
 
4.4 Discussion 
In common with previous other studies (Kononen J et al. 1998; Hoos A et al. 2001), 
this work demonstrated that TMA performs as well as full sections for 
immunocytochemical evaluation of malignancy and provides a high throughput 
approach. Concordance between IHC analysis of three TMA cores of FL and ten 
randomly cases for which full sections were also scored with the validation antibody 
panel was more than 90%. Prior to this study, very little work using the TMA 
technique had been performed on haematological malignancies and FL in particular. 
A single study in 2002 analysed a series of 193 B cell NHLs and 29 Hodgkins 
lymphoma and compared full section staining results to those obtained using TMA 
and found a high correlation (Hedvat CV et al. 2002). There were initial concerns 
that extracting small cores of FL might not include enough neoplastic follicles for 
analysis. To address this issue, the core diameter chosen was 1mm as compared to 
0.6mm diameter which is more frequently chosen in other tissues such as breast 
cancer (Torhorst J et al. 2001). In addition three cores of tissue were extracted from 
every sample. The high concordance with full section evaluation has verified this 
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technique as an appropriate method for analysis of haematological malignancies. 
Subsequent studies have been performed on haematological malignancies and have 
demonstrated good correlation between full sections and tissue microarray cores 
(Garcia JF et al. 2003; Tzankov A et al. 2003; Zettl A et al. 2003).  
 
Gene expression profiling of de novo DLBCL has allowed division of this disease 
into three different groups; germinal centre cell type (GC), activated B cell type 
(ABC) and type 3 with direct correlation to prognosis (Alidazeh AA et al. 2000). 
This genetic work has been translated to protein detection in tissue samples of de 
novo DLBCL using IHC (Hans CP et al. 2004). This work has demonstrated that FL 
transforms to DLBCL of GC phenotype in the majority of cases. This result is 
unsurprising as FL is a neoplasm of the germinal centre B lymphocytes. However, 
five year survival for the transformed patients from the time of transformation is only 
38% despite the majority of these patients (89%) having a phenotype shown to be 
favourable in de novo DLBCL. It is unlikely that the cell of origin for these 
neoplasms is different as they both have the same phenotype. This may be a 
reflection of treatment effect. In patients with de novo DLBCL the disease is an acute 
initial presentation, they will have not received any prior treatment; however patients 
with transformed FL may have presented with FL many years before and have 
potentially received numerous therapies. Evidence indicates that administration of 
chemotherapeutic agents can produce alterations in cell biology in neoplastic cells 
which are not eradicated (Zaslav A-L, Stamberg J, Shende A 1988; Offit K et al. 
1991; Liu Z-L et al. 2002). It is possible that genetic pathways increasing tumour 
aggressiveness have been activated whilst GC phenotype is retained. Patients with 
transformed FL will usually have been diagnosed for several years and consequently 
the tumour cells may have acquired numerous mutations which account for the 
increased tumour aggressiveness. 
 
The confirmation of up-regulation of AURKB at protein level in a subset of patients 
is interesting as it is an attractive therapeutic target. Disruption of the AURKB kinase 
function in a t(14;18) DLBCL cell line results in apoptosis (Harrington EA et al. 
2004). These results indicate that targeting the AURKB may be an effective 
therapeutic regime for some patients who transform from FL to DLBCL. The close 
correlation between gene transcript up-regulation and protein expression indicate that 
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immunocytochemistry is an efficient technique to identify those patients in whom 
AURKB directed therapies would be effective. This is valuable as gene expression 
analysis requires fresh tissue samples as well as being expensive and unavailable to 
clinicians who are not working in academic institutions with access to specialized 
laboratories. This study did not demonstrate a significant correlation with AURKB 
expression and survival. This may be a reflection of the small number of patients 
(n=31) with both pre-transformation and transformed samples available for analysis. 
In fact, within this disease entity and available from a single institution, this is a large 
series. In order to explore further any effect on survival larger sample numbers 
would be required possibly through collaborative studies with other institutions. 
 
The up-regulation of gene transcripts and protein levels of nm23 on transformation is 
also interesting. Studies in other haematological malignancies have demonstrated a 
correlation between poor prognosis and increased nm23 protein levels (Niitsu N et al. 
1999; Niitsu N et al. 2000). In DLBCL and peripheral T cell lymphoma the serum 
protein levels are an independent prognostic factor (Niitsu N et al. 2001). More 
interestingly, increased expression of nm23 in neoplastic tissue from patients with 
DLBCL correlated with reduced overall survival and progression free survival rates. 
Increased levels in the tissue corresponded with increased levels in serum (Niitsu N 
et al. 2004). This could prove to be a cost effective and less traumatic method of 
monitoring patients for evidence of transformation from FL to DLBCL as well as 
providing a clinical parameter for predicting survival. It may also provide an 
important target for therapeutic intervention, as the increase in serum levels of the 
protein in patients with positive tumours suggests that the lymphoma cells 
themselves may be producing nm23. The role of nm23 as a provider of high energy 
nucleosides (Parks RE Jr, Agarwal RP 1973) indicates that the tumours may be 
dependent on the provision of high energy compounds for survival thereby providing 
a potential selective therapeutic target. Unfortunately, nm23 levels are only elevated 
in a subset of patients on transformation. The high correlation between increase in 
gene transcript and detection of increased protein levels by immunocytochemistry 
identities immunocytochemistry as a cost effective and efficient method for selecting 
patients who may benefit from a compound targeting this molecule. Although there 
is no significant correlation between expression of nm23 and overall survival, this 
may be due to the small number of patients available for the study and may be 
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addressed by a larger collaborative study. 
 
Immunocytochemistry for FOXP1 in de novo DLBCL demonstrated a slightly higher 
number of tumours with increased expression than the data produced by Hans et al. 
(2004) (73% versus 61%). Increased protein levels were observed in tumours with a 
non-GC phenotype. This is in contrast to the findings of a previous study where 
FOXP1 expression was present only in patients lacking a GC phenotype (Barran SL 
et al. 2004) but is in keeping with the data produced by Hans et al. (2004). 
 
Finally, immunocytochemistry on TMA composed of samples from patients with 
transformed FL in association with the clinical history is a powerful tool for 
analyzing the protein changes occurring throughout the natural history of the disease. 
The ability to incorporate all biopsies from a single patient onto one slide removes all 
the procedural variables which might produce differences in immunocytochemical 
staining and increases confidence that any changes observed are true. It is also an 
important method of conserving valuable material, improving cost efficiency and 
increasing speed of analysis. This approach can aid the selection of patients who are 
most likely to benefit from directed therapeutic approaches.  
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CHAPTER FIVE: 
Number of CD4-positive cells and location of FOXP3-
positive cells in diagnostic follicular lymphoma tissue 
microarrays correlates with outcome 
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5.1 Introduction 
The heterogeneous nature of FL makes the treatment of patients with this disease 
difficult. There are numerous treatment options available ranging from a simple 
‘watch and wait’ strategy through various chemotherapeutic options to bone marrow 
transplantation. It is essential that patients are allocated to the most appropriate 
therapeutic option for them. Currently, this is based on varying clinical factors 
encompassed in the Follicular Lymphoma International Prognostic Index (FLIPI) 
(Solal-Celigny P et al 2004). Although the FLIPI is useful as an aid to stratify 
patients it has limited discriminative power and better prognostic biomarkers are 
needed. The observation that it was possible to predict survival in FL based on the 
molecular features of the TILs using gene expression profiling renewed interest in 
the role of the microenvironment in FL pathogenesis (Dave SS et al. 2004). There are 
disadvantages with gene expression profiling in that it is a technique which requires a 
level of expertise and equipment which may be beyond many general hospitals. In 
addition, it is expensive and requires fresh tissue for optimal results. Finally, the 
presence of these changes at a protein level in numerous samples would be a stronger 
indicator of importance than gene expression data alone.  
 
 
5.1.1 Aims and Objectives: 
In order to further explore and validate the gene expression data at a protein level a 
patient population with survival at the extremes of FL expected survival (<5 years 
and >15 years) was selected. Using paraffin-embedded diagnostic biopsies of FL, a 
TMA from 59 patients was constructed. The relationship between immune 
microenvironment phenotype and survival in FL was examined with particular 
regard to Tregs.   
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5.2 Materials and Methods 
5.2.1 Patient samples 
Ethical approval for this study was obtained from the Local Regional Ethics Board.   
Thirty four initial diagnostic paraffin-embedded lymph node blocks samples from FL 
patients with survival of less than five years from diagnosis and 25 from patients 
whose survival was more than 15 years from diagnosis were identified from those 
treated at St. Bartholomew’s Hospital between 1974 and 1999. Patients were treated 
according to the current protocol over the 25-year period (Gallagher CG et al.1986; 
Johnson P et al. 1995; Apostolidis J et al. 2000). Broadly, at presentation those with 
stage I disease were treated with involved-field irradiation, the remainder were 
managed expectantly, until chemotherapy was instituted when there was an 
indication for intervention. Following achievement of remission, management was 
again expectant.  
 
5.2.2 Tissue microarray construction 
Tissue microarrays (TMA) were constructed of 1mm cores of patient tissue taken 
from representative areas of lymphoma (>5 neoplastic follicles) using pre-marked 
H&E stained sections and from reactive tonsil and appendix controls, in triplicate 
using a manual arrayer (Beecher Scientific, Silver Spring, MD) as previously 
described (Hedvat CV et al. 2002; Kononen J et al. 1998). Approximately 120 cores 
were applied per slide.  
 
5.2.3 Immunohistochemistry 
The test panel of antibodies and dilutions used for immunohistological analysis are 
shown in Table 7. TMA blocks were cut to 4 microns and applied to TESPA-coated 
slides, then dewaxed and blocked in hydrogen peroxide/methanol solution. Antigen 
retrieval was performed by pressure-cooking in citrate, or in the case of FOXP3, 
EDTA (Norton AJ, Jordan S, Yeomans P 1994). Sections were then stained using the 
Vector Elite ABC kit (PK6100, Vector Laboratories, Peterborough, UK) or for 
FOXP3, CSA II tyramide amplification system (DAKO, Denmark), followed by 
diaminobenzidine chromogen (Biostat, Stockport, UK). Appropriate negative and 
positive controls were always used. 
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Table 7 Antibodies used for the investigation of the immune microenvironment 
Test Antibody  
 
Clone  Source  Dilution 
CD4 
 
NCL-CD4-368 
clone4B12 
 
Novocastra, 
Newcastle, UK 
 
1/100 
 
CD7 
 
NCL-CD7-272 
clone 272 
 
Novocastra, 
Newcastle, UK 
 
1/50 
 
CD8 
 
C8/144B 
 
Dako 
 
1/50 
 
CD25 
 
NCL-CD25-305 
clone 4C9 
 
Novocastra, 
Newcastle, UK 
 
1/100 
 
CD68 
 
KP1 
 
Dako 
 
1/4000 
 
Granzyme-B 
 
NCL-GRAN-B 
clone 11F1 
 
Novocastra, 
Newcastle, UK 
 
1/40 
 
TIA-1 
 
Ab2712 
 
Abcam, 
Cambridge, UK 
 
1/50 
 
FOXP3 
 
Supernatant 
Clone 236A/E7 
 
Gift from Alison 
Banham, John 
Radcliffe, 
Oxford (Roncador 
G et al. 2005 )  
 
Neat 
 
 
 
 
5.2.4 Double staining for CD4 and FOXP3 
After antigen retrieval by pressure cooking in citrate, staining for CD4 was 
performed using Vectastain Elite ABC kit with diaminobenzidine as chromogen. 
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This was followed by staining for FOXP3 using Vectastain Elite ABC-AP (alkaline 
phosphatase) with Fast Red as chromogen.  
 
5.2.5 Immunohistochemical analysis 
Presence of adequate FL tumour cells in the tissue cores was confirmed by scoring 
with a diagnostic lymphoma antibody panel comprising CD3, CD5, CD10, CD20, 
CD21, CD23, BCL-2, BCL-6, Ki-67, TP53, MUM-1 as previously described in 
Chapter 4 (data not shown). 
 
The entire 1mm diameter core was analysed at low power (x5 magnification) and 
high power (x40 magnification) in each case. Where one of three cores could not be 
scored due to insufficiency of tissue, consensus of 2 cores was accepted although this 
was necessary in only 10% of the total 1,416 cores analysed. If two cores of three 
were insufficient, no scoring was attempted and the result was noted as ‘absent’ for 
that sample with the antibody in question. As a result, the maximum number of 
patient cases (34 for the short-survival group and 25 for the long-survival group) 
were not always assessable for each of the test panel antibodies. 
 
Staining using a test panel of immune-cell-associated antigens CD4, CD7, CD8, 
CD25, CD68, TIA-1, Granzyme B and FOXP3 was evaluated for number of positive 
cells. Scoring was divided into the following categories, <5 cells/high power (x40 
magnification) field (hpf), 5-10 cells/hpf, 10-15 cells/hpf, 15-30 cells/hpf and >30 
cells/hpf.  Topographical distribution of positive cells was also evaluated. Location 
relative to the neoplastic follicle (perifollicular, intrafollicular and not bearing either 
of those patterns but being evenly distributed) was recorded. 
 
5.2.6 Statistical analysis 
Fisher’s Exact Test was performed to determine whether the incidence of antigen 
expression was significantly different between samples from patients at the extremes 
of survival  
 
5.3 Results 
5.3.1 Patient Characteristics 
Diagnostic FL biopsies from patients at the extremes of survival were studied in this 
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work (Lee AM et al. 2006). Histology was reviewed in all cases. The characteristics 
of the 59 patients are shown in Table 8. Patients who lived less than 5-years from 
diagnosis, the ‘short survivor group’, had a median survival of 2 years and all died of 
disease.  Patients who lived more than 15 years from diagnosis, the ‘long survivor 
group’ had a median survival of 21 years. Although the short survivor group, were 
significantly older than the long survivor group with a median age of 61 and 46 years 
respectively, as shown in Table 8, there was no significant difference in the 
incidence of transformation, of bone marrow involvement, stage or grade between 
these two patient groups. 
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 Table 8 Demographics of patients from the extremes of survival 
Characteristics  ‘Short Survivor 
Group’ 
‘Long Survivor 
Group’  
N=59  34  (25 male, 9 
female) 
25 (16 male, 9 
female) 
Median survival  (years) 2  (0.08-4.8) 21 (15.3-30.4) 
Median age at Diagnosis  61 years (range 
28-80 years) 
46 years(range 24-
63 years) 
Stage at   
diagnosis  
I 
II 
III 
IV 
4 (12%) 
3 (9%) 
4 (12%) 
23 (68%) 
3 (12%) 
6 (24%) 
4 (16%) 
12 (48%) 
Histological pattern Follicular: 33 
(97%) 
Follicular and 
Diffuse: 1 (3%)      
Follicular: 24 
(96%) 
Follicular and 
Diffuse: 1 (4%) 
Grade at 
diagnosis 
1 
1&2 
2 
2&3 
3 
3b 
18 (53%) 
3 (9%) 
8 (24%) 
1 (3%) 
4 (12%) 
0 
16 (64%) 
4 (16%) 
2 (8%) 
3 (12%) 
0  
0 
Proceeded to Transform 9/34 (26%) 3/25 (12%) 
Time to 
Transformation 
2 at 1-yr, 2 at 2-yrs 
and 5 at 3-yrs 
2, 7 and 16-yrs 
 
Cause of death 
 
Disease: 34 
(100%) 
 
Still alive: 15 
(60%) 
Disease: 3 (12%) 
Other disease or 
unrelated 
infection:  7  
(28%) 
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Bone marrow involvement 17/34 (50%) 12/25 (48%)  
Treatments  
Exp.Management 
1 
2 
3 
4 
5 
6 
7 
8 
 
1 (3%) 
7 (21%) 
6 (18%) 
4 (12%) 
5 (15%) 
2 (6%) 
6 (18%) 
3 (9%) 
0 
 
1 (4%) 
6 (24%) 
6 (24%) 
3 (12%) 
3 (12%) 
2 (8%) 
0  
1 (4%) 
3(12%) 
 
 
5.3.2 Analysis of the TMAs 
For each antibody, 2 (maximum of 10% cases over all the antibodies studied) or 3 
replicate cores were assessable from 31 to 34 cases from the short-survival group and 
22 to 25 cases from the long-survival group. Scoring was also divided into the 
following categories, <5 cells/hpf, 5-10 cells/hpf, 10-15 cells/hpf, 15-30 cells/hpf and 
>30 cells/hpf.  Analysis of these categories did not reveal any additional correlation 
with outcome and for further analysis the categories <5 cells/hpf and >5 cells/hpf 
were used (Table 10). 
 
5.3.3 CD4; Incidence is significantly different between short and long survivor 
groups 
CD4 expression was assessable in 56 out of 59 (95%) total cases; the 3 unassessable 
cases were all from the long survivor group. CD4-expressing cells were observed at 
levels >5/hpf in 36/56 (66%) cases; 18/34 (53%) cases from the short survivor group 
and 18/22 (82%) biopsies from the long survivor group (p=<0.05; Table 9). 
Representative CD4 stained TMA cores are shown in Figure 35.  
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Table 9 Expression of immune cell antigens in diagnostic FL lymph nodes 
Antigen Number of 
assessable cases 
(N=) 
<5 cells 
positive/high power 
field 
>5 cells  
positive/high 
power field 
 
Short 
Survivor 
Group 
Long 
Survivor 
Group 
Short 
Survivor 
Group 
Long 
Survivor 
Group 
Short 
Survivor 
Group 
Long 
Survivor 
Group 
CD4 34 22 16/34 
47% 
4/22 
18% 
18/34 
53% 
18/22 
82% 
 
  P=<0.05  
FOXP3 31 24 11/31 
35% 
3/24 
13% 
20/31 
65% 
21/24 
87% 
 
  P=0.07  
CD8 33 22 3/33 
9% 
0/22 
0% 
30/33 
91% 
22/22 
100% 
 
  P=0.27  
CD7 34 23 6/34 
18% 
1/23 
4% 
28/34 
82% 
22/23 
96% 
 
  P=0.22  
CD25 33 23 11/33 
33% 
4/23 
17% 
22/33 
67% 
19/23 
83% 
 
  P=0.23  
CD68 33 22 3/33 
9% 
2/22 
9% 
30/33 
91% 
20/22 
91% 
 
  P=1.00  
TIA-1 32 24 3/32 
9% 
1/24 
4% 
29/32 
91% 
23/24 
96% 
 
  P=0.63  
Granzyme B 31 25 24/31 
77% 
20/25 
80% 
7/31 
23% 
5/25 
20% 
   P=1.00  
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Figure 35  CD4 expression on TMA cores from diagnostic FL biopsies taken at low 
power (OMx 10 magnification) (A, C) and high power (OMx 40 magnification) (B, 
D). Cases with absence (<5 cells / high power field) (A, B) and presence (C, D) of 
CD4 expression (>5 cells/high power field) are illustrated. 
 
 
  
    
A B 
C D 
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The incidence of a very high level of expression of CD4 (>30 cells/hpf) was the same 
between the two groups (Table 10).  
 
Table 10 Incidence of CD4 + cells in the short and long survivor groups of FL 
demonstrating no advantage in smaller divisions of cell number 
Cell no. 
/high power field 
Short Survivor 
Group  
(number of cases) 
Long Survivor 
Group  
(number of cases) 
Difference 
between the 
two 
survivor 
groups 
<5 16 4 p=0.045 
5-10 3 6 p=0.133 
10-15 3 2 p=1.000 
15-30 6 5 p=0.736 
>30 6 5 p=0.736 
Total cases 34 22  
 
Amongst all the patients studied (56 assessable for CD4) those with <5 CD4 cells/hpf 
in their diagnostic sample had a median age of 62-years (range 34-77 years old) 
while the median age of those bearing >5 CD4 cells/hpf was 54-years (range 24-80 
years old) (p=0.08). 
 
We examined the location of positively staining cells in relation to the neoplastic 
follicle (intrafollicular, perifollicular and evenly distributed with no intra- or 
perifollicular pattern). Absence of CD4 correlated with poor outcome (p=<0.05, 
Table 8), and in cases where CD4-positive cells were present, there was a trend 
towards a significant difference in their location between the two survivor groups 
(Fishers exact 3 x 2, p=0.09; Table 11). 
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Table 11 Location of CD4+, CD25+, or FOXP3-Positive cells in short and long survival groups with FL, and correlation with survival 
 CD4 CD25 FOXP3 
Location of positive cells No. of Short  
Survivor 
Cases/34 
No. of Long 
Survivor 
Cases/22 
No. of Short  
Survivor 
Cases/33 
No. of Long 
Survivor 
Cases/23 
No. of  
Short  
Survivor 
Cases/31 
No. of  
Long 
Survivor 
Cases/24 
Absence  16 (47%) 4 (18%) 11 (33%) 4 (17%) 11 (35%) 3 (13%) 
Perifollicular  10 (29%) 11 (50%) 3 (9%) 7 (30%) 2 (6%) 8 (33%) 
Throughout 8 (24%) 7 (32%) 19 (58%) 12 (52%) 18 (58%) 13 (54%) 
Difference in distribution 
between the survivor groups 
Fisher’s Exact 
 
p=0.09 
 
p=0.1 
 
p=0.02 
 
Key 
Absence: <5/hpf 
Perifollicular: intrafollicular <5/hpf; perifollicular 5-30/hpf 
Throughout: positive cells (>5/hpf) evenly distributed across the cores and no clear perifollicular pattern observed 
Chapter Five: CD4 positve lymphocytes and FOXP3 positive cells in FL 
 
164 
5.3.4 T regulatory cells and outcome 
There was a trend towards patients with long survival being more likely to contain 
FOXP3 positive cells in their biopsy (p=0.07) but none of the other immune cell 
associated antigens studied showed any significant association between frequency 
and survival (Table 9), In addition, the pattern of FOXP3 expression was 
significantly different in the short and long survivor groups (Fishers Exact 3 x 2 
p=0.02; Table 11). Examples of the different staining patterns observed for FOXP3 
expression are shown in Figure 36. Patients from the long survivor group had 
FOXP3-positive cells at a higher incidence in a perifollicular location than the 
patients of the short survivor group (collapsed 2 x 2 Fisher’s Exact p=0.01; Table 
12).  
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 Figure 36 FOXP3 expression on TMA cores from diagnostic FL biopsies taken at 
low power (OM x10) (A, C, E) and high power (OM x40) (B, D, F). Cases with 
absence (<5 cells / high power field) (A, B) and presence of FOXP3 expression (>5 
cells/high power field) in a perifollicular pattern (C, D) or evenly distributed 
throughout the tissue (E, F) are illustrated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
A B 
E 
D 
F 
C 
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The location of CD25 expression showed a trend towards occurrence in a 
perifollicular location amongst the samples from patients within the long survivor 
group (collapsed 2x2 Fisher’s Exact p=0.07; Table 12) 
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Table 12 Locations of CD4, CD25 or FOXP3-positive cells in short and long survivor groups with FL, and correlation with survival 
 CD4 CD25 FOXP3 
 No. of 
Short  
Survivor 
Cases/34 
No. of 
Long 
Survivor 
Cases/22 
No. of 
Short  
Survivor 
Cases/33 
No. of 
Long 
Survivor 
Cases/23 
No. of  
Short  
Survivor 
Cases/31 
No. of 
Long 
Survivor 
Cases/24 
Absence+throughout  
 
Perifollicular 
24 
 
10 
11 
 
11 
30 
 
3 
16 
 
7 
29 
 
2 
16 
 
8 
Difference in distribution between the survivor groups.  
Fisher’s Exact 
p=0.16 p=0.07 p=0.02 
Absence+perifollicular  
 
Throughout 
26 
 
8 
25 
 
7 
14 
 
19 
11 
 
12 
13 
 
18 
11 
 
13 
Difference in distribution between the survivor groups. 
Fisher’s Exact 
p=1.00 p=0.79 p=0.59 
 
Key 
Absence: <5/hpf 
Perifollicular: intrafollicular <5/hpf; perifollicular 5-30/hpf 
Throughout: positive cells (>5/hpf) evenly distributed across the cores and no clear perifollicular pattern observed 
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The finding that CD4 incidence and FOXP3 distribution at diagnosis were important 
to outcome implied the involvement of the Treg subset that variably bear these 
antigens.  The incidence of cells expressing CD4, CD25 or FOXP3 on the same cases 
from the short survivor group (n=30) and the long survivor group (n=20) is shown in 
Table 13.  
 
Table 13 Incidence of CD4, CD25 and of FOXP3 in same diagnostic biopsies of 
short and long survivors of FL 
 Short Survivor Group Long Survivor Group 
Cell no. /high 
power field 
CD4 CD25 FOXP3 CD4 CD25 FOXP3 
<5 14 9 10 5 3 3 
5-10 2 4 8 3 10 8 
10-15 3 7 7 2 6 7 
15-30 6 7 4 5 1 1 
>30 5 3 1 5 0 1 
Total cases N=30 N=20 
 
 
Double staining with CD4 and FOXP3 revealed cells co-expressing these antigens in 
a case from the long survivor group (Figure 37 (A) and (B))  
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Figure 37 Double staining for CD4 (membranous brown) and FOXP3 (nuclear red) 
Long survivor-group – A) low power (OM x10), B) high power (OM x63) 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
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5.4 Discussion 
This study of 59 diagnostic samples taken from FL patients whose outcome was 
either good or poor draws attention to the importance of the immune system in the 
setting of haematological malignancy and provokes speculation as to the roles and 
mechanisms involved. We identified that CD4-positive cells and a perifollicular 
pattern of FOXP3-positive cells are more commonly found in the diagnostic FL 
lymph node from patients whose subsequent outcome was favourable. These findings 
are in keeping with the hypothesis that the presence of CD4-positive cells are of 
benefit to the host. This has been previously observed in a study where significantly 
more CD4-positive T lymphocytes were present in the biopsies of untreated FL 
patients who underwent spontaneous remission (Strickler S et al. 1988).  
 
The finding that the presence of CD4 T lymphocytes is more commonly observed in 
the biopsies from patients with an improved prognosis is in keeping with the gene 
expression data (Dave SS et al. 2004). Although CD7 appears as a member of the 
immune response gene expression signature correlating with better outcome (IR-1) in 
FL (Dave SS et al. 2004) expression of CD7 protein alone did not correlate with 
survival in the data presented here. The data generated by Farinha and colleagues 
using immunohistochemistry for CD68, a macrophage marker, observed a short 
survival correlated with >15 positive staining cells/hpf in diagnostic biopsies 
(Farinha P et al. 2005). Immunocytochemical expression of CD68 was used as a 
surrogate for the macrophage IR-2 signature. In the patient groups examined in this 
work no correlation was found between the numbers or the location of CD68 positive 
cells and survival. This may be a reflection of the very different patient populations 
studied, the patient group studied by Farinha et al. was composed of younger patients 
(median age 44 years range 19 – 61 years) with aggressive disease treated with 
multi-agent chemotherapy (Farinha P et al. 2005). Alternatively it may result because 
CD68 is not one of the 24 genes in the IR-2 signature (Dave SS et al. 2004) and other 
genes from that signature should be assessed.   
 
It is known that age-related changes in the immune system occur; function is 
impaired as exemplified by reduced vaccination efficacy (Cook JM et al. 1987; Phair 
J et al. 1978) and by higher incidence of certain infections, cancers and autoimmune 
disease (Yoshikawa TT 2000). While absolute numbers of lymphocytes are 
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maintained throughout life (Hulstaert F et al. 1994; Pido-Lopez J et al. 2002) the T-
cell subset composition and distribution may alter (Wallace DL et al. 2004). The 
frequency of CD4-positive cells in the FL lymph nodes showed a trend towards 
correlation with age in the present study. A larger sample size may therefore 
demonstrate that the adverse relation between age and outcome in FL is associated 
with age-related changes in the immune cell composition. 
 
In non-neoplastic lymphoid tissue, distribution of FOXP3-positive cells varies. 
Within tonsils FOXP3 cells are in a predominantly perifollicular distribution whereas 
within reactive lymph nodes an evenly distributed pattern is seen (Roncador G et al. 
2005). The data from this study shows FOXP3-positive cells occur in the 
perifollicular region more commonly in samples from patients with longer survival.  
This would seem to differ from data in epithelial malignancies where recruitment of 
FOXP-3 positive Tregs within the tumour appears to promote tumour tolerance 
(Curiel TJ et al. 2004). FL is a malignancy of the haematopoietic system from which 
the Tregs are an integral part and so their impact on tumours of this system may be 
very different. It has been shown that activated CD4+CD25+ T lymphocytes can kill 
B lymphocytes in a cell-contact dependent manner, induction of death is caused by 
up-regulation of perforin and granzyme in the CD4+CD25+ T cells (Zhao DM et al. 
2006). CD4+CD25+ T cells have also been shown to lyse antigen presenting B cells 
by Fas-Fas ligand interaction (Janssens W et al. 2003). CD4+CD25+ T cells can 
down-regulate the expression of the co-stimulatory molecules CD80 and CD86 on 
dendritic cells (Cederbom L, Hall H, Ivars F 2000). In addition, regulatory T cells 
can suppress immunoglobulin production and class switch recombination by direct 
action on B lymphocytes (Lim HW et al. 2005). All of these actions of Tregs can act 
on neoplastic B lymphocytes which comprise FL and prevent its effective survival 
and expansion. The findings in this study are in keeping with others in 
haematological malignancies. Carreras et al. recently reported that a high number of 
FOXP3-positive cells correlated with improved survival in FL although the location 
of these cells was not important (Carreras J et al. 2006). Minor differences in their 
study and this study may be explained by variance in samples and methodology. 
Carreras et al. used computer-analysis of full sections, studied more patients with a 
mixed and diffuse histology and defined location differently (Carreras J et al. 2006). 
Chapter Five: CD4 positve lymphocytes and FOXP3 positive cells in FL 
 
172 
In classical Hodgkins disease (cHD) an inverse relationship between TIA-1 and 
FOXP3 expression and survival has been demonstrated; higher levels of FOXP3 
twinned with low TIA-1 being beneficial (Alvaro T et al. 2005). Analysis of TIA-1 
and FOXP3 in this study of FL did not demonstrate the same findings. FOXP3-
positive cells are the rate limiting subset of the immune response. Their presence 
surrounding the highly active germinal centre in an infected tonsil would support this 
function and leads to speculation that patients who do well after diagnosis of FL may 
do so in part because of an active immune response at the time of developing the 
tumour, with the lymphoma cells either as target or as bystander.   
 
The Treg-associated markers CD4, CD25 and FOXP3 did not consistently correlate, 
most likely because these antigens are variably expressed. It is known there is a 
subset of CD8 Tregs (Xystrakis E et al. 2004). Additionally, in humans FOXP3 
positive cells can be CD25high or CD25low (Fontenot JD et al. 2005a). 
 
The prognostic significance of the immune microenvironment in FL at diagnosis may 
reflect factors involved in determining the inherent ‘aggression’ of the tumour and its 
ability to recruit infiltrating cells on the one hand or co-exist with naturally occurring 
cells of the lymph node on the other. This study has identified that CD4-expressing 
cells and perifollicular distribution of FOXP3-expressing cells occurs more 
commonly in the diagnostic tumour microenvironment of FL patients with better 
outcome compared to those with poor outcome. Elucidating the phenotype and 
functional capabilities of these cells is likely to provide a better understanding of the 
impact of the immune microenvironment on tumour progression in FL and may 
identify novel targets for the potentiation of tumour immunotherapy. The findings in 
this current study can be easily translated to the routine diagnostic histopathology 
setting and may be a method to aid identification of patients with potentially 
aggressive disease at the time of diagnosis.  
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6.1 Introduction  
CD4+CD25+ regulatory T lymphocytes isolated from human peripheral blood 
suppress the proliferation and cytokine production of naïve and memory T cells in 
vitro.  
 
Two different isoforms of FOXP3 have been identified in CD4+CD25+ Tregs with 
one version lacking the second coding exon. Human CD4+CD25+ Tregs co-express 
the two isoforms of FOXP3 and it is only when both isoforms are expressed is there 
consistent and strong suppression of IL-2 and IFN-γ production (Allan SE et al. 
2005).  
 
Previous work has demonstrated an increase in CD4+CD25+ T cells with Treg 
characteristics in the peripheral blood of patients with epithelial malignancies as 
compared to healthy controls. These CD4+CD25+ cells were able to suppress the 
proliferation of CD4+CD25- T cells and could inhibit NK-cell-mediated cytotoxicity 
(Wolf AM et al. 2003).  
 
The aim of this work was to determine the proportion of CD4 positive Tregs within 
the PBMC of healthy controls and patients with FL. In addition, the number of CD8 
positive Tregs in healthy controls and patients was assessed and a more detailed 
phenotype of Tregs performed by flow cytometry. There are reports of Tregs which 
are CD25 negative (Fontenot JD et al. 2005).  FOXP3 expression has been 
demonstrated to be transiently up-regulated in a small proportion of CD4+ and CD8+ 
cells upon in-vitro stimulation. These cells were unable to suppress T helper 1 
cytokine expression (Gavin MA et al. 2006). In a non-suppressive cell population 
FOXP3 expression was demonstrated to be transient (Wang J et al. 2007). Recent 
studies have identified the α chain of the IL-7 receptor, CD127, to be down-regulated 
on cells expressing FoxP3 and exhibiting suppressive activity (Liu W et al. 2006; 
Seddiki N et al. 2006). Consequently CD127 was included in flow cytometry to 
ensure that true regulatory cells were assessed.  
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6.2 Materials and Methods 
Ethical approval was sought and approved by the East London and The City HA 
Local Research Ethics Committee 3; REC reference number 05/Q0605/140. Frozen 
peripheral blood mononuclear cells (PBMCs) from pre-treated patients with 
confirmed FL were obtained from the Tissue Bank maintained by the Medical 
Oncology Unit of St Bartholomew’s Hospital. Fresh samples were also obtained 
from patients in clinic. Fresh peripheral blood was also obtained from healthy 
controls. All patients and controls consented to the storage and use of their samples 
for ethically approved research. 
 
6.2.1 Quantification of the percent of regulatory T cells in fresh PBMC 
Peripheral blood mononuclear cells from patients with FL and healthy controls were 
separated from whole blood by ficoll-hypaque density gradient. The monolayer was 
removed and the cells washed and a cell count performed after resuspension in 5mLs 
of washing buffer. Aliquots of 1 million cells were removed for flow cytometry 
analysis at this point and stored on ice.  
 
6.2.2 Thawing of cryopreserved cells 
The vial was removed from liquid nitrogen and thawed immediately in a water bath 
at 37˚C and transfer to an empty sterile 15mL Falcon tube. RPMI medium was added 
dropwise to a volume of 10mL. The tube was centrifuged at 393g for 10 minutes at 
room temperature. The supernatant was removed and the pellet resuspended in 5mLs 
of RPMI and the dead cells separated using ficoll-hypaque density gradient. The 
monolayer was removed and the cells washed and a cell count performed after 
resuspension in 5mLs of washing buffer. Aliquots of 1 million cells were removed 
for flow cytometry analysis at this point and stored on ice. We noted no differences 
between fresh and frozen samples. 
 
6.2.3 Flow cytometry 
One mL of degassed buffer was added to each aliquot and the samples centrifuged at 
393g for 10 minutes at 4-8ºC. Ten µL of each required antibody was then added to 
the appropriate tubes and the samples incubated for 30 minutes at 4ºC. The cells 
were than washed in degassed buffer and centrifuged at 393g for 10 minutes at 4ºC. 
If required, intracellular staining for FoxP3 was then performed. The supernatant was 
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removed and the cells resuspended in 500µL of degassed buffer. The antibodies and 
conjugates used are indicated in Table 14.  
 
Table 14 Antibodies used for Flow Cytometry 
Antigen Conjugate Amount 
(µL) 
Dilution Isotype Manufacturer 
CD3 APC 10 1:11 IgG2a Miltenyi Inc 
CD4 FITC 10 1:11 IgG2a Miltenyi Inc 
CD8 FITC 10 1:11 IgG2a Miltenyi Inc 
CD19 APC 10 1:11 IgG1 Miltenyi Inc 
CD25 PE 10 1:11 IgG2b Miltenyi Inc 
CD127 PE 20 1:10 IgG1 eBioscience 
FOXP3 APC 10 1:11 Mouse 
IgG1 
Miltenyi Inc 
Isotype 
control 
FITC 10 1:11 Mouse 
IgG2a 
Miltenyi Inc 
Isotype 
control 
APC 10 1:11 Mouse 
IgG1 
Miltenyi Inc 
Isotype 
control 
PE 10 1:11  Mouse 
IgG2a 
Miltenyi Inc 
Isotype 
control 
PE 20 1:11 Mouse 
IgG1 
Miltenyi Inc 
 
 
Flow cytometry was performed on a LSR cytometer (BD Biosciences, Cowley, 
Oxford). FlowJo software (Treestar Inc) was used for analysis. The initial voltage 
settings were obtained using an unlabelled cell sample. The unlabelled cell sample 
was also used to draw a gate over the lymphocyte region as determined by forward 
(FSC) and side scatter (SSC). Compensation levels between FL1 (FITC) and FL2 
(PE) were set using cell samples stained with a single fluorochrome.  
 
6.2.3.1 Identification of regulatory T cells 
The lymphocyte gate determined using the unlabelled cell sample was applied to the 
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stained samples. Within this gate the CD4 or CD8 positive cells were identified using 
the isotype control as a gating measure. The CD4 or CD8 positive cells were selected 
and those positive for FOXP3 were identified using the isotype control as a gating 
measure. Finally the CD4/FOXP3 positive or CD8/FOXP3 positive cells were 
selected and the amount of CD127 positivity assessed. Those cells which were 
negative for CD127 were designated as regulatory T cells.  
 
6.3 Results 
6.3.1 The use of FOXP3 and CD127 identifies a smaller population of Tregs than use 
of CD4 and FOXP3 
As described in the Materials and Methods (6.2.2.1) Tregs were identified using both 
FOXP3 positivity and negativity for CD127. The use of both of these markers 
identified a population of cells which was smaller than the population identified 
using FOXP3 positivity. This demonstrated in Figure 38 below; the first graph 
shows a CD4 and FOXP3 positive population of 0.76%. The expression of CD127 in 
this population demonstrates that not all of these cells are CD127 negative. Using the 
histogram setting 64.3% of this cell population were identified as CD127 negative 
therefore the percent of Tregs which are CD4+FOXP3+ and CD127 negative is 
64.3% of the originally identified percentage 
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Figure 38 Flow cytometry graphs demonstrating that FOXP3 and CD127 together 
identify a smaller population of Tregs than FOXP3 staining alone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.3.2 CD4 positive FOXP3 positive cells are not all CD25 high 
The expression of CD25 in the CD4+FOXP3+ cell population was explored. The 
CD25 expression of this cell population was demonstrated to be predominantly high 
although a reasonable population of these cells were low and medium (Figure 39). 
This finding agrees with previous data (Fontenot JD et al. 2005). 
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Figure 39 Flow cytometry plots demonstrating the variable expression of CD25 in 
the CD4 positive FOXP3 positive cell population 
 
 
 
 
 
 
 
 
 
 
6.3.3 Phenotypic analysis of peripheral blood mononuclear cells in healthy controls 
compared to patients with FL 
Phenotypic analysis was performed on the lymphocyte population of peripheral 
blood mononuclear cells of 13 age matched healthy controls and 18 pre-treated 
patients with follicular lymphoma. The mean percentage of the lymphocyte gate CD3 
positive cells in healthy controls was significantly higher (67.08%) than the 
percentage of CD3 positive cells in patients with FL (45.18%) (p=0.0074) (Figure 
40). The treatment regimes of the patients are listed in Table 15 
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Table 15 Clinical treatment and status of patients at time blood sample taken 
Patient Diagnosis Age at 
diagnosis 
(years) 
Treatment Status at time 
sample taken 
1 FL 35 CHOP Expectant 
management at 
first relapse 
2 FL 59 Radiotherapy CR post 
treatment 
3 FL 27 Transplant Remission post 
transplant 
4 FL 34 CVP Expectant 
management at 
fourth relapse 
5 FL 56 Expectant management Expectant 
management 
6 FL  50 Velcade and rituximab Fourth relapse 
initial GPR 
7 FL  37 Transplant CR post 
transplant 
8 FL  27 Transplant CR post 
transplant 
9 FL  60 Transplant CR post 
transplant 
10 FL  67 Expectant management Expectant 
management 
11 FL 32 Chlorambucil GPR 
12 FL 46 Transplant CR post 
transplant 
13 FL 81 Radiotherapy Expectant 
management at 
first relapse 
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14 FL 34 FMD CR 
15 FL 40 Transplant Expectant 
management at 
sixth relapse 
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 Figure 40 Percent of CD3 positive cells peripheral blood mononuclear cells in 
healthy controls compared to patient samples from patients with FL  
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition, the variability of percentage of CD3 positive cells was significantly 
higher in the patient population compared to the healthy controls (p=0.0005). 
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6.3.4 Phenotypic analysis of regulatory T lymphocytes in PBMC from healthy 
controls and patients with FL 
There was no significant difference between the percent of CD4 Tregs defined as 
CD4+FOXP3+CD127-, expressed as a percentage of the total CD4 positive cell 
population, in the patient samples (3.57%) compared to the healthy control samples 
(1.84%)(p=0.24)(Figure 41). The variation between patient samples and healthy 
controls was statistically significant (p=0.0001) (Figure 42). 
 
Figure 41 Percent of CD4 regulatory T cells expressed as a percentage of total CD4 
positive lymphocytes in the peripheral blood of patient samples from patients with 
FL compared to healthy controls 
 
 
 
 
 
 
 
 
 
 
 
Controls Patients
0
5
10
15
20
25
Pe
rc
en
t o
f C
D
4 
Tr
eg
s
Chapter Six: Immunophenotyping of regulatory T cells in Peripheral Blood 
 
184 
Figure 42 Graph to demonstrate the variance in percent of CD4 regulatory T cells 
expressed as a percentage of total CD4 positive lymphocytes in the peripheral blood 
of patient samples from patients with FL compared to healthy controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
As expected, there were fewer numbers of CD8 positive Tregs. There was no 
significant difference between the percent of CD8 positive regulatory T cells 
expressed as a percentage of the total CD8 positive cell population, in the peripheral 
blood mononuclear cell patient samples from patients with FL (0.34%) as compared 
to the samples from healthy controls (0.33%) (p=0.93)(Figure 43). There was no 
significant variation between samples in patients or healthy controls (Figure 44). 
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Figure 43 Percent of CD8 regulatory T cells expressed as a percentage of total CD8 
positive lymphocytes in the peripheral blood of patient samples from patients with 
FL compared to healthy controls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44 Graph to demonstrate the variance in percent of CD8 regulatory T cells 
expressed as a percentage of total CD8 positive lymphocytes in the peripheral blood 
of patient samples from patients with FL compared to healthy controls 
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6.4 Discussion 
This study has investigated the percentage of regulatory T lymphocytes in the 
peripheral blood of patients with FL. It is commonly observed that immunological 
dysregulation is present in people with malignancy. This may be as a result of several 
factors including the impact of the tumour on the T lymphocytes causing dysfunction 
(Gorgun G et al. 2005) or the regulation of the immune system by regulatory T 
lymphocytes. The presence of increased regulatory T lymphocytes has been 
correlated to worse outcome in numerous epithelial malignancies (Curiel TJ et al. 
2004; Loddenkemper C et al. 2006; Fu J et al. 2007). The work outlined in Chapter 
Five of this thesis also demonstrated an association between the perifollicular 
location of FOXP3 positive cells and improved outcome. In contrast, recent work has 
observed the association between shorter OS and the presence of intrafollicular 
FOXP3 positive cells (Kelley T et al. 2007). All of these studies have been 
performed on lymph node biopsies of FL, to date no data had been produced 
investigating the levels of regulatory T lymphocytes in the peripheral blood of 
patients with FL. In CLL, the presence of increased levels of CD4 positive regulatory 
T cells in the peripheral blood of patients with untreated or progressive disease as 
compared to peripheral blood of controls was observed. These regulatory T cells 
were functional and their numbers decreased after treatment with fludarabine (Beyer 
M et al. 2005).  
 
This work has demonstrated that there is no significant increase in the percent of 
CD4 positive regulatory T lymphocytes in the peripheral blood of patients with FL 
compared to healthy controls. This is different to the observations in epithelial 
malignancies however, as previously discussed, the differences between 
haematological malignancies and epithelial are wide. The relationship to outcome in 
patients with haematological malignancies, particularly FL, is much less clear. 
Previous work has demonstrated the presence of functional Tregs in B-Non 
Hodgkin’s Lymphomas (Carreras J et al. 2006; Yang ZZ et al. 2006) and the 
expression of FOXP3 has been shown to correlate with improved outcome in FL 
(Carreras J et al. 2006, Lee AM et al. 2006). Therefore, it is not surprising that the 
levels of regulatory T lymphocytes in the peripheral blood of patients with FL should 
not be in keeping with that observed in patients with epithelial malignancies. In 
addition, previous work has used CD4+CD25high to identify Tregs, a method which 
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will include some effector T lymphocytes. More recently, FOXP3 has also been used 
to indicate the presence of regulatory T lymphocytes. It has been demonstrated that T 
lymphocytes which are not regulatory in nature can transiently express FOXP3 
(Gavin MA et al. 2006; Wang J et al. 2007). The inclusion in this study of CD127, 
which has been demonstrated to be down-regulated on FOXP3 expressing cells 
which exhibit suppressive activity (Liu W et al. 2006; Seddiki N et al. 2006), has 
improved the accuracy of detecting regulatory T lymphocytes. This was not the case 
in many previous studies which may account for some of the differences observed. In 
addition, the patients selected were at varying points within their disease and some 
may have received treatment which may have affected the results. Although there is 
no increase in the percent of CD4 positive regulatory cells in the peripheral blood of 
patients with FL as compared to controls, there was a statistically significant increase 
in variability in the patient group. This work has also confirmed the variability of 
CD25 expression on regulatory T cells. 
 
The levels of CD8 regulatory T cells in patients with malignant tumours have not 
been investigated. This work has demonstrated that CD8 positive regulatory cells 
comprise only a small percent of the normal CD8 T lymphocyte compartment with a 
mean of 0.34% in healthy controls. There is no increase of CD8 positive regulatory 
cells in the peripheral blood of patients with FL as compared to healthy controls. 
CD8 positive regulatory T cells are not identified in lymph node biopsies of FL using 
double immunofluorescence for FOXP3 and CD8 (data not shown).  
 
In addition, a decrease in the percent of CD3 positive cells was observed in the 
peripheral blood of patients with FL as compared to controls. This has been 
previously observed in patients with stomach cancer and was related to advanced 
stage of disease (Hong WS et al. 1995). These results suggest that host immunity is 
impaired with advancing disease. Alternatively this could be a reflection of treatment 
although, treated patients were observed to have higher CD3 counts compared to 
patients treated by expectant management only. 
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7.1 Introduction 
Further to the previous data in FL we wished to determine if the immune 
microenvironment in diagnostic lymph node biopsies from patients with FL could 
predict the likelihood of rapid transformation of FL to DLBCL. Transformation is a 
relatively common and catastrophic clinical event. There are few reliable methods to 
predict likelihood of transformation, although histological grading is prognostic for 
outcome (Martin AR et al. 1995; Barlett NL et al. 1994) it is poorly reproducible 
(Metter GE et al. 1985). The aim of this work was to study the non-malignant 
immune infiltrate in diagnostic biopsies of FL and explore if the likelihood of rapid 
transformation could be determined from the composition of the immune infiltrate at 
diagnosis. 
 
7.2 Materials and Methods 
7.2.1 Patient samples 
Patients diagnosed with FL at St Bartholomews’ Hospital who had initial diagnostic 
paraffin embedded lymph nodes blocks and who subsequently transformed to 
DLBCL were eligible for this study. Twenty six samples were identified from 
patients who transformed from FL to DLBCL in less than 3 years from initial 
diagnosis and twenty five samples were identified from patients who transformed 
after eight years from initial diagnosis. Ethical approval for this study was obtained 
from the local regional ethics board. 
 
7.2.2 TMA construction 
Full sized haematoxylin and eosin stained sections were marked to indicate 
appropriate areas and 1mm cores taken in triplicate from the paraffin embedded 
tissue using a manual arrayer (Beecher Scientific, Sun Prairie, WI, USA). Six cores 
of control lymphoid tissue (appendix and tonsil) were also included on all TMAs.  
 
7.2.3 Immunocytochemistry 
The panel of antibodies applied to the TMA for analysis is listed in Table 16. TMA 
blocks were cut to a thickness of 4µm and applied to 3-aminopropyltrioxysilane-
coated slides, dewaxed and blocked in hydrogen peroxide/methanol solution. 
Antigen retrieval was performed by pressure cooking in citrate except for FOXP3 
where pressure cooking was performed in EDTA (Norton AJ, Jordan S, Yeomans P 
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1994). Sections were stained using the Vector Elite ABC kit (PK6100; Vector 
Laboratories, Peterborough, UK) or for FOXP3, CSA II tyramide amplification 
system (DAKO, Glostrup, Denmark) followed by diaminobenzidine chromogen 
(Biostat, Stockport, UK). Appropriate positive and negative controls were always 
used. 
 
Table 16 Antibodies used for the investigation of the immune microenvironment 
Test Antibody  Clone  Source  Dilution 
CD4 NCL-CD4-368 
clone 
4B12 
Novocastra, 
Newcastle, UK 
1/100 
CD8 C8/144B Dako 1/50 
CD68 KP1 Dako 1/4000 
FOXP3 Ab236A/E7 Abcam, 
Cambridge, UK 
1/40 
CD21 NCL-CD21- 2G9 Novocastra, 
Newcastle, UK 
1/50 
CD23 NCL-CD23-1B12 Novocastra, 
Newcastle, UK 
1/50 
 
7.2.4 Immunocytochemistry analysis 
The presence of adequate amounts of FL was confirmed using a routine diagnostic 
lymphoma panel composed of CD3, CD5, CD10, CD20, CD21, CD23, Bcl-2, Bcl-6, 
and Ki-67 (data not shown).  
 
The TMAs were scored by myself and another independent histopathologist and 
consensus reached in all cases. The entire 1mm core was analysed at both low and 
high power in each case. Where a single core could not be scored a consensus of two 
cores for a case was accepted although this occurred in only 10% of the cores 
analysed. If two of the three cores were unassessable no scoring was attempted. 
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7.3 Results 
7.3.1 Patient characteristics  
Fifty one patients with diagnostic FL biopsies were eligible to be included within this 
study. The histology was reviewed in all cases. The characteristics of the patient 
population are listed in Table 17. Patients who underwent transformation of FL to 
DLBCL within three years of diagnosis, the rapidly transforming group (n=26), had a 
median time to transformation of 1.14 years (range 0-2.99). Patients who 
transformed eight years or more after diagnosis, the slow transforming group (n=25), 
had a median time to transformation of 19.02 years (range 8.15-34.02). The members 
of the rapidly transforming were older than the slowly transforming, with median 
ages of 61 years and 47 years respectively. This was not statistically significant 
(p=0.18).  
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Table 17 Demographic and Clinical Characteristics of Patients from the Rapidly 
Transforming and Slow Transforming Groups 
  Rapidly 
transforming 
group 
 Slow transforming group 
Total no. of patients 
(n=51)  
  26   25 
 Sex 
  Male 
  Female 
 
 18 
  8 
  
 15 
 10 
Time to transformation 
(years) 
  Median 
  Range 
  
 
  1.14 
  0 – 2.99 
  
 
  19.02 
  8.15 – 34.02 
Age at diagnosis (years) 
 Median 
 Range 
  
 61.04 
 30.8 - 72.6 
  
  47 
  30.5 - 65 
 Grade   Grade 1 = 13 
  Grade 2 = 11 
  Grade 3a = 2  
  Grade 1 = 14 
  Grade 2 =  8 
  Grade 3a =  3 
Stage 
I 
II 
III 
IV 
 2 unknown 
 0 
 5 
 8 
 11 
 
 1 
 6 
 6 
 12 
Number of repeat 
biopsies    
  15 cases: 1-6 relapses, 1-7 
biopsies 
6 cases: no relapse, no biopsies 
1 case: no relapse, 3 biopsies 
3 cases: 1 relapse, no biopsies 
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7.3.2 Analysis of TMA 
 For each of the antibodies studied, two (for a maximum of 10% of the patients’ 
samples over all antibodies studied) or three cores were available for analysis from 
24 to 25 of the rapidly transforming group and 21 to 25 of the slow transforming 
group. Scoring was performed as described previously based on location with respect 
to the neoplastic follicle and number of cells with categories as follows: less than 
five cells/hpf, five to 10 cells/hpf, 10-15 cells/hpf, 15-30 cells/hpf, and more than 30 
cells/hpf. The analysis of these categories did not reveal any additional correlation 
with time to transformation and consequently the categories of less than five 
cells/hpf and more than five cells/hpf were used except for CD68; where the value 
less than 15 cells/hpf and more than 15 cells/hpf were substituted to correlate with 
the work by Farinha et al. (Farinha P et al. 2005).  
 
7.3.3 CD68 positive cell numbers are not significantly different between rapidly 
transforming and slow transforming groups 
CD68 expression was assessable in 48 of 51 (94%) total patients; two of the 
unassessable patients were from the slowly transforming group and one of the 
patients was from the rapidly transforming group. CD68 positive cells were observed 
at levels of >15/hpf in 23 of 48 (48%) patients; 15 of 25 (65%) rapidly transforming 
group and 8/23 (35%) of biopsies from the slowly transforming group (p=0.08; 
Table 18) (Figure 45).  
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Table 18 Number of CD68 positive cells in diagnostic lymph node biopsies 
                                           Number of assessable  
                                                      samples                                                         <15 cells/hpf                                              >15 cells/hpf 
 
Antigen Rapid transforming 
group 
Slow transforming 
group 
Rapid transforming 
group 
Slow transforming 
group 
Rapid transforming 
group 
Slow transforming 
group 
 
CD68  25  23 10/25 40% 15/23 65% 15/25 60% 8/23  35% 
 
 P                                                                                                 0.08 
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Figure 45 Immunocytochemistry for CD68 on diagnostic FL samples, A) <15/hpf 
positive cells OM x10, B) <15/hpf positive cells OM x40, C) >15/hpf positive cells 
OM x10, D) >15/hpf positive cells OM x40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD4 expression was assessable in 49 of 51 (96%) total patients; the two unassessable 
patients were both from the rapidly transforming group. The absence or presence of 
CD4 positive cells did not correlate with time to transformation. All patient samples 
analysed contained CD8 positive cells. FOXP3 expression was assessable in 48 of 51 
(94%) of patients. Two of the patients whose samples were not assessable were from 
the rapidly transforming group and the other patient was from the slowly 
transforming group. The presence or absence of FOXP3 positive cells did not 
correlate with time to transformation (Table 19). 
A B 
C D 
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Table 19 Expression of immune cell antigens in diagnostic lymph node biopsies 
                          Number of assessable                          <5 cell/hpf                               >5 cells/hpf 
                                  Samples 
Antigen Rapid 
transforming 
group 
Slow 
transforming 
group 
Rapid 
transforming 
group 
Slow 
transforming 
group 
Rapid 
transforming 
group 
Slow 
transforming 
group 
CD4  24  24 2/24  8% 4/24   16% 22/24  92% 20/24  84% 
 
P                                                                                      0.4 
CD8  25  21 0/25  0% 0/21   0% 25/25 100% 21/21  100% 
 
 
FOXP3 
 
 24  24 4/24  16% 7/24   29% 
 
20/24  84% 17/24   71% 
P                                                                                       0.24 
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7.3.4 Location of CD4 positive cells correlates with time to transformation 
Patients from the rapidly transforming group had CD4 positive cells at a higher 
incidence within follicles (intrafollicular) than patients in the slow transforming 
group. Patients from the slowly transforming group contained FOXP3 positive cells 
in a predominantly intrafollicular location as compared to the patients in the rapidly 
transforming group. The location of CD8 positive cells did not differ significantly 
between the groups (Table 20). 
 
Table 20 Location of immune cell antigens in diagnostic lymph nodes 
 
Number of assessable 
samples 
Intrafollicular Predominantly perifollicular 
Antigen Rapid 
transforming 
group 
Slow 
transforming 
group 
Rapid 
transforming 
group 
Slow 
transforming 
group 
Rapid 
transforming 
group 
Slow 
transforming 
group 
CD4  24  24 15/24  63% 7/24   29% 6/24  25% 14/24  58% 
 
P     0.01 
CD8  25  23 14/25  56% 12/23   51% 11/25 44% 11/23  48% 
 
P     0.2 
FOXP3  24  24 8/24  33% 13/24   54% 
 
12/24  50% 4/24   17% 
P     0.04 
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7.4 Discussion 
This work highlights the importance of the immune microenvironment in outcome of 
haematological malignancy. The transformation of FL to DLBCL is a common event 
(Horning S & Rosenberg S 1984) which is clinically catastrophic for most patients 
(Acker B et al. 1983; Gallagher CJ et al. 1986). The biological mechanisms which 
underlie transformation are still unclear with numerous proposed molecular 
mechanisms including mutation of TP53 (Lo Coco F et al. 1993; Sander CA et al. 
1993; Davies AJ et al. 2005), cytogenetic abnormalities (Goff LK et al. 2000; Hough 
RE et al. 2001), amplifications of c-REL (Goff LK et al. 2000), deletions of 
CDKN2A and CDKN2B (Elenitoba-Johnson KS et al. 1998), mutations of Bcl-2 
(Matolcsy A et al. 1996) and mutations of Bcl-6 (Lossos T, Levy R 2000). Each of 
these has been identified in small numbers of patients, however if treatments and 
survival for patients who undergo transformation are to be improved further insight 
into the biological mechanisms is required. Previous work has identified the 
importance of the immune microenvironment in outcome of FL both at the level of 
gene expression (Dave SS et al. 2004) and protein expression within biopsies of 
tumour (Farinha P et al. 2005; Carreras J et al. 2006; Lee AM et al. 2006). This work 
has examined the immune microenvironment in diagnostic FL lymph node biopsies 
and evaluated its prognostic significance with respect to time to transformation.  
 
There was a suggestion that increased numbers of CD68 positive macrophages, 
defined according to the criteria used by Farinha et al., were more commonly found 
in the diagnostic FL lymph nodes of patients who underwent rapid transformation to 
DLBCL with a trend towards statistical significance (p=0.08) These findings are in 
keeping with the hypothesis that the lymphoma-associated macrophage content is an 
independent predictor of survival in FL but this will require further validation using a 
larger sample size. The data produced by Farinha et al. is not directly comparable 
with this study as the endpoints used were progression-free survival and overall 
survival (Farinha P et al. 2005) whereas this work used time to transformation as the 
endpoint. However, these results are indicative that high numbers of macrophages 
are important in outcome of FL either time to transformation or survival. Moreover 
the use of immunocytochemistry and defined criteria for analysis of this biomarker 
would enable widespread utilisation and may be of prognostic help to clinicians 
when determining treatment. The role which macrophages play in this setting is not 
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fully understood. Macrophages are attracted into the tumour microenvironment by 
chemokines produced by the tumour cells. Dependent upon the environment 
macrophages can be activated either into an M1 form which is activated in response 
to microbial products and cytokines particularly interferon-γ (Adams DO, Hamilton 
TA 1984) or an M2 (alternatively activated) form (Stein M et al. 1992). Conversion 
into the M2 form is induced by IL-4 (Stein M et al. 1992), IL-13 and IL-10 (Goerdt 
S; Orfanos CE 1999). These two polarised macrophage types differ in receptor 
expression, cytokine production and function. The alternatively activated 
macrophages are able to endocytose mannosylated ligands and demonstrate enhanced 
expression of MHC class II molecules. They also produced less pro-inflammatory 
cytokines (Stein M et al. 1992). In addition, phagocytosis of immune complexes and 
production of superoxide were inhibited by exposure of macrophages to IL-4. This 
effect was reversed by exposure to IFN-γ (Becker S, Daniel EG 1990). Generally the 
M1 macrophages produced plentiful pro-inflammatory cytokines and mount effective 
cytotoxic responses against micro-organisms and tumours whereas the M2 
macrophages are responsible for remodelling and healing. Activated macrophages 
appear to have several mechanisms of action. They express anti-inflammatory 
cytokines e.g. IL-10 (Fenton MJ, Buras JA, Donnelly RP 1992) and they lack 
expression of proinflammatory cytokines e.g. IL-1, IL-6, IL-12, macrophage 
inflammatory protein and TNFα (Cheung DL et al. 1990; Standiford TJ et al. 1993; 
Bonder CS et al. 1998). 
 
The presence of increased numbers of macrophages correlating with worse outcome 
is unsurprising on consideration of the functions the M2 group perform. The 
presence of these cells would reduce any inflammatory reaction against the tumour 
cells as well as producing angiogenic factors which could increase the 
vascularisation of the tumour. Immune manipulation of the host may prevent 
recruitment of the M2 cells into the tumour microenvironment allowing a host 
immune response to destroy the tumour.   
 
A study performed by Glas et al. has produced similar results for the number and 
location of CD4 positive T lymphocytes. Patients who transformed rapidly from FL 
to DLBCL (within three years from diagnosis) demonstrated a predominantly 
perifollicular pattern in only 3/24 cases and a predominantly intrafollicular pattern in 
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10/24 cases. Patients who did not transform within seven years of diagnosis, 
demonstrated a predominantly perifollicular pattern in 20/32 cases and a 
predominantly intrafollicular pattern in 2/32 cases (Glas AM et al. 2007) The data 
presented here is also similar to the work of Glas et al. as both did not find any 
association with the number of CD8 positive T cells. The hypothesis generated by 
their gene expression data indicated that gene expression patterns in rapidly 
transforming FL were more comparable to those in non-malignant follicular 
hyperplasia, while the non transforming group demonstrated overall down-regulation 
of immune related genes and resembled non-activated lymphoid tissue (Glas AM et 
al. 2007). This would certain fit with the data presented here. In addition, the 
presence of FoxP3 positive cells being present intrafollicularly in 13/24 cases from 
the slow transforming group could be explained by the FoxP3 positive cells acting to 
suppress the activation of the lymphocytes and so maintain an immunologically 
inactive state (Glas AM et al. 2007). 
 
The findings relating to CD4 lymphocytes support the model proposed by Glas et al. 
where FL resembling non-malignant hyperplasia was associated with rapid 
transformation (Glas AM et al. 2007). It also implies that the presence of FoxP3 
positive cells within the neoplastic follicle can improve prognosis by exerting a 
suppressive effect on the non-malignant immune infiltrate so attaining a non-
activated lymphoid tissue phenotype which is associated with a non-transforming FL. 
The presence of high numbers of macrophages correlating with rapid transformation 
is in keeping with the data produced by Farinha et al. as transformation can be a 
catastrophic event which results in death at a much earlier timepoint than if 
transformation did not occur (Farinha P et al. 2004). 
 
The results also indicate that the nature of the non-immune infiltrate at diagnosis is 
important in determining prognosis as well as providing biomarkers which may help 
identify patients who may rapidly transform and so need close observation and 
possibly more aggressive therapy. In addition, these markers can be assessed 
routinely at the time of diagnosis with little increased work to the reporting 
histopathologist. 
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8.1 Introduction 
As previously outlined, the immune microenvironment is extremely important in the 
natural history of FL. Transformation of FL to DLBCL is a relatively common and 
clinically catastrophic event. The aim of this work was to investigate the impact of 
the microenvironment on the process of transformation. This was achieved by 
analysis of TMAs composed of 1mm triplicate cores of biopsies from paired pre-
transformation and transformed samples from patients who presented with FL. The 
samples were analysed to determine the composition of the immune 
microenvironment in the pre-transformation biopsies and whether this changed after 
transformation had occurred.  
 
8.2 Patients and methods 
8.2.1 Patient samples  
A cohort of 31 patients with diagnostic paraffin embedded FL biopsies who 
subsequently transformed to DLBCL was identified and the immune 
microenvironment analysed. In addition a further cohort of 31 patients with initial 
diagnostic paraffin-embedded de novo DLBCL biopsy samples was identified from 
the archives of the Pathology department of St Bartholomew’s Hospital. The immune 
microenvironment was analysed in these samples and compared with the immune 
microenvironment in the transformed samples.  
 
A cohort of 34 patients diagnosed with FL who subsequently transformed to DLBCL 
with at least one pre-transformation and post-transformation paraffin-embedded 
biopsy samples was identified from the archives of the Pathology department of St 
Bartholomew’s Hospital as described previously. Ethical approval for this study was 
obtained from the local regional ethics board. Tissue microarrays (TMAs) were 
constructed from these samples (transformed TMA). 
 
8.2.2 TMA construction 
Full sized haematoxylin and eosin stained sections were marked to indicate 
appropriate areas and 1mm cores taken in triplicate from the paraffin embedded 
tissue using a manual arrayer (Beecher Scientific, Sun Prairie, WI, USA). All cores 
from a single patient were included on the same TMA. Six cores of control lymphoid 
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tissue (appendix and tonsil) were also included on all TMAs.  
 
8.2.3 Immunocytochemistry 
The panel of antibodies and dilutions applied to the TMAs for analysis are listed in 
Table 21. TMA blocks were cut to a thickness of 4µm and applied to 3-
aminopropyltrioxysilane-coated slides, dewaxed and blocked in hydrogen 
peroxide/methanol solution. Antigen retrieval was performed by pressure cooking in 
citrate except for FOXP3 where pressure cooking was performed in EDTA (Norton 
AJ, Jordan S, Yeomans P 1994). Sections were stained using the Vector Elite ABC 
kit (PK6100; Vector Laboratories, Peterborough, UK) or for FOXP3, CSA II 
tyramide amplification system (DAKO, Glostrup, Denmark) followed by 
diaminobenzidine chromogen (Biostat, Stockport, UK). Appropriate positive and 
negative controls were always used. 
 
Table 21 Antibodies used for the investigation of the immune microenvironment 
Test Antibody  Clone  Source  Dilution 
CD4 NCL-CD4-368 
clone 
4B12 
Novocastra, 
Newcastle, UK 
1/100 
CD8 C8/144B Dako 1/50 
CD68 KP1 Dako 1/4000 
FOXP3 Ab236A/E7 Abcam, 
Cambridge, UK 
1/40 
CD21 NCL-CD21- 2G9 Novocastra, 
Newcastle, UK 
1/50 
CD23 NCL-CD23-1B12 Novocastra, 
Newcastle, UK 
1/50 
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8.2.4 Immunocytochemistry analysis 
The presence of adequate amounts of FL or DLBCL was confirmed using a routine 
diagnostic lymphoma panel composed of CD3, CD5, CD10, CD20, CD21, CD23, 
Bcl-2, Bcl-6, and Ki-67 (data not shown).  
 
The TMAs were scored by myself and a second independent histopathologist who 
were blinded to the layout and consensus reached in all cases. The entire 1mm core 
was analysed at both low and high power in each case. Where a single core could not 
be scored a consensus of two cores for a case was accepted although this occurred in 
only 10% of the cores analysed. If two of the three cores were unassessable no 
scoring was attempted.  
 
Staining was evaluated based on the number and location relative to the neoplastic 
follicle of positively stained cells in the follicular lymphoma biopsies. Numerical 
evaluation was divided into the following categories; less than five cells/hpf, five to 
10 cells/hpf, 10-15 cells/hpf, 15-30 cells/hpf, and more than 30 cells/hpf. 
 
8.3 Results  
8.3.1 Immune microenvironment in transformed TMA 
8.3.1.1 Patient characteristics 
Biopsies from 34 FL patients who transformed to DLBCL with at least one pre-
transformation and post-transformation paraffin-embedded biopsy samples available 
were identified. The clinical characteristics are detailed in Table 22.  
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Table 22 Patient characteristics of patients in transformed TMA 
 FL (n=34) 
Median age at diagnosis 52 years (range 31-71 years) 
Male to female  Male: 17 
Female: 17 
Stage Unknown = 5 
Stage 1 = 1 
Stage 2 = 4 
Stage 3 = 10 
Stage 4 = 14 
Grade Grade 1 = 16 
Grade 2 = 18 
Grade 3 = 0 
Median time to transformation 
from diagnosis (years) 
3.3 years (range 0-15 years) 
Median OS from diagnosis (years) 
(to death or last follow-up) 
7.1 years (range 0.5 -17.3 years) 
8 patients still alive  
Median time from transformation 
to death/last follow up (years) 
2.4 years (range 0.17 – 12.7 years) 
 
 
8.3.1.2 CD4 positive lymphocytes 
Twenty two paired samples were available for analysis from a possible 34 due to 
core loss. The number of CD4 positive cells was generally high in all samples. The 
number of CD4 positive lymphocytes either increased or remained high on 
transformation in 15/22 cases (68%). The numbers decreased or remained low on 
transformation in 7/22 cases (32%) (p=0.003). There was no significant difference in 
overall survival or survival from transformation based on changes of CD4 positive 
lymphocytes on transformation. 
 
8.3.1.3 CD8 positive lymphocytes 
Twenty two paired samples were available for analysis from a possible 34 due to 
core loss and the number of CD8 positive cells was high in all FL samples. The 
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number of CD8 positive lymphocytes increased or remained high in 17/22 cases 
(77%). The numbers decreased in 5/22 cases (23%)(p=<0.05). There was no 
significant difference in overall survival or survival from transformation based on 
changes of CD8 positive lymphocytes on transformation. 
 
8.3.1.4 FOXP3 positive cells 
Twenty three paired samples were available for analysis from a possible 34 due to 
core loss. The number of FOXP3 positive cells fell or remained low on 
transformation in 13/23 cases (56%). The numbers of FOXP3 positive cells increased 
marginally (from 5-10 cells/hpf to 10-15 cells/hpf) in 8/23 cases (35%). In two 
paired samples the number of FOXP3 positive cells remained high (9%)(p=0.23). 
There was a statistically significant difference in OS in patients based on the change 
in FOXP3 numbers on transformation from FL to DLBCL. Patients with biopsies in 
which the number of FOXP3 positive cells decreased on transformation survived for 
a median of 10.9 years from initial diagnosis of FL compared to patients whose 
numbers of FOXP3 cells increased on transformation who survived a median of 3.9 
years from initial diagnosis (p=0.01) (Figure 46)  
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Figure 46  Kaplan-Meier estimates of overall survival of patients with transformed 
FL by change in number of FOXP3 positive cells (p=0.01). Blue indicates samples in 
which the number of FOXP3 positive cells decreased or remained low in both the FL 
and transformed DLBCL samples. Red indicates those samples where the numbers of 
FOXP3 positive cells increased or remained high in the transformed DLBCL sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8.3.1.5 CD68 positive macrophages  
Twenty four paired samples were available for analysis from a possible 34 due to 
core loss. The number of CD68 positive macrophages remained high or increased in 
23/24 cases (96%). In a single case a marginal decrease was observed (p=<0.05). 
 
8.3.2 Assessment of immune microenvironment in de novo DLBCL 
8.3.2.1 Patient characteristics 
Twenty two patients with diagnostic de novo DLBCL paraffin embedded biopsies 
were available for analysis from 31 potential patients. The patient characteristics are 
described in Table 23. Twelve patients are still alive, all deceased patients died as a 
result of their disease. 
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Table 23 Clinical features of patients with de novo DLBCL 
 De novo DLBCL (n=22) 
Median age at diagnosis 50 (range 18-83 years) 
Male: female 9 male 
13 female 
Stage at diagnosis Stage 1=3 
Stage 2=1 
Stage 3=6 
Stage 4=8 
Stage 1E=1 
Stage IIE=3 
Median survival (years) 4 years (range 0.5–11.4 years) 
12 patients still alive 
International Prognostic 
Index (IPI) 
Unknown = 3 
Low risk = 13 
Low-intermediate = 2 
High intermediate = 3 
High risk = 1 
Germinal centre type 
versus Non germinal 
centre 
GC type = 9 
Non GC type = 13 
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8.3.2.2 CD4 positive cells 
Of the twenty two evaluable cases, 15 biopsies were assessable for number of CD4 
positive cells. Three of the 15 cases (20%) contained <5 cells/hpf and 12 of the 15 
cases (80%) contained >5 cells/hpf.  
 
8.3.2.3 CD8 positive cells 
Sixteen of twenty two evaluable cases were suitable for expression of CD8 positive 
cells; only one case (6%) contained <5 positive cells/hpf. The remaining 15 cases 
(94%) contained >5 positive cells/hpf.  
 
8.3.2.4 CD68 positive macrophages 
Fifteen of twenty two available cases were assessable for expression of CD68 
positive macrophages. Only one case (7%) contained <5 positive cells/hpf. The 
remaining 14 cases (93%) contained >5 positive cells. Seven of 15 cases (47%) 
contained >15 positive cells/hpf and 8 cases (53%) contained <15 positive cells/hpf 
 
8.3.2.5 FOXP3 positive cells 
Seventeen cases of twenty two were suitable for analysis of FOXP3 positive cells. 
Four cases (24%) contained <5 positive cells/ hpf; 13 cases (76%) contained >5 
positive cells/ hpf. 
 
Table 24 Cumulative results for the immune microenvironment composition in de 
novo DLBCL samples 
 CD4 (n=15) CD8 (n=16) CD68 (n=15) FOXP3 n=17) 
<5 cells/hpf 3 (20%) 1 (6%) 1 (7%) 4 (24%) 
5-10 cells/hpf 0 (0%) 1 (6%) 4 (27%) 5 (29%) 
10-15 cells/hpf 1 (7%) 1 (6%) 3 (20%) 2 (12%) 
15-20 cells/hpf 0 (0%) 0 (0%) 0 (0%) 2 (12%) 
>30 cells/hpf 11 (73%) 13 (81%) 7 (47%) 4 (24%) 
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8.3.2.6 The immune microenvironment does not influence outcome in de novo 
DLBCL 
The group of twenty two patients was then divided according to their OS with the 
median OS of the whole group (4 years) used to split the patients.The median OS of 
the patient group below the median was 1 year and the median OS of the patient 
group above the median was 7.3 years which was statistically significant (p=0.02). 
The patient group with a worse OS had a higher median age at diagnosis (54 years ) 
than the patient group with an improved OS (49 years) however this was not 
statistically significant (p=0.6). 
 
Table 25 Patient characteristics of two groups of patients with de novo DLBCL 
divided on the basis of OS 
 Survival < median 
(n=11) 
Survival >median 
(n=11) 
Median age at 
diagnosis (years) 
54 years 49 years 
Male/ female ratio Male = 2 
Female =9 
Male = 7 
Female = 4 
Median OS (years) 1 year 
1 patient still alive 
7.3 years 
All alive at the present 
time 
GC type versus non 
GC type 
GC = 4 
Non GC = 7 
GC = 5 
Non GC = 6 
Stage Stage 1 = 0 
Stage 2 = 0 
Stage 3 = 3 
Stage 4= 6 
Unknown = 2 
Stage 1 = 3 
Stage 2 = 1 
Stage 3 = 3 
Stage 4 = 2 
Unknown = 2 
IPI Low = 3 
Low intermediate = 2 
High intermediate = 2 
High = 1 
Unknown = 3 
Low = 10 
Low intermediate = 0 
High intermediate = 1 
High = 0 
Unknown = 0 
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All four markers; CD4, CD8, CD68 and FOXP3 were analysed for their impact on 
outcome in de novo DLBCL. There were no significant differences between the 
groups for any of the markers. It was observed however that all samples from 
patients in the longer survival group contained >30 CD4 positive cells per hpf 
however this was not statistically significant. The only prognostic marker appeared 
to be the IPI, all patients in the long survivor group were classified in the low IPI 
group except for one patient classified as high –intermediate. The patients who died 
quickly from their disease were in varying IPI groups; three were in the high and 
high intermediate groups and five were in the low and low intermediate groups. The 
IPI of three patients in this survival group were unknown. 
 
8.3.3 Immune microenvironment in diagnostic FL samples of patients who 
subsequently transform to DLBCL 
 
8.3.3.1 Patient characteristics 
The patient characteristics from thirty one patients diagnosed with FL who 
subsequently transformed to DLBCL and whose initial diagnostic lymph nodes were 
available are listed in Table 26. 
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Table 26 Patient characteristics for patients diagnosed with FL who subsequently 
transformed to DLBCL 
 Diagnostic FL who transform 
(n=31) 
Median age at diagnosis (years) 56 (range 31 – 79) 
Male to female ratio Male = 22 
Female = 9 
Grade Grade 1 = 16 
Grade 2 = 13 
Grade 3 = 2 
Stage Unknown = 3 
Stage 1 = 1 
Stage 2 = 4 
Stage 3 =8 
Stage 4= 14 
Median time to transformation 
from diagnosis of FL (years) 
2 years (range 0.1 – 13.6 years) 
Median OS from diagnosis of FL 
(years) 
4 years (range 0.5 - 26.1 years) 
 
 
8.3.3.2 CD4 positive lymphocytes 
Twenty nine cases from thirty one possible were evaluable for analysis of CD4 
positive lymphocytes. Twenty four cases (83%) contained more than 5 positive 
cells/hpf and 5 cases (17%) contained less than 5 positive cells/hpf. Of the twenty 
four cases thirteen of these (45%) contained CD4 positive cells in a predominantly 
perifollicular pattern and 11 cases (38%) the cells were evenly distributed both 
within and around the neoplastic follicle. 
 
8.3.3.3 CD8 positive lymphocytes 
Thirty cases of thirty one available were analysed for expression of CD8 positive 
lymphocytes. All thirty cases contained >5 positive cells/hpf. Twenty three cases 
(73%) contained CD8 positive cells in a predominantly perifollicular pattern and in 7 
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cases (27%) the cells were evenly distributed both within and around the neoplastic 
follicle. 
 
8.3.3.4 CD68 positive macrophages 
Thirty cases were available for analysis of expression of CD68 positive 
macrophages. Twenty seven of thirty cases contained >5 positive cells/hpf (90%) and 
three cases contained <5 positive cells/hpf (10%). Fourteen of thirty cases (47%) 
contained >15 positive cells/hpf; sixteen cases (53%) contained <15 positive 
cells/hpf.  
 
8.3.3.5 FOXP3 positive cells 
Of the twenty nine evaluable cases twenty four cases (83%) contained >5 positive 
cells/hpf and five cases (17%) contained <5 positive cells/hpf. Of the twenty four 
cases; fifteen cases (52%) contained cells in a predominantly perifollicular location; 
1 case (3%) contained cells in a predominantly intrafollicular location. The cells 
were evenly distributed in 8 cases (28%).  
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Table 27 Cumulative results for the immune microenvironment composition in 
diagnostic FL samples from patients who transform to DLBCL 
 
 CD4 (n=29) CD8 (n=30) CD68 (n=30) FOXP3 
(n=29) 
<5 cells/hpf 5 (17%) 0 (0%) 3 (10%) 5 (17%) 
5-10 cells/hpf 1 (3%) 5 (17%) 12 (40%) 11 (38%) 
10-15 cells/hpf 4 (14%) 4 (13%) 1 (3%) 6 (21%) 
15-20 cells/hpf 4 (14%) 4 (13%) 3 (10%) 2 (7%) 
>30 cells/hpf 15 (52%) 17 (57%) 11 (37%) 5 (17%) 
 
 
8.3.3.6 The impact of the immune environment at diagnosis on outcome in patients 
with FL who transform to DLBCL 
Thirty one patients were analysed; eleven patients had an OS beyond the median for 
the group (4 years) and were termed patients with ‘good survival’. Twenty patients 
had an OS below the median for the group and were termed patients with ‘poor 
survival’. These numbers are very small to assess the impact of the immune 
microenvironment at diagnosis on OS. The patient characteristics of these groups are 
outlined in Table 28. There was no statistically significant difference in median age 
at diagnosis between the two patient groups (61 years versus 52 years; p=0.4). There 
was no significant correlation with survival when the numbers of immune infiltrating 
cells were analysed for any of the populations. It is worth noting that the biopsies 
from the majority of patients with a survival above the median contained <15 
macrophages per hpf (73%)(Table 29). 
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Table 28 Patient characteristics for two groups of patients with diagnostic samples 
who transform to DLBCL divided on the basis of median OS 
 Patients who survived < 
median (poor survival) 
(n = 20) 
Patients who survived > 
median (good survival) 
(n = 11) 
Median age at 
diagnosis (years) 
61 years (range 31 – 79) 52 years (range 31 – 71) 
Male : female ratio Male = 15 
Female = 5 
Male = 7 
Female = 4 
Median OS (years) 3 years (range 0.5 – 3.4) 8.1 years (range 4.8 – 
26.1) 
Grade Grade 1 = 11 
Grade 2 = 8 
Grade 3 = 1 
Grade 1 = 5 
Grade 2 = 5 
Grade 3 = 1 
Stage Unknown = 2 
Stage 1 = 1 
Stage 2 = 3 
Stage 3 = 4 
Stage 4 = 10 
Unknown = 1 
Stage 1 = 0 
Stage 2 = 1 
Stage 3 = 4 
Stage 4 = 5 
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Table 29 Cumulative results for the number of cells present in the immune microenvironment in initial diagnostic samples from 
patients who transformed to DLBCL 
 CD4 (n=29) 
 
CD8 (n=30) CD68 (n=30)  FOXP3 (n=29)  
Number of cells <5/hpf >5/hpf <5/hpf >5/hpf <15/hp
f 
>15/hpf <5/hpf >5/hpf 
Poor survival 
(n=18) 
3 
(17%) 
15 
(83%) 
0 (0%) 19 
(100%) 
8 
(40%) 
11 
(60%) 
4 
(22%) 
14 
(78%) 
Good survival 
(n=11) 
2 
(18%) 
9 (82%) 0 (0%) 11 
(100%) 
8 
(73%) 
3 (27%) 1 (9%) 10 
(91%) 
P value  P= 0.6  N/A  P= 0.1  P= 0.4 
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8.3.3.7 Impact of location of immune microenvironment cells on OS 
The location of infiltrating immune cells with regard to the neoplastic follicle was 
also assessed. The location of any of the assessed immune cell populations did not 
appear to impact on survival (Table 30).  
Chapter Eight: Immune Microenvironment and transformation of FL to DLBCL 
 
218 
Table 30 Cumulative results for the location of immune infiltrating cells with regard to the neoplastic follicle in the diagnostic FL 
biopsies of patients who subsequently transformed to DLBCL 
 
 CD4 (n=29) CD8 (n=30) CD68 (n=30) FOXP3 (n=29) 
Location 
of cells 
<5/hpf Perif Intraf Evenly <5/hpf Perif Intraf Evenly <15/hpf Perif Intraf Evenly <5/hpf Perif Intraf Evenly 
Poor 
prognosis 
(n=20) 
3 
(15%) 
10 
(50%) 
0 
(0%) 
5 
(25%) 
0  
(0%) 
13 
(65%) 
0 
(0%) 
6 
(30%) 
8 
(40%) 
5 
(25%) 
1 
(5%) 
5 
(25%) 
4 
(20%) 
9 
(45%) 
1 
(5%) 
4 
(20%) 
Good 
prognosis 
(n==11) 
2 
(18%) 
3 
(27%) 
0 
(0%) 
6 
(55%) 
0  
(0%) 
9 
(82%) 
0 
(0%) 
2 
(18%) 
8 
(72%) 
2 
(18%) 
0 
(0%) 
1  
(9%) 
1  
(9%) 
6 
(55%) 
0 
(0%) 
4 
(36%) 
P value  P= 0.2  P=0.67  P =0.47  P =0.75 
 
Evenly = evenly distributed both within and around the neoplastic follicle 
Perif = predominantly perifollicular in location 
Intraf= predominantly intrafollicular in location
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8.4 Discussion 
Previous work in this thesis has demonstrated the importance of the immune 
microenvironment in the natural history of FL. Transformation to DLBCL is a 
catastrophic and relatively common clinical event but to date examination of the 
microenvironment on transformation of FL to DLBCL has been limited. Carreras et 
al. demonstrated a reduction in numbers of FOXP3 positive cells on transformation 
of FL to DLBCL (Carreras J et al. 2006). My work has demonstrated that the number 
of cells positive for FOXP3 decreased or remained low in 56% of cases which 
transformed from FL to DLBCL however the number of FOXP3 positive cells 
increased or remained high in 45% of patients. This was not statistically significant 
and differs to the Carreras data. This may be a reflection of the differing methods 
used to count the FOXP3 positive cells as well as sample variance, Carreras et al. 
used computer-analysis of full sections, studied more patients with a mixed and 
diffuse histology and defined location differently (Carreras J et al. 2006). There was 
a statistically significant difference in OS in patients based on the change in FOXP3 
numbers on transformation from FL to DLBCL. Patients with biopsies in which the 
number of FOXP3 positive cells decreased on transformation survived for a median 
of 10.9 years from initial diagnosis of FL compared to patients whose numbers of 
FOXP3 cells increased on transformation who survived a median of 3.9 years from 
initial diagnosis (p=0.01) This may represent the impact of the immune system being 
able to regulate the tumour growth without regulatory cells inhibiting the anti-tumour 
response. The number of CD68 positive macrophages was high in all samples of FL 
prior to transformation except one and remained so on transformation to DLBCL. 
This would be in keeping with the observations of Farinha et al. who using 
immunohistochemistry for CD68 observed a short survival correlated with >15 
positive staining cells/hpf in diagnostic biopsies (Farinha P et al. 2005). 
Transformation of FL to DLBCL is a clinically catastrophic event associated with 
shortened OS which would correlate with the findings of Farinha et al. (Farinha P et 
al. 2005). For both CD4 and CD8 lymphocytes the majority of cases (68% and 77% 
of cases respectively) demonstrated an increase in numbers or remained high on 
transformation. This could represent an attempt by the immune system to regulate the 
now rapidly growing tumour. The morphological changes in the tumour might be 
accompanied by development of tumour antigens to which the immune system could 
respond and try to destroy the tumour. There was no significant difference in OS or 
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survival from transformation based on changes in the numbers of CD4 or CD8 
lymphocytes on transformation.  
 
Gene expression profiling has previously identified a subtype of de novo DLBCL 
including one delineated by host inflammatory response. This subtype was 
characterised by having higher numbers of infiltrating T and NK cells. The immune 
microenvironment did not impact on overall survival in patients with de novo 
DLBCL in my work. Although there was no statistically significant impact on OS of 
any subset of immune cells it was observed however that all samples from patients in 
the longer survival group contained >30 CD4 positive cells per hpf. This would be in 
keeping with previous work where the presence of high numbers of CD4 positive T 
lymphocytes was associated with significantly longer 5 year failure-free survival as 
well as being an independent predictor of relapse free and overall survival (Ansell 
SM et al. 2001). This was also demonstrated in a study using flow cytometry where 
cases with high numbers of T lymphocytes (>20%) and a CD4:CD8 ratio of >2.0 
demonstrated significantly improved overall survival (Xu Y et al. 2001). The lack of 
impact on overall survival of FOXP3 positive cells in this work has also been 
demonstrated in another study (Hasselblom S et al. 2007). Eighty one percent of the 
de novo DLBCL cases contained high numbers of CD8 positive T lymphocytes and 
there was no correlation with OS which differed from previously published work. 
This work, although conflicting did demonstrate a correlation with OS; low numbers 
of CD8 positive T lymphocytes were associated with a poor outcome in one study 
(Lippman SM et al. 1990) however the presence of >15% of activated cytolytic T 
lymphocytes was strongly associated with failure to reach complete remission, with a 
poor progression-free and overall survival in a different study (Muris JJ et al. 2004). 
The study by Lippman et al did observe that most cases of DLBCL contained high 
numbers of CD8 lymphocytes, as we observed in this work and the lack of 
correlation with OS in our study may represent a lack of patient samples (n=22) as 
compared to the Lippman study (n=82) (Lippman SM et al. 1990). The study by 
Muris et al. used immunohistochemistry for CD3 and granzyme B and a software 
system to overlay the staining (Muris JJ et al. 2004). My work has used CD8 to 
identify cytolytic T lymphocytes and scoring was performed by histopathologists as 
well as being performed on a much smaller number of cases (n=22 versus n=70) 
which could account for the differences. The only predictor of outcome in this work 
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appeared to be the IPI with all patients who survived longer than the median survival 
being in the low IPI group apart from one in the high intermediate group. 
 
The number of immune cells in the diagnostic FL lymph node biopsies did not have 
prognostic significance in predicting outcome in patients with FL who transformed. 
It is worth noting however, that the biopsies from the majority of patients with a 
survival above the median contained <15 macrophages per hpf. The location of the 
immune infiltrating cells in the diagnostic FL biopsies did not have prognostic 
significance in predicting survival outcome either. This is similar to the situation in 
de novo DLBCL where the immune microenvironment at diagnosis did not impact 
on survival outcome.  
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9.1 Introduction  
The morphology of follicular lymphoma resembles a reactive germinal centre and the 
neoplastic cells are closely associated with non-neoplastic cells which are observed 
in normal reactive follicles. This includes both T lymphocytes and follicular 
dendritic cells (FDCs). The presence of FDC in non-malignant lymph nodes was first 
observed as a result of studies on the distribution of antigens within lymph nodes of 
rats (Nossal GJV et al. 1965). Injection of iodide labelled flagellin antigens showed 
distribution of the antigen in a diffuse pattern throughout the follicle within primary 
follicles. In secondary follicles, the antigen formed a cresentic shape in the 
superficial aspect of the follicle (Nossal GJV et al. 1965).  
 
9.1.1 Functions of FDC 
9.1.1.1 Architectural 
 FDC have many functions within non-malignant lymphoid tissue and provide a 
cellular architecture composed of long cytoplasmic processes which maintain the 
structure of the lymphoid follicle (Chen LL, Adams JC, Steinman RM 1978).  
Analysis of FDC within germinal centres in mouse spleen demonstrated that FDC 
have large nuclei often with two nuclear lobes with lack of heterochromatin. 
Visualisation by electron microscopy demonstrated a relative lack of cell body with 
the cytoplasm forming long arms which extended in several directions. These 
processes were flat in FDC positioned at the periphery of the nodule or deep within 
the germinal centre however at the junction of the mantle and germinal centre the 
processes became folded and coiled. The numbers and complexity of FDCs reduced 
on moving away from the mantle zone towards the middle of the germinal centre. 
There is also a lack of organelles particularly secretory granules (Chen LL, Adams 
JC, Steinman RM 1978).   
 
9.1.1.2 Formation of Germinal Centres 
FDCs are unique cells which present antigen to germinal centre B lymphocytes in the 
form of immune complexes composed of antigen and antibody (Kosco MH, Szakal 
AK, Tew JG 1988).  FDCs express both Fc receptors (White RG et al. 1975; Heinen 
E et al. 1985) and complement receptor antigens, CR1, CR2 and CR3 (Reynes M et 
al. 1985). Immune complexes are captured by their complement receptors (Klaus 
GG, Humphrey JH 1977) and their FcγRs (Yoshida K, Van Den Berg TK, Dijkstra 
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CD 1993; Qin D et al. 2000) and presented to GC B lymphocytes which present 
antigen to T lymphocytes to obtain T lymphocyte help (Kosco MH, Szakal AK, Tew 
JG 1988). Some ICs are converted by FDCs into coated bodies, ‘iccosomes’ which 
can be endocytosed by GC B cells (Szakal AK, Kosco MH, Tew JG 1983). IC alone 
are poorly immunogenic (Muta T et al. 1994) suggesting that a function of FDCs is 
to convert poorly immunogenic IC into highly antigenic complexes to elicit a B cell 
response (Wu J et al. 1996). Expression of the IgG receptor FcγRIIB on murine FDC 
is essential for immune complex tapping, retention and conversion to a highly 
immunogenic form which elicits immune response (Qin D et al. 2000). Interaction of 
IC alone with B lymphocytes results in ITIM signalling and lack of B cell 
responsiveness. This is due to coligation of the B cell antigen receptor and B cell 
FcγRII (Diegel ML et al. 1994). The result of the coligation is reduction of cell 
proliferation (Pani G et al. 1995), inhibition of blastogenesis (Phillips NE, Parker DC 
1984) and inhibition of immunoglobulin production (Ono M et al. 1996). The ability 
of IC on FDC to stimulate GC proliferation indicates that the interactions between IC 
and FDC can result in B cell activation. This may be as a result of rapid up-
regulation of FDC FcγRII which minimizes IC-induced ITIM signalling (Aydar Y et 
al. 2004). Numerous adhesion molecules are present on FDCs which are essential to 
maintenance of FDC-B lymphocyte clusters including high levels of the adhesion 
receptors intercellular adhesion molecule 1 (ICAM-1 [CD54]) and vascular cell 
adhesion molecule 1 (VCAM-1), while the B lymphocytes express lymphocyte 
function-associated antigen 1 (LFA-1 [CD11a/18]), very late antigen 4 (VLA-4 
[CD49d]), and CD44. Both the LFA-1/ICAM-1 and VLA-4/VCAM-1 adhesion 
pathways are involved in FDC-B lymphocyte binding (Koopman G et al. 1991). 
Soluble mediators are also important in germinal centre formation; interleukin-6 (IL-
6) is produced by FDCs in the germinal centre and is important for formation of 
normal germinal centres and production of immunoglobulin G antibodies. This is 
dependent upon a C3 complement component (Kopf M et al. 1998). 
 
9.1.1.3 Survival of Germinal centre B cells 
FDCs are able to rescue germinal centre B lymphocytes from apoptotic cell death by 
physical contact (Lindhout E et al. 1993). This has been shown to be mediated 
through the LFA-1(CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-
VCAM-1 (CD106) pathways (Koopman G et al. 1994). In addition, stromally 
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produced sonic hedgehog protein is produced by FDCs and is essential for survival 
of germinal centre B cells (Sacedon R et al. 2005) and malignant lymphomas (Dierks 
C et al. 2007). Inhibition of the hedgehog pathway in lymphomas induced apoptosis 
via BCL-2 but was independent of p53 (Dierks C et al. 2007). 
 
9.1.1.4 Activation, proliferation and differentiation of B lymphocytes 
Culture of activated B lymphocytes with FDC demonstrated that the presence of 
FDC augmented B cell proliferation in a dose dependent manner. Depletion of the 
FDC abrogated this proliferation. This data supports the idea that FDC support B cell 
proliferation via costimulatory interactions (Burton GF et al. 1993). CD21 is 
essential for proliferation within GC. In murine models, high-affinity B lymphocytes 
which lack CD21 can be activated by antigen and enter GC but fail to proliferate. 
The expression of CD21 provides a survival signal for B lymphocytes within the 
germinal centre as well as reducing the threshold for B cell activation (Fischer MB et 
al. 1998). A monoclonal antibody against a human FDC molecule, 8D6, inhibits 
FDC-mediated costimulation of B cells as well as being able to inhibit growth of a 
lymphoma of GC origin which is dependent upon FDCs for growth. These findings 
indicate that a primary function of FDCs in GC is to stimulate B cell growth (Li L et 
al. 2000). Cytokines as well as direct cell contact are also important in stimulating 
proliferation; functionally active IL-15 is produced by human FDC in vivo and by an 
FDC cell line and is important for GC B cell proliferation (Park C-S et al. 2004). 
Human FDCs are also able to enhance cytokine-dependent growth and differentiation 
of CD40-activated B lymphocytes with high levels of immunoglobulin produced in 
cultures in the presence of FDC with IL-2 and IL-10 (Grouard G et al. 1995). In 
addition, FDC can help resting B lymphocytes to become effective antigen 
presenting cells by increasing levels of MHC class II molecules and CD86 (Kosco-
Vilbois MH et al. 1993). Stromally produced sonic hedgehog protein is produced by 
FDCs and is essential for the survival, proliferation and antibody production by 
germinal centre B cells (Sacedon R et al. 2005).  
 
9.1.2 Origin of FDC 
The origin of FDCs remains unclear. Polymerase chain reaction analysis of single 
cells demonstrated that FDCs contain a very restricted mRNA pattern with high 
levels of message for the C3d receptor (CR2, Epstein Barr-virus/EBV receptor, 
Chapter Nine: FDC and FL 
 
226 
CD21) and lack of mRNA for CD20, CD45, CD4, fibronectin, and platelet-derived 
growth factor receptor alpha and beta. These observations are consistent with the 
hypothesis that FDCs may not be of classical haematopoietic or fibroblastic origin 
(Schreiver F, Freeman G, Nadler LM 1991). Another hypothesis is that antigen 
transporting cells, which can trap immune complexes on their cell surface and move 
them into lymph nodes (Szakal AK, Holmes KL, Tew JG 1983) and are reactive with 
monoclonal antibody produced against FDC (Kosco MH, Pflugfelder E, Gray D 
1992) may be FDC precursors. However, the monoclonal antibody KiM4 which is 
specific for human FDC reacts with a mononuclear cell within blood suggesting that 
these cells are FDC precursors. As the KiM4 antibody was raised against a 
macrophage cell line this suggested that FDCs may be of haematopoietic cell origin 
(Parwaresch MR et al. 1983). Work in severe combined immunodeficiency (SCID) 
mice showed that FDC of donor phenotype can be found in SCID mice after 
reconstitution with primary lymphoid tissue from mice or rats. This suggests that 
FDC can be derived from precursors in primary lymphoid tissues which migrate into 
secondary lymphoid tissue and that maybe FDC can be derived from local stromal 
cells (Kapasi ZF et al. 1998). The successful isolation and maintenance of FDC cell 
lines isolated from human tonsils in fibroblast medium together with the expression 
of alpha smooth muscle action and STRO-1 suggested that FDC are closely related to 
bone marrow stromal cell progenitors. The expression of alpha smooth muscle actin 
indicates that FDC are related to myofibroblasts and suggests that they may represent 
a specialised form (Muñoz-Fernández R et al. 2006). The development of FDCs and 
their niche is dependent upon activated B lymphocytes in the absence of T 
lymphocytes and is driven by lymphotoxin-alpha (Gonzalez M et al. 1998; Fu Y-X et 
al. 1998). Once FDC clusters, FDC surrounded by B cells, are formed by the 
lymphotoxin alpha expressing B cells, T cells can interact with the B cells to 
generate GCs and allow class switching to occur (Fu Y-X et al. 1998).  Recent data 
from murine studies has demonstrated activation of FDCs by T lymphocytes via 
CD40 and T cell lymphokines (Selvakumar S et al. 2006). This would be in keeping 
in humans with hyper-IgM syndrome whose T lymphocytes lack CD40 ligand and in 
whom GC do not form (Facchetti F et al. 1995).  
 
9.1.3 Immunophenotype of FDC 
As mentioned previously, FDCs contained high levels of mRNA for CD21, the 
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complement receptor C3d (CR2, Epstein Barr-virus/EBV receptor) (Schreiver F, 
Freeman G, Nadler LM 1991). Immunostaining using CD21 reveals a web-like 
staining pattern over the entire area of the GC and sometimes extends in the marginal 
zone (Maeda K et al. 2002). Human follicular dendritic cells also express CR1 and 
CR3 complement receptor antigens as well as Cr2 (Reynes M et al. 1985). There are 
several other monoclonal antibodies which have been identified as showing 
relatively specific staining for FDCs. CNA.42 monoclonal antibody recognises a 
120-kd glycosylated antigen which is formalin resistant and which is mainly 
expressed by FDCs (Raymond I et al. 1997). The staining pattern in reactive lymph 
nodes of both Ki-M4p and CNA.42 was a web-like pattern within the germinal 
centre and/or mantle zones (Maeda K et al. 2002). The monoclonal antibodies 
against human low-affinity Fcε receptor (FcεRII/CD23) display a web-like 
immunoreactivity with GC of reactive lymphoid follicles but with expression 
restricted to the light zone especially the apical area with no staining observed in the 
dark zone (Maeda K et al. 2002). In routine diagnostic immunocytochemistry CD21 
and CD23 are used as immunophenotypic markers of FDCs. CD35 is also a 
complement receptor and binds C3b and C4b. CD35 has an inhibitory effect on 
complement activation (Fearon DT, Ahearn JM 1989) and generates ligands for 
CD21 by catalyzing the conversion of C3b. The staining pattern for CD35 in reactive 
lymph nodes demonstrates a web-like pattern extended throughout the area of the GC 
(Maeda K et al. 2002).  
 
Analysis of human fetal and adult lymph nodes has demonstrated an 
immunophenotypic alteration of FDC during development. The antigens CNA.42 
and Ki-M4p were expressed in a small number of cells with dendritic morphology in 
underdeveloped lymph nodes from the foetus of gestational ages 19-22 weeks. In 
foetal lymph nodes aged 25-40 gestational weeks primary lymphoid follicles were 
present and FDC within these expressed CD21, CD35 and NGFR as well as CNA.42 
and Ki-M4p. In addition, variable expression of CD23 was seen. The presence of 
CD23 implies that these cells are able to capture and retain immune complexes, an 
essential function of FDC. These molecules were termed ‘essential’ FDC molecules. 
Additional molecules were also expressed in the FDC of full developed secondary 
lymphoid follicles; CD55, VCAM-1 and S100α. These were referred to as activated 
FDC molecules implying an activated state (Kasajima-Akatsuka N, Maeda K 2006). 
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Immunostaining for S100α demonstrated an intense cytoplasmic and nuclear stain in 
FDCs mainly in the dark zone of the GC ( Maeda K et al. 2002). 
 
9.1.4 FDC and lymphoma 
The intimate association and requirement for FDC in GC reactions would suggest 
that these cells are also important in follicular lymphoma; a germinal centre derived 
lymphoma which morphologically resembles a reactive germinal centre, as well as 
other haematological malignancies. The presence of FDC in lymphomas outside the 
lymphoid system implies that their presence is essential to survival of the neoplasm. 
Studies in murine models have demonstrated that the induction of apoptosis as a 
result of anti-Fas, etoposide, cyclophopshamide and busulfan was significantly 
reduced by the presence of FDC at ratios of FDC to B lymphocytes as low as 1:16. 
Prevention of apoptosis was not due to alterations in Bcl-2, Bax or Bcl-XL. 
Conversely the ability of adriamycin to cause apoptosis was not affected by the 
presence of FDC. This data suggests that FDC can protect B lymphoma cells from 
Fas induced cell death. (Schwarz YX et al. 1999). This may be important in 
mechanisms of drug resistance; there is evidence which indicates defective activation 
of the CD95 (APO-1/Fas) pathway may cause drug resistance in human leukaemic 
cells. Indeed some chemotherapeutic agents have been shown to up-regulate Fas 
levels in leukaemia cells (Friesen C et al. 1996). In humans, proliferation of NHL 
lymphocytes in vitro has been demonstrated to be dependent upon FDC interactions 
(Petrasch S et al. 1992). In Hodgkins lymphoma FDCs have been shown to be 
associated with prognosis; retrospective analysis of 102 patients with the most 
common types of Hodgkins disease (nodular lymphocyte predominant, nodular 
sclerosing and mixed cellularity) demonstrated that FDC status in the neoplastic 
areas was prognostically important with a positive FDC status predicting a 
favourable response and a negative FDC status an unfavourable one (Alavaikko MJ 
et al. 1994). It is known that FDC secrete CXCL13 (Ansel KM et al. 2000) which 
binds to the receptor CXCR5, expressed on mature B cells and a subpopulation of T-
helper memory cells (Dobner T et al. 1992), FL cells have been shown to express 
CXCR5 and migrate in response to CXCL13. In addition a synergistic effect between 
CXCL13 and CXCL12, a chemokine produced by stromal cells in lymphoid tissue, 
was observed. This is postulated to be important in the accumulation of FL cells 
within specific anatomic sites (Husson H et al. 2002). In addition, FDCs have been 
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demonstrated to produce monocyte chemoattractant protein-1 (MCP-1) which may 
induce chemotaxis of FL cells (Husson H et al. 2001). 
 
9.1.5 Clusterin 
Clusterin is a glycoprotein encoded by a gene in the region 8p21 (Purrello M et al. 
1991). The protein is present in many tissues and all human fluids and has roles in 
many diverse human processes. There are two different isoforms of clusterin, a 
secreted form sCLU, which is a glycosylated protein of 76-80kDa and appears as two 
bands on Western blot. A band at 60kDa represents the full length protein and a 
second 40kDa smear is also seen (Leskov KS et al. 2003). The second form is a 
nuclear isoform which is produced as a 49kDa protein (pnCLU) and is located in the 
cytoplasm of human cells (Jin G, Howe PH (1999). As a result of cell damage, the 
pnCLU protein is modified and a mature 55kDa proapoptotic form is generated 
which can induce apoptosis (Leskov KS et al. 2003). It has been proposed that 
tumour cell survival is connected with overexpression of sCLU and loss of nCLU 
(Pucci S et al. 2004). Clusterin inhibits apoptosis by interacting with activated Bax 
preventing release of cytochrome c from mitochondria and caspase activation (Zhang 
H et al. 2005). Overexpression of sCLU has been shown in many epithelial tumours 
including prostate cancer (Scaltriti M et al. 2004), lung cancer (July LV et al. 2004), 
colon carcinoma (Pucci S et al. 2004), and breast carcinoma (Redondo M et al. 
2000). sCLU has been demonstrated to be a sensitive marker for both human and 
murine intestinal tumours suggesting that its expression may be a potential biomarker 
(Chen X et al. 2003). In addition, clusterin has been demonstrated to be a marker for 
anaplastic large cell lymphoma although an association with prognosis has not been 
evaluated. The same study demonstrated the expression of clusterin in residual FDC 
in Hodgkins lymphoma (Nascimento A et al. 2004). Clusterin expression has also 
been observed in some DLBCL neoplastic cells (Saffer H et al. 2002). Clusterin has 
been demonstrated to be an FDC marker and possibly an FDC-derived trophic factor 
for GC B cells (Huber C et al. 2005). Drugs which silence clusterin using antisense 
oligonucleotides and short interfering double-stranded RNAs (si RNAs) 
chemosensitise human lung adenocarcinoma cells both in vitro and in vivo and 
indicate that clusterin is a valid therapeutic target for cancer therapy (July LV et al. 
2004). A single study has examined clusterin expression in FL as part of a larger 
study of malignant lymphomas. Twenty four cases of FL were examined and staining 
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of tumour cells was not observed. The presence of staining in FDC was observed 
(Saffer H et al. 2002). 
 
9.1.6 Aims 
The aim of this work was to study in closer detail the FDC present in FL samples and 
their impact on the natural history of FL. This involved analysis of 
immunophenotype of FL biopsies and comparison of the immunophenotype to that 
of reactive lymph nodes using double immunofluorescence. Subsequently, 
immunophenotypic markers, including clusterin, were assessed by 
immunocytochemistry on TMA of FL to determine if their absence or presence had 
any effect on outcome (overall survival and time to transformation) in patients and as 
such could be used as a biomarker. In addition, gene expression profiling of paired 
pre- and post-transformation samples identified down-regulation of CD21 and CD23 
on transformation. Protein confirmation of the gene expression changes on 
transformation was obtained by immunocytochemistry of paired pre- and post-
transformation biopsies. 
 
9.2 Materials and Methods 
9.2.1 Patients 
Three groups of patients were identified to investigate the role of FDCs in the natural 
history of FL. A cohort of 94 patients with diagnostic paraffin embedded FL biopsies 
in the archives of St Bartholomew’s Hospital was identified. The patients were 
selected on the basis of availability of paraffin embedded tissue and clinical data. 
From this primary cohort of 94 patients a second cohort of twenty six samples were 
identified from patients who transformed from FL to DLBCL in less than 3 years 
from initial diagnosis and twenty five samples were identified from patients who 
transformed after eight years from initial diagnosis. A third cohort of patients with 
FL who subsequently transformed to DLBCL was identified. In this cohort of 
patients paired pre and post transformation samples (n=126) were obtained from 34 
patients. Ethical approval for this study was obtained from the local regional ethics 
board. 
 
9.2.2 Immunofluorescence 
Full sections from five reactive lymph nodes and five diagnostic follicular lymphoma 
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lymph nodes were cut to a thickness of 4 microns and applied to TESPA-coated 
slides, then dewaxed and blocked in hydrogen peroxide/methanol solution. Antigen 
retrieval was performed by pressure-cooking in citrate (Norton AJ, Jordan S, 
Yeomans P 1994). Sections were then stained using the Vector M.O.M 
immunodetection kit (Vector Laboratories, Inc, California). Appropriate negative 
controls were always used. The antibodies used and the dilutions are listed in Table 
31. 
 
Table 31 Antibody sources, dilutions and antigen retrieval 
Antibody Clone Source Dilution Method of 
Antigen 
Retrieval 
CD21 NCL-CD21- 
2G9 
 
Novocastra, 
Newcastle, UK 
 
1/50 for 40 
minutes 
Pressure 
cooking 
citrate 
CD23 NCL-CD23-
IB12 
 
Novocastra, 
Newcastle, UK 
 
1/50 for 40 
minutes 
Pressure 
cooking 
citrate 
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9.2.2.1 Analysis of immunofluorescence stained sections 
Twenty secondary follicles from reactive lymph nodes were selected at random and 
were assessed at original magnification of x10. Twenty neoplastic follicles were 
selected at random from the FL lymph nodes ensuring all areas of the node were 
represented and analysed at an original magnification X10. 
 
9.2.3 Gene expression profiling 
Lymphochip cDNA microarrays were used to quantitate mRNA expression 
according to previously described methodology (Alizadeh et al. 2000; Rosenwald et 
al. 2002). A list of genes that significantly differed between FL and DLBCL was 
constructed using the random variance model t-test (Wright and Simon 2003), with 
the cut off value for P set at <0.001. The probability of belonging to a particular sub-
class of DLBCL was determined using the Bayesian statistical predictor and clone 
set previously reported (Wright et al. 2003). 
 
9.2.4 Construction of TMAs and Immunocytochemistry 
Tissue microarrays (TMA) were constructed of 1mm cores of patient tissue taken 
from representative areas of lymphoma (>5 neoplastic follicles) using pre-marked 
H&E stained sections and from reactive tonsil and appendix controls, in triplicate 
using a manual arrayer (Beecher Scientific, Silver Spring, MD) as previously 
described (Hedvat CV et al. 2002; Kononen J et al. 1998). Approximately 120 cores 
were applied per slide.  
 
The test panel of antibodies and dilutions used for immunocytological analysis are 
shown in Table 32. TMA blocks were cut to 4 microns and applied to TESPA-coated 
slides, then dewaxed and blocked in hydrogen peroxide/methanol solution. Antigen 
retrieval was performed by pressure-cooking in citrate (Norton AJ, Jordan S, 
Yeomans P 1994). Sections were then stained using the Vector Elite ABC kit 
(PK6100, Vector Laboratories, Peterborough, UK), followed by diaminobenzidine 
chromogen (Biostat, Stockport, UK). Appropriate negative and positive controls 
were always used.  
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Table 32 Table of antibodies used, dilution and method of antigen retrieval 
Antibody Clone Source Dilution Method of 
antigen 
retrieval 
CD21 NCL-CD21-2G9 Novocastra, 
Newcastle, 
UK 
1/50 for 40 
minutes 
Pressure 
cooking 
citrate 
CD23 NCL-CD23-IB12 
 
Novocastra, 
Newcastle, 
UK 
1/50 for 40 
minutes 
Pressure 
cooking 
citrate 
CD35 Ber-MAC-DRC Dako UK Ltd, 
Cambs, UK 
1/50 for 40 
minutes 
Pronase 
CAN.42 CNA.42 Dako UK Ltd, 
Cambs, UK 
1/50 for 40 
minutes 
Pressure 
cooking 
Clusterin 7D1 Novocastra, 
Newcastle, 
UK 
 Pressure 
cooking 
 
 
 
9.2.5 Immunocytochemical analysis 
Presence of adequate FL tumour cells in the tissue cores was confirmed by scoring 
with a diagnostic lymphoma antibody panel comprising CD3, CD5, CD10, CD20, 
CD21, CD23, BCL-2, BCL-6, Ki-67, TP53, MUM-1 as previously described in 
Chapter 4. 
 
The entire 1mm diameter core was analysed at original magnification x5 initially and 
then at high power (x40 magnification) in each case. Where one of three cores could 
not be scored due to insufficiency of tissue, consensus of 2 cores was accepted 
although this was necessary in only 10% of the total cores. If two cores of three were 
insufficient, no scoring was attempted and the result was noted as ‘absent’ for that 
sample with the antibody in question. 
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The FDC meshwork was scored into four categories based on pattern as shown in 
Figure 47. 
 
Figure 47 Immunocytochemistry for CD21 demonstrating four patterns of staining 
which were used for scoring. A) Well formed meshwork, B) Sparse meshwork, C) A 
few fragments of mesh remaining, D) negative. All photomicrographs are at original 
magnification x40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Meshwork was defined as a web-like immunoreactivity corresponding to the 
lymphoid follicles (Maeda K et al. 2002). 
A B 
C D 
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9.2.6 Western Blotting of tonsil sample and FL samples using anti-human polyclonal 
antibody to Clusterin 
A tonsil sample and two FL samples were identified and the protein was extracted 
using 200 µL of extraction /labelling buffer (Clontech Lab Inc.). The amount of 
protein analysed using the BCA™ Protein Assay Kit (Pierce, Rockford, IL). Fifteen 
micrograms of protein was suspended with loading buffer and reducing agent and 
denatured by heating at 95˚C for ten minutes. The mixture was loaded onto the gel 
and run for 35 minutes at 200V. The gel was transferred to a nitrocellulose 
membrane and blocked for one hour with blocking solution. The primary antibody 
was incubated overnight at 4˚C at a dilution of 1:200. The secondary antibody was 
applied at a dilution of 1:2000 for two hours. A housekeeping antibody, GAPDH, 
was analysed to ensure equal protein loading of wells. 
 
9.3 Results 
9.3.1 The distribution of FDC meshwork is different in reactive lymph nodes as 
compared to FL 
Double immunofluorescence for CD21 and CD23 was performed on full sections of 
reactive lymph nodes (n=5) and FL lymph node biopsies (n=5). In the secondary 
follicles of all the reactive lymph node sections CD21 was observed in a diffuse 
mesh located throughout the germinal centre in the areas of the dark zone, basal light 
zone and apical light zone. CD23 was observed in a polarized band located around 
the follicle edge in the apical light zone (Figure 48). These findings are in keeping 
with those observed by Hardie et al. (1993) who used immunofluorescence to 
analyse molecules distinguishing functional compartments in germinal centres 
(Hardie DL et al. 1993).  
 
In all the FL sections analysed there was loss of polarity of CD23 with a CD23 
positive meshwork present throughout the neoplastic follicle. A CD21 positive 
meshwork was also present throughout the follicle as seen in reactive lymph nodes 
(Figure 49).  
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 Figure 48 Immunofluorescence images stained with CD21 monoclonal antibody 
(green) and CD23 monoclonal antibody (red) of secondary follicles in a reactive 
lymph node demonstrating, A) Presence of CD21 meshwork throughout the GC, B) 
CD23 meshwork polarized to the apical light zone of the GC, C) Merged images of 
CD21 and CD23 demonstrating some areas of coexpression of markers depicted as 
orange colouration. All images OM x10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
C 
Chapter Nine: FDC and FL 
 
237 
 Figure 49 Immunofluorescence images stained with CD21 monoclonal antibody 
(green) and CD23 monoclonal antibody (red) of neoplastic follicles in lymph node of 
FL demonstrating, A) Presence of CD21 meshwork throughout the neoplastic 
follicle, B) CD23 meshwork throughout the neoplastic follicle, C) Merged images of 
CD21 and CD23 demonstrating areas of coexpression of markers depicted as orange 
colouration. All images OM x10 
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9.3.2 Analysis of immunophenotype of FDC in TMAs composed of diagnostic 
lymph node biopsies from patients with FL 
A cohort of ninety four patients diagnosed with FL on whom initial diagnostic 
biopsies were available was identified. Histology was reviewed in all cases. The 
patient characteristics are detailed in Table 33 
 
Table 33 Patient Characteristics of 94 patients diagnosed with FL 
 Patients with FL (n=94) 
Sex Male = 60 
Female =34 
Median age (years) 56 (range 27 – 80) 
Grade at diagnosis Grade 1 =39 
Grade 2 = 33 
Grade 3a = 15 
Stage at diagnosis Stage 1 = 6 
Stage 2 = 11 
Stage 3 = 19 
Stage 4 = 53 
Median OS (years) 5.10 (range 0.02 – 34.86) 
Proceeded to transformation 31/94 (33%) 
 
 
9.3.2.1 Analysis of FDC meshwork using immunocytochemistry for CD21 
Eighty five cases from a possible ninety four were evaluable for the analysis of 
CD21 staining of FDC due to core loss from the TMA. Scoring was originally 
performed as indicated in the materials and methods however the three categories; 
sparse meshwork, fragmented meshwork and negative were combined into a single 
category termed disrupted meshwork. The well formed meshwork category remained 
as described in the materials and methods. This brought the scoring system in line 
with that used by Glas et al. (Glas AM et al. 2007) in their analysis of FDC. Forty 
two cases (49%) demonstrated a disrupted meshwork and forty three (51%) 
demonstrated a well formed meshwork. The overall survival of patients with a non 
disrupted FDC meshwork as assessed by CD21 expression was worse (median 3.7 
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years from diagnosis) than patients with a disrupted FDC meshwork at diagnosis 
(median 8.15 years from diagnosis; p=0.15) although this was not significant (Figure 
50).  
 
Figure 50  Overall survival in years, of patients with FL, based on integrity of FDC 
meshwork assessed by CD21 expression in initial diagnostic biopsies. The blue line 
indicates patients with a preserved FDC meshwork in the initial diagnostic FL biopsy 
(n=43). The red line indicates patients with a disrupted FDC meshwork in the initial 
diagnostic FL biopsy (n=42). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transformation to DLBCL occurred in twenty six assessable cases. The median time 
to transformation was 3.07 years from diagnosis. The presence of an intact or 
disrupted FDC meshwork as assessed by CD21 immunocytochemistry was not 
predictive of likelihood of transformation (p=0.7) (Figure 51). 
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 Figure 51 Time to transformation in years, of patients with FL, based on integrity of 
FDC meshwork assessed by CD21 expression in initial diagnostic biopsies.The blue 
line indicates patients with a preserved FDC meshwork in the initial diagnostic FL 
biopsy (n=15). The red line indicates patients with a disrupted FDC meshwork in the 
initial diagnostic FL biopsy (n=11). 
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9.3.2.2 Analysis of FDC meshwork using immunocytochemistry for CD23 
Eighty cases from a possible ninety four were evaluable for the analysis of CD23 
staining of FDC. Scoring was performed as described for CD21. Fifty six cases 
(70%) demonstrated an intact FDC meshwork and twenty four cases (30%) disrupted 
FDC meshwork. There was no difference between the median overall survival of 
patients with an intact FDC meshwork and patients with a disrupted FDC meshwork, 
as assessed by CD23 staining in the initial diagnostic FL biopsy (p=0.13). 
 
Transformation to DLBCL occurred in twenty five assessable cases. The median 
time to transformation from diagnosis was 2.99 years. There was no difference in the 
median time to transformation for patients with an intact FDC meshwork (n=16) and 
patients with a disrupted FDC meshwork (n=9), as assessed by CD23 staining in the 
initial diagnostic FL biopsy (p=0.7). 
 
9.3.2.3 Analysis of FDC meshwork using immunocytochemistry for CD35 
Seventy three cases from a possible ninety four were evaluable for the analysis of 
CD35 staining of FDC. Scoring was performed as described for CD21 and CD23. 
Sixty two cases (85%) demonstrated a disrupted FDC meshwork and eleven cases 
(15%) an intact FDC meshwork. There was no difference between the median overall 
survival of patients with an intact FDC meshwork and patients with a disrupted FDC 
meshwork, as assessed by CD35 staining in the initial diagnostic FL biopsy 
(p=0.48)(Figure 52). 
 
Transformation to DLBCL occurred in twenty five assessable cases. The median 
time to transformation was 3.2 years. Twenty three patients (92%) with a disrupted 
FDC meshwork transformed to DLBCL compared to 2 patients (8%) with an intact 
FDC meshwork (p=0.01). The median time to transformation of patients with an 
intact FDC meshwork as assessed by CD35 staining was 0.38 years compared to 3.59 
years for patients with a disrupted FDC meshwork (p=0.09). It should be noted that 
only two cases demonstrated an intact FDC meshwork (Figure 53). 
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 Figure 52 Overall survival in years, of patients with FL, based on integrity of FDC 
meshwork assessed by CD35 expression in initial diagnostic biopsies.The blue line 
indicates patients with a preserved FDC meshwork in the initial diagnostic FL biopsy 
(n=11). The red line indicates patients with a disrupted FDC meshwork in the initial 
diagnostic FL biopsy (n=62). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 53 Time to transformation, in years, of patients with FL based on integrity of 
FDC meshwork assessed by CD35 expression in initial diagnostic biopsies.The blue 
line indicates patients with a preserved FDC meshwork in the initial diagnostic FL 
biopsy (n=2). The red line indicates patients with a disrupted FDC meshwork in the 
initial diagnostic FL biopsy (n=23). 
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9.3.2.4 Analysis of FDC meshwork using immunocytochemistry for Clusterin 
Clusterin is not a traditionally used immunocytochemical marker to highlight FDC 
however on application to numerous reactive lymph nodes and lymphoid tissue it 
was observed to highlight the FDC meshwork (Figure 54) 
 
Figure 54 Immunocytochemistry for Clusterin performed on a reactive lymph node 
demonstrating, A) Low power image depicting positive FDC meshwork within a 
reactive lymphoid follicle, original magnification x10, B) High power image 
depicting positive staining of FDC within a reactive lymph node, original 
magnification x40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Consequently, clusterin staining of FDC in FL was analysed in the same way as 
previous described. Eighty three cases from a possible ninety four were evaluable, 
sixty nine cases (83%) demonstrated a disrupted FDC meshwork and fourteen cases 
(17%) demonstrated an intact FDC meshwork.  The median overall survival of 
patients whose initial diagnostic biopsy demonstrated an intact FDC meshwork was 
8.18 years. The median overall survival of patients whose initial diagnostic biopsy 
contained a disrupted FDC meshwork was 5.1 years. Overall survival was not 
statistically significant (p=0.8). 
 
A B 
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Figure 55  Overall survival in years, of patients with FL, based on integrity of FDC 
meshwork assessed by Clusterin expression in initial diagnostic biopsies. The blue 
line indicates patients with a preserved FDC meshwork in the initial diagnostic FL 
biopsy (n=14). The red line indicates patients with a disrupted FDC meshwork in the 
initial diagnostic FL biopsy (n=69). 
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Transformation to DLBCL occurred in twenty eight assessable cases. The median 
time to transformation of patients with an intact FDC meshwork as assessed by 
Clusterin staining was 9.04 years compared to 3.4 years for patients with a disrupted 
FDC meshwork (p=0.04) (Figure 56). 
 
Figure 56 Time to transformation, in years, of patients with FL based on integrity of 
FDC meshwork assessed by Clusterin expression in initial diagnostic biopsies. The 
blue line indicates patients with a preserved FDC meshwork in the initial diagnostic 
FL biopsy (n=10). The red line indicates patients with a disrupted FDC meshwork in 
the initial diagnostic FL biopsy (n=18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 9.3.2.5 Analysis of FDC meshwork using immunocytochemistry for CNA.42  
Eighty cases of a possible ninety four were evaluable for the expression of CNA.42. 
Initially scoring of CNA.42 staining was performed as described previously 
however, only two cases of intact meshwork were observed. This is strikingly 
different to reactive lymph nodes and reactive lymphoid tissue where the FDC 
meshwork within reactive germinal centres is clearly highlighted by CNA.42. 
Consequently CNA.42 was scored on the presence or absence of FDC stained 
positively. 
 
Forty eight cases (60%) were negative for CNA.42 staining and thirty two cases 
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(40%) contained FDCs stained positively for CNA.42. The median overall survival 
of patients with biopsies which contained positively stained FDC was not 
significantly different to patients with biopsies which were negative for CNA.42 
(5.05 years versus 7 years)(p=0.6) (Figure 57).  
 
Figure 57 Overall survival in years, of patients with FL, based on staining of FDC 
by CNA.42 in initial diagnostic biopsies. The blue line indicates patients with a 
positively stained FDC present in the initial diagnostic FL biopsy (n=32). The red 
line indicates patients without positively stained FDC in the initial diagnostic FL 
biopsy (n=48). 
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9.3.2.6 The minority of FDC in FL are mature as determined by mmunocytochemical 
staining for CD21, CD23 and CD35 
According to the developmental model of immunophenotypic differences in FDC 
developed by Kasajima-Akatsuka and Maeda; mature FDC are designated as 
expressing CD21, CD23 and CD35 (Kasajima-Akatsuka.N, Maeda K 2006). Only 
six cases of 94 (6.4%) in this study demonstrated an intact FDC meshwork stained by 
immunocytochemistry for CD21, CD23 and CD35 and would consequently be 
classified as mature. The finding that a minority of FL cases contain FDC of mature 
immunophenotype has previously been observed although the percentage of cases 
with a mature immunophenotype was much higher (40%) (Chang K et al. 2003) than 
in my study. 
 
The results for patterns of immunocytochemical staining are detailed in Table 34. 
 
Table 34 Table to demonstrate the immunocytochemical pattern of staining of 
meshwork using monoclonal antibodies to CD21, CD23, CD35 and Clusterin 
 
 
Antibody Intact 
Meshwork 
Disrupted Meshwork Total 
  Sparse Fragments None  
CD21 43 17 12 14 86 
CD23 56 11 8 5 80 
CD35 11 10 18 34 73 
Clusterin 14 15 40 14 83 
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9.3.2.7. The number of macrophages in FL is not related to the integrity of the FDC 
meshwork 
FDC produce monocyte chemoattractant protein-1 (MCP-1) which may recruit FL 
cells (Husson H et al. 2001). The secretion of these factors may also be responsible 
for the varied immune cells infiltrates present in the FL microenvironment. The 
presence of an intact FDC meshwork may provide an increased stimulus for the 
recruitment of macrophages, a known adverse prognostic factor (Farinha P et al. 
2005), to the neoplastic follicles via MCP-1. Using the macrophage counting criteria 
of Farinha et al. (Farihna P et al. 2005), the number of macrophages present was 
correlated with the integrity of the FDC meshwork. There was no association 
between the integrity of the FDC meshwork and the number of CD68 positive 
macrophages present in the FL biopsies. 
 
Table 35 Table to demonstrate correlation between the integrity of the FDC 
meshwork assessed by immunocytochemistry for four antigens on FDC and number 
of CD68 positive macrophages present 
Stain/pattern Macrophage 
number <15/hpf 
Macrophage 
number (>15/hpf) 
P-value 
CD21 
Intact 
20 (33%) 12 (50%) 
Disrupted 41 (67%) 12 (50%) 
0.1 
CD23 
Intact 
35 (59%) 11 (46%) 
Disrupted 24 (41%) 13 (54%) 
0.2 
CD35 
Intact  
7 (14%) 3 (16%) 
Disrupted 42 (86%) 16 (84%) 
0.6 
Clusterin 
Intact 
6 (10%) 5 (25%) 
Disrupted 53 (90%) 15 (75%) 
0.1 
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9.3.2.8 Soluble clusterin is increased in FL samples as compared to tonsil 
Western blotting of a two tonsil controls and a single sample of FL cell lysate for 
clusterin demonstrated an increased band in the FL lane as compared to the tonsils at 
a level of 60KDa. This is the level for the Clusterin precursor protein and this has 
been demonstrated to be present at higher levels in tumour tissue as compared to 
healthy tissue (Pucci S et al. 2004). The amounts of GAPDH were the same for all 
wells indicating equal loading of the wells with protein lysate. 
 
Figure 58 Western blotting of two tonsil protein lysates and a FL protein lysate 
using anti-human rabbit polyclonalClusterin-α/β antibody demonstrating an 
increased band in the FL sample at the level of 60KDa.  
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9.3.3 The presence of an intact FDC meshwork can predict time to transformation in 
initial diagnostic biopsies of FL 
 
9.3.3.1 Patient characteristics 
Fifty one patients with diagnostic FL biopsies were eligible to be included within this 
study. The histology was reviewed in all cases. The characteristics of the patient 
population are listed in Table 36. Patients who underwent transformation of FL to 
DLBCL within three years of diagnosis, the rapidly transforming group (n=26), had a 
median time to transformation of 1.14 years (range 0-2.99). Patients who 
transformed eight years or more after diagnosis, the slow transforming group (n=25), 
had a median time to transformation of 19.02 years (range 8.15-34.02). This 
difference was significant (p=0.0001). The members of the rapidly transforming 
were older than the slowly transforming, with median ages at diagnosis of 61 years 
and 47 years respectively however this was not statistically significant (p=0.18).  
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Table 36 Demographic and Clinical Characteristics of Patients from the Rapidly 
Transforming and Slow Transforming Groups 
  Rapidly transforming group  Slow transforming group 
Total no. of patients 
(n=51)  
  26   25 
 Sex 
  Male 
  Female 
 
 18 
  8 
  
 15 
 10 
Time to transformation 
(years) 
  Median 
  Range 
  
 
  1.14 
  0 – 2.99 
  
 
  19.02 
  8.15 – 34.02 
Age at diagnosis (years) 
 Median 
 Range 
  
 61.04 
 30.8 - 72.6 
  
  47 
  30.5 - 65 
 Grade   Grade 1 = 13 
  Grade 2 = 11 
  Grade 3a = 2  
  Grade 1 = 14 
  Grade 2 =  8 
  Grade 3a =  3 
Stage 
I 
II 
III 
IV 
 2 unknown 
 0 
 5 
 8 
 11 
 
 1 
 6 
 6 
 12 
Number of repeat 
biopsies    
  15 cases: 1-6 relapses, 1-7 
biopsies 
6 cases: no relapse, no 
biopsies 
1 case: no relapse, 3 biopsies 
3 cases: 1 relapse, no 
biopsies 
Chapter Nine: FDC and FL 
 
251 
9.3.3.2 Disruption of FDC meshwork assessed by immunocytochemistry for CD21 
can predict rapid transformation of FL to DLBCL 
Analysis of the FDC meshwork using immunocytochemistry for CD21 and CD23 
was performed according to the scoring system described in the Materials and 
Methods. The markers CD35, Clusterin and CNA.42 were not used as this work was 
performed chronologically prior to the work described earlier in this chapter. The 
presence of an intact FDC meshwork as assessed by CD21 immunocytochemistry 
was significantly associated with rapid transformation from FL to DLBCL whereas 
the presence of a disrupted FDC meshwork as assessed by CD21 
immunocytochemistry was significantly associated with slow transformation from 
FL to DLBCL (p = 0.0025). Disruption of the FDC meshwork as analysed by CD23 
immunocytochemistry was not associated with any differences in time to 
transformation (p=0.4) (Table 37). 
 
Table 37 Correlation of speed of transformation with integrity of the FDC meshwork 
as assessed by immunocytochemistry for CD21 and CD23  
Antigen Pattern Fast 
transforming 
group 
Slow-
transforming 
group 
CD21 Disrupted 6/23 (26%) 17/24 (71%) 
  Non-disrupted 17/23 (74%) 7/24 (29%) 
CD23 Disrupted 7/24 (29%) 5/23 (22%) 
  Non-disrupted 17/24 (71%) 18/23 (78%) 
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9.3.4 Follicular dendritic cell markers are lost on transformation 
9.3.4.1 Gene expression profiling of pre- and post-transformation sample of FL 
As previously indicated, transformation of follicular lymphoma to an aggressive high 
grade lymphoma is a common and adverse prognostic event. The gene expression 
data described in Chapter 4 was obtained from lymph node samples of follicular 
lymphoma (FL) which subsequently transformed to diffuse large B cell lymphoma 
(DLBCL) using the Lymphochip cDNA microarray. A list of seventy-six genes 
whose expression was significantly altered on transformation was generated using 
the random variance model t-test. The cut off value for P was set at <0.001. Twenty 
nine genes demonstrated up-regulation and 47 genes are down-regulated upon 
transformation (Davies AJ et al. 2006). In order to assess concordance between 
mRNA and protein expression gene products were chosen for further study using 
immunocytochemistry. The follicular dendritic cell antigens CR2 (CD21) and 
FCER2 (CD23) were the most significantly down-regulated genes on transformation 
of FL to DLBCL (Figure 59) and their protein expression in tumour samples was 
analysed. Therefore, the protein expression of these genes was analysed on an 
independent validation set of 34 patients with at least one pre-transformation and one 
post-transformation paraffin embedded biopsy. 
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Figure 59 A selection of genes with significant differential expression on 
transformation of follicular lymphoma to diffuse large B-cell lymphoma (20 paired 
samples) is shown on the right hand side. Green represents downregulated and red 
upregulated. Arrows indicate genes chosen for this project. Original image by Dr A J 
Davies with permission. 
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9.3.4.2 Loss of FDC markers CD21 and CD23 on transformation of FL to DLBCL 
confirmed by immunocytochemistry on transformation TMA 
The gene expression data has been validated at a protein level on TMA using 
immunocytochemistry. Samples comprising both FL and t-FL (DLBCL) were 
available to evaluate expression of both markers in 28 patients. For each antibody, 2 
(maximum of 10% cases over all the antibodies studied) or 3 replicate cores were 
assessable. The CD21 positive FDC meshwork was lost in 15/28 (54%) of patients 
upon transformation however results demonstrated a clear FDC meshwork in the 
remaining cases of tFL (Figure 60). Similarly CD23 marked the FDC meshwork but 
was present occasionally on tumour cells. The presence of the FDC meshwork 
highlighted by CD23 expression was lost in 17/28 (61%) of patients on 
transformation. The remainder of the cases retained an FDC meshwork on 
transformation of FL to DLBCL (Figure 61). The concordance between the loss of 
both markers was 71%. There was no correlation with overall survival or survival 
from transformation for either CD21 (Figures 62, 63) or CD23 (Figures 64, 65).  
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Figure 60 Immunocytochemistry for CD21 on paired FL and transformed FL 
(DLBCL) on TMA demonstrating, A) Well formed discrete meshworks of FDC in 
FL OM x10, B) DLBCL transformed from FL demonstrating loss of FDC meshwork 
OM x10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
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Figure 61 Immunocytochemistry for CD21 demonstrating, A) A neoplastic follicle 
of FL with a well developed and demarcated FDC meshwork original magnification 
x20, B) DLBCL transformed from FL demonstrating retention of FDC meshwork 
within the tumour. Original magnification x20. 
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Figure 62 Kaplan-Meier estimate of survival from transformation by expression of 
CD21 protein analysed by immunocytochemistry (p=0.80). The blue line represents 
cases where the expression of CD21 by FDC was maintained on transformation of 
FL to DLBCL. The red line represents cases where the expression of CD21 was lost 
on transformation of FL to DLBCL 
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Figure 63 Kaplan-Meier estimate of overall survival by expression of CD21 on 
transformation of FL to DLBCL. The blue line represents cases where the expression 
of CD21 by FDC was maintained on transformation of FL to DLBCL. The red line 
represents cases where the expression of CD21 was lost on transformation of FL to 
DLBCL (p=0.4) 
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Figure 64 Kaplan-Meier estimate of survival from transformation by expression of 
CD23 protein on FDC analysed by immunocytochemistry (p=0.9). The blue line 
represents cases where the expression of CD23 by FDC was maintained or increased 
on transformation of FL to DLBCL. The red line represents cases where the 
expression of CD23 on FDC was lost on transformation of FL to DLBCL 
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Figure 65 Kaplan-Meier estimate of overall survival by expression of CD23 protein 
by immunocytochemistry (p=0.3). The blue line represents cases where the 
expression of CD23 by FDC was maintained or increased on transformation of FL to 
DLBCL. The red line represents cases where the expression of CD23 by FDC was 
lost on transformation of FL to DLBCL. 
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9.4 Discussion 
The Follicular Dendritic Cell is an enigmatic cell which is difficult to study. The 
cells are fragile and are closely apposed to B lymphocytes within the germinal centre 
making analysis of these cells problematic. In addition, there are few cell lines which 
are truly representative of the FDC. The important role of FDC in germinal centre 
formation and the maturation and survival of B lymphocytes is well recognized (Liu 
YJ et al 1991; Kosco MH, Pflugfelder E, Gray D 1992) and there is evidence that 
FDC are important in lymphomageneis (Petrasch S et al. 1992). This coupled with 
the observation that FDC are present within FL even when the neoplasm is present at 
sites where reactive lymphoid tissue is not normally seen suggest that FDC are 
important in the biology and possibly the survival of FL. This work has examined the 
FDC and their immunophenotype in FL biopsies and correlated the expression of 
markers with overall survival and transformation.    
 
The FDC meshwork has been demonstrated to differ in secondary follicles in 
reactive lymph nodes compared to neoplastic follicles in FL lymph nodes. There is 
loss of the polarity of FDC meshwork observed in secondary follicles on analysis of 
CD23 immunocytochemistry in neoplastic follicles of FL and a consequent increase 
in colocalization of CD21 and CD23 expression within neoplastic follicles as 
compared to secondary follicles in reactive lymph nodes. This demonstrates that the 
FDC meshwork is changed in FL as compared to reactive lymph nodes.  
 
Analysis of the immunocytochemical staining was performed in 94 diagnostic 
biopsies from patients with FL to analyse whether any markers could be used as 
prognostic markers to inform treatment at diagnosis. The presence of an intact or 
disrupted FDC mesh assessed by immunocytochemistry for CD21, CD23 or CD35 
was not associated with overall survival or transformation. The presence of an intact 
FDC meshwork as assessed by immunocytochemistry for Clusterin was significantly 
associated with increased time to transformation but not overall survival with 
patients with an intact meshwork as indicated by Clusterin immunocytochemistry 
more likely to transform. These results indicate that Clusterin present on FDC cells is 
important in the biology of FL cells as the presence of Clusterin indicates a cohort of 
patients who are more likely to transform to DLBCL. This result suggests a more 
widespread role for the use of Clusterin immunocytochemistry in diagnostic biopsies 
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of FL to try and provide prognostic information to clinicans and aid treatment 
selection. The lack of association between the integrity of the FDC meshwork as 
assessed using immunocytochemistry for the other FDC markers CD21, CD23 and 
CD35 and overall survival indicate that the results are not conclusive and require 
further investigation. In addition, the median survival of the patient cohort examined 
is below the median which would be expected for this disease suggesting that by 
chance a subset of patients with worse prognosis have been selected for 
investigation. Analysis of a group of patients with a higher median survival may 
highlight a survival advantage/disadvantage. The other conclusion is that FDC 
expressing these markers are not important for FL survival. 
 
Preliminary results indicate that pre-soluble clusterin, a precursor of secretory 
clusterin which is antiapoptotic, is increased in FL samples as compared to tonsil. 
This result and the presence of an intact FDC meshwork being associated with 
increased likelihood of transformation may be linked. If the main location of 
clusterin within the neoplastic follicle is on the FDC meshwork as described in this 
work the presence of an intact meshwork may provide a scaffold for increased 
soluble levels of clusterin which could prevent neoplastic cells undergoing apoptosis. 
The survival of the neoplastic cells could allow accumulation of mutations which 
push the tumour from a FL phenotype towards a DLBCL phenotype. The presence of 
FDC have been demonstrated to protect B lymphocytes from chemotherapeutic 
agents in murine studies (Schwarz YX et al. 1999) and the presence of a well 
developed FDC meshwork may represent a mechanism of drug resistance for the FL 
which could result in reduced overall survival and faster transformation. The 
overexpression of soluble clusterin may provide a therapeutic target for the treatment 
of FL. 
 
Histopathologists have long observed the loss of follicular dendritic cell meshwork, 
as indicated by immunocytochemical staining for CD21 and CD23, on 
transformation of FL to DLBCL. These observations are confirmed both by gene 
expression profiling which shows reduction in transcripts for these markers and by 
the immunocytochemical results of this study. CD21 and CD23 are strongly 
expressed by follicular dendritic cells within normal germinal centres and are 
required for survival of the germinal centre. Although used as an indicator of tumour 
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progression (Chang KC et al 2003) there is no clear indication as to whether loss of 
these antigens results in tumour progression from low grade FL to the more 
aggressive DLBCL or whether this is a marker to indicate transformation has 
occurred. This study cannot answer this question. The lack of significant correlation 
between loss or retention of expression of both CD21 and CD23 and survival could 
suggest that it is merely a surrogate marker and not biologically important. However, 
this may simply be a reflection of the relatively small sample size analysed. Analysis 
of cases (n=15) of FL demonstrated a stable expression of CD21 and CD23 over time 
in 7 patients (median time between biopsies 2.2 years); a loss of CD21 and CD23 
expression over time in 7 patients (median time between biopsies 3.1) and an 
increase in expression in a single patient (Chang KC et al. 2003). Transformation to 
DLBCL was not assessed. CD23 expression was lost at an earlier stage than 
expression of CD21 (Chang KC et al 2003). This suggests that loss of FDC 
meshwork is an important factor in a subset of patients. The important architectural 
role of the FDC meshwork in the germinal centre could explain why the loss of the 
meshwork may be a precipitating factor in transformation of FL to DLBCL. 
However, if the presence of an intact FDC meshwork, as assessed by CD21 
immunocytochemistry, is associated with worse outcome and rapid transformation to 
DLBCL as described above the presence of the FDC meshwork may aid 
transformation of FL to DLBCL. The meshwork may provide biological factors 
which prevent apoptosis and enhance survival as well as providing protection against 
chemotherapeutic agents which allow tumour cells to acquire mutations which give 
them a selective advantage.  
 
FDC have been demonstrated to produce and secrete CXCL13 (Ansel KM et al. 
2000) which binds to CXCR5, expressed on mature B lymphocytes and a 
subpopulation of T-helper memory cells (Dobner T et al. 1992). FL cells also express 
CXCR5 and migrate in response to CXCL13 (Husson H et al. 2002). FDC also 
produce monocyte chemoattractant protein-1 (MCP-1) which may also recruit FL 
cells (Husson H et al. 2001). This suggests that FDC may play a crucial role in the 
recruitment of FL to sites within the body and raises the questions as to whether 
treatment with targeted therapy against the FDC, in combination with other therapy 
targeting the neoplastic cells, could be effective in the treatment of FL. The secretion 
of these factors may also be responsible for the varied immune cells infiltrates 
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present in the FL microenvironment. The presence of an intact FDC meshwork may 
provide an increased stimulus for the recruitment of macrophages, a known adverse 
prognostic factor (Farihna P et al. 2005), to the neoplastic follicles via MCP-1. This 
again supports the idea that targeted treatment against the FDC, in combination with 
treatment against the neoplastic cells, could prove an increasingly effective treatment 
of FL.  
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Follicular lymphoma is a disease characterised by numerous relapses and remissions 
and a median survival of 8-10 years. In addition, a large number of potential 
therapeutic interventions are available ranging from a simple ‘watch and wait’ 
strategy through more aggressive treatments depending upon the requirements of 
individual patients. Although the median survival is approximately 8-10 years from 
diagnosis there is a great deal of variability with some patients dying of their disease 
very rapidly (<5 years from diagnosis) and other patients surviving over thirty years 
from initial diagnosis. At the present time there is no consensus on which treatments 
should be used to treat FL (Solal-Celigny P et al. 2004; Gribben J 2007) and 
predicting patients whose disease will behave in an aggressive manner and so may 
require intensive therapy is difficult. The FLIPI uses clinical parameters to stratify 
patients and provides a consistent method to compare clinical trials and evaluate 
treatments (Solal-Celigny P et al. 2004) however the FLIPI has only limited 
discriminative power and is rarely used in the clinical setting to drive treatment 
choices. It has been shown that in patients with FL at first relapse the FLIPI can be 
used with the presence of B symptoms to predict five-year survival from progression 
(Montoto S et al. 2004). Between 25-35% of patients with FL transform to DLBCL 
(Acker B et al. 1983; Gallagher CJ et al. 1986; Montoto S et al. 2007) although post-
mortem data suggests a much higher rate of transformation; 68% (Garvin AJ et al. 
1983). Transformation is typically a clinically catastrophic event with death often 
occurring quickly (Bastion Y et al. 1997). 
 
There is a need to identify prognostic biomarkers which can reliably predict the 
likelihood of a patient having an aggressive disease and the risk of transformation at 
diagnosis. This would allow stratification of patients into risk groups with 
appropriate treatment options, preventing the over-treatment of those patients with 
truly ‘indolent’ disease. In addition, there is little information about the biology of 
transformation. Transformation is a complicated process which probably can occur 
via many pathways, investigation into these mechanisms is important in predicting 
those patients who will transform as well as identifying putative therapeutic targets. 
The inference that the immune microenvironment is important in the biology of FL is 
not a novel idea; the presence of CD4 T lymphocytes was observed within FL in the 
1980’s (Swerdlow SH et al. 1985) and their importance was implied by the 
observation that significantly more CD4 T lymphocytes were present in the biopsies 
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of untreated FL patients who underwent spontaneous regression (Strickler JG et al. 
1988). Gene expression profiling of FL biopsies from untreated patients produced 
two gene signatures which allowed the grouping of patients into quartiles with 
difference in survival. The gene signatures were as a result of gene expression of 
tumour infiltrating cells and were independent of clinical parameters (Dave SS et al. 
2004). Corroboration of the findings at a gene expression level were provided by 
Farinha et al. who demonstrated a correlation between increased numbers of CD68 
positive macrophages and poor prognosis although the presence of T lymphocytes 
did not identify an improved prognosis (Farinha P et al. 2005). 
 
The work outlined in this thesis has validated tissue microarray as a technique for a 
high throughput approach to the assessment of immunocytochemical markers in FL. 
Prior to this work a single study had used TMA to analyse a series of 193 B cell 
NHLs and 29 cases of Hodgkins lymphoma and compared full section staining 
results to those obtained using TMA and found a high correlation (Hedvat CV et al. 
2002). This work demonstrated concordance between scoring immunocytochemistry 
from TMA cores and full sections of more than 90%. This has verified the technique 
as an appropriate method for analysis of haematological malignancies. This has been 
further corroborated by subsequent studies in haematological malignancies (Garcia 
JF et al. 2003; Tzankov A et al. 2003; Zettl A et al. 2003).  
 
The work reported here has examined the role of the microenvironment in predicting 
outcome of patients with FL including the likelihood of transformation. A study of 
59 diagnostic samples obtained from patients with poor survival (<5 years from 
diagnosis) and good survival (>15 years from diagnosis) identified CD4 positive T 
lymphocytes and a perifollicular pattern of FOXP3-positive cells were more 
commonly found in diagnostic lymph nodes from patients with favourable outcome. 
These observations are in keeping with the hypothesis that the presence of CD4 
positive T lymphocytes within the tumour are of benefit to the host (Strickler JG et 
al. 1988) and are consistent with the gene expression data (Dave SS et al. 2004). We 
found no correlation between survival and the presence or location of CD68 positive 
macrophages, in contrast to a previous report (Farinha P et al. 2005). This may be a 
reflection of the different patient populations studied since the patients studied here 
were older and had less aggressive disease than those of Farinha et al (Farinha P et 
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al. 2005). However, our results are in keeping with the gene expression profiling data 
in that CD68 was not one of the 24 genes identified by Dave et al (Dave SS et al. 
2004) and other genes from that signature should be assessed. 
 
The presence of peri-follicular FOXP3 positive cells was observed in samples from 
patients with longer survival. This implied regulatory T lymphocytes were important 
in the biology of FL. Similar results were published by Carreras et al. who observed 
a high number of FOXP3-positive cells correlated with improved overall survival in 
FL although no association with location was observed (Carreras J et al. 2006). The 
association of improved survival and the presence of FOXP3-positive cells is the 
opposite of that observed in epithelial malignancies where their presence seems to 
promote tumour tolerance (Curiel TJ et al. 2004). This could be explained by the fact 
that activated CD4+CD25+ T lymphocytes can kill B lymphocytes using perforin 
and granzyme (Zhao DM et al. 2006) or that they can lyse antigen presenting B cells 
by Fas-Fas ligand interaction (Janssens W et al. 2003). In addition regulatory T cells 
can suppress immunoglobulin production and class switch recombination (Lim HW 
et al. 2005). All these actions could allow regulatory T cells to disrupt survival and 
expansion of neoplastic FL cells. The importance of the immune microenvironment 
on prognosis in FL has been further demonstrated by the observation of differing 
impact dependent upon different treatment protocols. The presence of a high number 
of FOXP3 positive cells, numerous macrophages in an interfollicular pattern and 
preserved FDC meshworks was associated with an improved time to progression in 
patients treated with CVP, in patients treated with fludarabine this microenvironment 
was a poor prognostic feature (de Jong D et al. 2009). This treatment effect may 
explain some of the conflicting evidence currently published with regard to the 
impact of the immune microenvironment in FL and prognosis. 
  
Although our own findings and those of Farinha are indicative that high numbers of 
macrophages are important in the outcome of FL, the role macrophages play in the 
setting of FL is not fully understood. Macrophages migrate into the tumour 
microenvironment as a result of cytokines produced by tumour cells and MCP-1 
produced by FDC (Husson H et al. 2001). Macrophages are polarised into either M1 
or M2. M1 is activated in response to microbial products and cytokines (Adams DO, 
Hamilton TA 1984) and M2 is induced by IL-4 (Stein M et al. 1992), IL13 and IL-10 
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(Goerdt S, Orfanos CE 1999). The M2 macrophage group are responsible for 
remodelling and healing and the exposure of macrophages to IL-4 inhibits the 
phagocytosis of immune complexes and superoxide production (Becker S, Daniel EG 
1990). The presence of increased numbers of M2 type macrophages which act to 
reduce inflammatory reaction against tumour cells could explain the observations of 
Farinha et al. and this work. 
 
The work in this thesis has also examined the changes in the immune 
microenvironment on transformation of FL to DLBCL. The observation that the 
numbers of CD68 positive macrophages was high in all samples except one of FL 
prior to transformation and remained so on transformation is consistent with the 
hypothesis proposed by Farinha et al. who observed that short survival from 
diagnosis of FL correlated with >15 positive cells /hpf in diagnostic biopsies 
(Farinha P et al. 2005). Transformation of FL to DLBCL is a clinically catastrophic 
event associated with reduced survival and the results in this study would be in 
keeping with those of Farinha et al. In contrast to the work of Carreras et al. there 
was no observed decrease in the number of FOXP3-positive cells on transformation 
in this work which could as a result of the differing methods used to count the 
FOXP3-positive cells as well as sample variance (Carreras J et al. 2006). The median 
overall survival for patients in whose biopsies the number of FOXP3-positive cells 
decreased on transformation was 10.9 years compared to 3.9 years for those patients 
whose biopsies contained increased numbers of FOXP3 positive cells on 
transformation. This result appears different to the results previously observed in this 
work; a perifollicular location of FOXP3-positive cells was more commonly found in 
diagnostic lymph nodes from patients with favourable outcome. There are 
differences in assessment of outcome, as in this part of the study all the patients 
transformed from FL to DLBCL and in the previous work the overall survival was 
the outcome factor being assessed. The presence of FOXP-3 positive cells in a 
perifollicular location in patients with favourable outcome could be explained by the 
ability of regulatory T cells to kill (Zhao DM et al. 2006; Janssens W et al. 2003) or 
inhibit B lymphocytes (Lim HW et al. 2005). This could be an effective means of 
inhibiting tumour growth in a relatively slow growing tumour such as FL. In a 
rapidly growing tumour such as DLBCL these mechanism may be unable to control 
tumour growth and may worsen the situation by inhibiting the immune system which 
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may be trying to produce an anti-tumour effect. This hypothesis could be supported 
by the observation of high numbers of CD4 and CD8 positive lymphocytes in the 
tumour samples both pre- and post-transformation. The observation that the immune 
microenvironment did not impact on outcome in de novo DLBCL against supports 
this hypothesis.  
 
Patients with initial diagnostic biopsies of FL who subsequently transformed to 
DLBCL were identified and two cohorts of patients were then established. The first 
cohort of 26 patients transformed to DLBCL in less than 3 years from initial 
diagnosis of FL and the second cohort of 25 patients transformed after eight years 
from initial diagnosis. Whilst the absolute numbers of CD4 positive lymphocytes did 
not correlate with time to transformation the location of these lymphocytes was 
important. Patients from the rapidly transforming group had CD4 positive cells at a 
higher incidence within follicles whereas the distribution of CD4 positive 
lymphocytes was predominantly perifollicular in patients in the slow transforming 
group. The data suggesting that FL resembling non-malignant hyperplasia including 
the presence of intrafollicular CD4 positive lymphocytes was associated with rapid 
transformation support those of a recently published study (Glas AM et al. 2007). 
Increased numbers of CD68 positive macrophages were more commonly found in 
the diagnostic FL lymph nodes of patients who underwent rapid transformation to 
DLBCL. This finding is in keeping with the hypothesis that the lymphoma-
associated macrophage content is an independent predictor of survival in FL (Farinha 
P et al. 2005). 
 
In addition to the impact of the immune microenvironment this work has also 
analysed some of the molecular mechanisms which might be important in 
transformation of FL to DLBCL. Currently the molecular mechanisms underlying 
transformation are poorly understood with numerous proposed mechanisms 
including mutation of TP53 (Lo Coco F et al. 1993; Sander CA et al. 1993; Davies 
AJ et al. 2005); cytogenetic abnormalities (Goff LK et al. 2000; Hough RE et al. 
2001); amplifications of c-REL (Goff LK et al. 2000); deletions of CDKN2A and 
CDKN2B (Elenitoba-Johnson KS et al. 1998); mutations of Bcl-2 (Matolcsy A et al. 
1996) and mutations of Bcl-6 (Lossos T, Levy R 2000). Each of these has been 
identified in relatively small numbers of patients and further investigations into the 
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biological mechanisms are required if treatments and survival for the patients who 
undergo transformation.  
 
A cohort of twenty nine patients diagnosed with FL which subsequently transformed 
to DLBCL with both fresh frozen and paraffin embedded pre-transformation and 
transformed biopsies were identified. The role of TP53 mutation in transformation 
was analysed in this patient cohort using a combination of mutation analysis and 
immunocytochemistry for p53, MDM2 and p21. In the initial diagnostic biopsies of 
FL no mutations in TP53 were observed and the percent of patients who acquired 
mutations on recurrence of lymphoma was low (28%). There were three patients with 
a FL sample containing a TP53 mutation prior to transformation. The time period 
between acquisition of the mutation and transformation to aggressive disease in these 
patients was variable but in two patients transformation did not occur for 2.5 years 
and 4 years respectively. The presence of TP53 mutation is therefore not an indicator 
of imminent transformation. In addition, the presence or absence of a TP53 mutation 
was not associated with survival. This work has also demonstrated that the detection 
of p53 protein over-expression using immunocytochemistry is not dependent upon 
TP53 gene mutation and that the absence of protein does not exclude mutation. There 
was increased expression of Mdm2 in a high proportion of cases independent of 
TP53 mutation suggesting a different mechanism of transformation. The use of 
small-molecule inhibitors of Mdm2, the Nutlins, may be an option in patients who 
transform to DLBCL. The nutlins bind to Mdm2 in the p53 binding pocket and their 
action increases wild-type p53 with subsequent increase in the levels of Mdm2 and 
p21 suggesting that an intact p53 pathway is required for these drugs to work 
(Vassilev LT et al. 2004). Initial results in haematological malignancies of treatment 
with nutlins are encouraging (Kojima K et al. 2005; Stühmer T et al. 2005; Coll-
Mulet L et al. 2006). 
 
Paired pre-and post-transformation paraffin embedded tissue samples were obtained 
from a cohort of 43 patients and using immunocytohemistry this work has 
demonstrated that FL transforms to DLBCL of GC phenotype. It is surprising that 
the five year survival from the time of transformation in this study is only 38% 
despite the majority of patients (89%) having a phenotype shown to be favourable in 
de novo DLBCL. This may reflect previous treatment effect or possibly the 
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acquisition of further mutations which are advantageous for tumour survival. Gene 
expression data identified two genes of potential therapeutic importance which were 
up-regulated on transformation. Aurora Kinase B was also up-regulated at a protein 
level in the same proportion of patients as identified at a gene expression level. This 
suggests that AURKB could be an effective target for treatment of patients who have 
transformed and this is further corroborated by the observation that disruption of 
AURKB function in a t(14;18) DLBCL cell line results in apoptosis (Harrington EA 
et al. 2004). With the advent of new drugs selectively targeting Aurora Kinase B 
which demonstrate anti-proliferative effect on tumours this could prove an important 
target in some patients who transform from FL to DLBCL. The second up-regulated 
gene was nm23 and there was a high correlation between the increase in gene 
transcript level and the increase in protein level detected in patient samples using 
immunocytochemistry. Increased protein levels of nm23 have previously been 
correlated with poor prognosis in DLBCL (Niitsu N et al. 1999; Niitsu N et al. 2000) 
and increased tissue levels of nm23 correlated with increased serum levels (Niitsu N 
et al. 2004). This could provide an effective method of monitoring patients for 
transformation of FL to DLBCL using only a relatively non-invasive blood test. As 
nm23 is only elevated in a subset of patients it cannot be the only method of 
assessment however. The role of nm23 is to provide high energy nucleosides (Parks 
RE Jr, Agarwal RP 1973) and these results suggest that the high grade DLBCL may 
be dependent upon the provision of high energy compounds for survival indicating 
that nm23 may be a potential therapeutic target.  
 
Follicular dendritic cells are enigmatic cells which are essential for the formation, 
survival (Lindhout E et al. 1993) and normal function of reactive germinal centres 
(Liu YJ et al 1991; Kosco MH, Pflugfelder E, Gray D 1992). The presence of FDC in 
FL which has developed at sites where there was previously no lymphoid tissue 
coupled with the extreme difficulty in culturing FL in vitro without stromal cells 
suggests that FDC are essential for development and survival of FL. This hypothesis 
is supported by the demonstration that proliferation of NHL lymphocytes in vitro 
was dependent upon FDC interactions (Petrasch S et al. 1992). The work in this 
thesis has demonstrated that the FDC meshwork is different in secondary follicles in 
reactive lymph nodes compared to the FDC meshwork in neoplastic follicles in FL. 
There is a loss of polarization of CD23 expression on the FDC meshwork in 
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neoplastic follicles with a pattern of expression similar to that observed in primary 
reactive follicles. In addition, a change in immunophenotype of FDC was observed. 
Kasajima-Akatsuka and Maeda observed an immunophenotypic difference in 
developmental stages and functional phases of human FDC. It was observed that 
CNA.42 was present on precursors of FDC through all stages of differentiation 
(Kasajima-Akatsuka N, Maeda K 2006). My own observations of reactive lymph 
nodes confirmed immunocytochemical staining of FDC meshwork with CNA.42. In 
all but two of the samples of FL analysed there was loss of the FDC mesh assessed 
using immunocytochemistry for CNA.42 with individual FDC being positive or 
negative. The majority of cases (60%) were negative for CNA.42. This suggests that 
there is a biological difference between FDC in reactive follicles compared to FDC 
in neoplastic follicles. The finding that only 6.4% of samples contained FDC of a 
mature immunophenotype (CD21, CD23 and CD35 positive) also indicates that there 
are differences between FDC in reactive follicles and FDC in neoplastic follicles. 
The importance of FDC in the biology of FL is implied by the finding that the 
presence of Clusterin on FDC is associated with increased transformation. Currently 
assessment of clusterin by immunocytochemistry is not routinely performed on FL 
diagnostic lymph node biopsies, however, these results suggest that its assessment 
may provide clinicians with some prognostic information to aid treatment choice. 
The lack of association between the integrity of the FDC meshwork as assessed using 
immunocytochemistry for the other FDC markers CD21, CD23 and CD35 and 
overall survival require further investigation. The preliminary results of this study 
indicate increased levels of a precursor of secretory clusterin, which is anti-apoptotic, 
in FL compared to tonsils. This factor could protect the neoplastic cells from 
apoptosis. It has already been demonstrated that FDC can protect B lymphocytes 
from chemotherapeutic agents in mice (Schwartz YX et al. 1999). FDC also produce 
CXCL13 (Ansel KM et al. 2000) the receptor for which CXCR5, is expressed by FL 
cells. FL cells migrate in response to CXCL13 (Husson H et al. 2002). This suggests 
that FDC may play a crucial role in the recruitment of FL to sites within the body and 
raises the questions as to whether treatment with targeted therapy against the FDC, in 
combination with other therapy targeting the neoplastic cells, could be effective in 
the treatment of FL. FDC also produce monocyte chemoattractant protein-1 (MCP-1) 
which may also recruit FL cells (Husson H et al. 2001) as well as potentially 
macrophages which have previously been shown to be an adverse prognostic factor 
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in FL (Farinha P et al. 2005). The data in this thesis has shown no association 
between the presence of an intact FDC meshwork and the number of macrophages 
suggesting that cytokine production by FDC is not the most important factor in 
macrophage recruitment. 
 
Is it possible to unite the molecular abnormalities present in the neoplastic cells of 
FL with the impact of the microenvironment into a model for the pathogenesis of 
follicular lymphoma? The cytogenetic abnormality which is the hallmark for FL is 
the t(14;18)(q32;q21) which is present in approximately 70-95% of cases (Horsman 
DE et al. 1995). This results in the BCL2 gene being juxtaposed to the 
immunoglogulin heavy chain gene and results in the over-expression of Bcl2. This 
cytogenetic abnormality is not sufficient for the development of FL and in the 
majority of cases there are numerous other abnormalities most commonly involving 
chromosomes 1, 2, 4, 5, 13, and 17 or additions of X, 7, 12, or 18 (Tilly H et al. 
1994). The average number of genetic aberrations increases with grade with 
increased numbers of complex abnormalities in patients with higher grade tumours 
(Viardot A et al. 2002). Investigation into the temporal relationship of cytogenetic 
abnormalities demonstrated -6q, der(18(t(14;18) and +7 are early changes (Hoglund 
M et al. 2004) with adverse prognostic significance associated with abnormality of 
chromosome region 1p21-22, 6q23-36 and the short arm of chromosome 17 (Tilly H 
et al. 1994). A dual pathway model has been proposed by de Jong where the initial 
early event is the apoptotic resistance conveyed by the t(14;18). Secondary 
cytogenetic alterations result in a division into two prognostic pathways. The poor 
prognostic pathway typically involves abnormalities such as -6q and +1q and this 
produces an immune microenvironment with an activated FDC meshwork and T 
cells, transformation would be an early event in this pathway. The good prognosis 
pathway typically possess mutations such as +7/+8, +der(18)(Hoglund M et al. 
2004). The result is stabilization of the tumour cells in an inactive immunologic 
context resembling inactive lymphoid tissue. The rate of genomic mutations is low 
and transformation occurs slowly and the prognosis is good (de Jong D 2005). The 
findings in my work would certainly support the immunological aspects of this 
theory, however the current dearth of information from numerous sources some of 
which conflict, requires multi-institutional studies of large patient numbers to 
conclusively answer some of the important questions about the impact of the immune 
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microenvironment. Once validated as prognostically important, the findings can be 
easily translated to the routine diagnostic histopathology setting and can be used to 
identify patients with potentially aggressive disease at the time of diagnosis. Only at 
this point can definitive treatment strategies which target the biology of the disease 
be developed. 
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